A BILL 
To provide for certain reforms with respect to the Medicare 
program under title XVIII of the Social Security Act, 
the Medicaid program under title XIX of such Act, the 
Food and Drug Administration, and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Lower Costs, More 
4
Cures Act of 2021’’. 
5
00:26 Apr 24, 2021
H19
2 
•HR 19 IH
SEC. 2. TABLE OF CONTENTS. 
1
The table of contents for this Act is as follows: 
2
Sec. 1. Short title. 
Sec. 2. Table of contents. 
TITLE I—MEDICARE PARTS B AND D 
Subtitle A—Medicare Part B Provisions 
Sec. 101. Improvements to Medicare site-of-service transparency. 
Sec. 102. Requiring manufacturers of certain single-dose container or single-use 
package drugs payable under part B of the Medicare program 
to provide refunds with respect to discarded amounts of such 
drugs. 
Sec. 103. Providing for variation in payment for certain drugs covered under 
part B of the Medicare program. 
Sec. 104. Establishment of maximum add-on payment for drugs and 
biologicals. 
Sec. 105. Treatment of drug administration services furnished by certain ex-
cepted off-campus outpatient departments of a provider. 
Subtitle B—Drug Price Transparency 
Sec. 111. Reporting on explanation for drug price increases. 
Sec. 112. Public disclosure of drug discounts. 
Sec. 113. Study of pharmaceutical supply chain intermediaries and merger ac-
tivity. 
Sec. 114. Making prescription drug marketing sample information reported by 
manufacturers available to certain individuals and entities. 
Sec. 115. Sense of Congress regarding the need to expand commercially avail-
able drug pricing comparison platforms. 
Subtitle C—Medicare Part D Benefit Redesign 
Sec. 121. Medicare part D benefit redesign. 
Subtitle D—Other Medicare Part D Provisions 
Sec. 131. Allowing the offering of additional prescription drug plans under 
Medicare part D. 
Sec. 132. Allowing certain enrollees of prescription drug plans and MA–PD 
plans under Medicare program to spread out cost-sharing 
under certain circumstances. 
Sec. 133. Establishing a monthly cap on beneficiary incurred costs for insulin 
products and supplies under a prescription drug plan or MA– 
PD plan. 
Sec. 134. Growth rate of Medicare part D out-of-pocket cost threshold. 
TITLE II—MEDICAID 
Sec. 201. Medicaid pharmacy and therapeutics committee improvements. 
Sec. 202. GAO report on conflicts of interest in State Medicaid program drug 
use review boards and pharmacy and therapeutics (P&T) com-
mittees. 
Sec. 203. Ensuring the accuracy of manufacturer price and drug product infor-
mation under the Medicaid drug rebate program. 
00:26 Apr 24, 2021
H19
3 
•HR 19 IH
Sec. 204. Improving transparency and preventing the use of abusive spread 
pricing and related practices in Medicaid. 
Sec. 205. T–MSIS drug data analytics reports. 
Sec. 206. Risk-sharing value-based payment agreements for covered outpatient 
drugs under Medicaid. 
Sec. 207. Applying Medicaid drug rebate requirement to drugs provided as part 
of outpatient hospital services. 
TITLE III—FOOD AND DRUG ADMINISTRATION 
Subtitle A—Pay-for-Delay 
Sec. 301. Unlawful agreements. 
Sec. 302. Notice and certification of agreements. 
Sec. 303. Forfeiture of 180-day exclusivity period. 
Sec. 304. Commission litigation authority. 
Sec. 305. Statute of limitations. 
Subtitle B—Advancing Education on Biosimilars 
Sec. 321. Education on biological products. 
Subtitle C—Other Provisions 
Sec. 331. Clarifying the meaning of new chemical entity. 
TITLE IV—REVENUE PROVISION 
Sec. 401. Safe harbor for high deductible health plans without deductible for 
insulin. 
TITLE V—MISCELLANEOUS 
Sec. 501. Payment for biosimilar biological products during initial period. 
Sec. 502. GAO study and report on average sales price. 
Sec. 503. Requiring prescription drug plans and MA–PD plans to report poten-
tial fraud, waste, and abuse to the Secretary of HHS. 
Sec. 504. Establishment of pharmacy quality measures under Medicare part D. 
Sec. 505. Improving coordination between the Food and Drug Administration 
and the Centers for Medicare & Medicaid Services. 
Sec. 506. Patient consultation in Medicare national and local coverage deter-
minations in order to mitigate barriers to inclusion of such per-
spectives. 
Sec. 507. MedPAC report on shifting coverage of certain Medicare part B 
drugs to Medicare part D. 
Sec. 508. Requirement that direct-to-consumer advertisements for prescription 
drugs and biological products include truthful and non-mis-
leading pricing information. 
Sec. 509. Chief Pharmaceutical Negotiator at the Office of the United States 
Trade Representative. 
00:26 Apr 24, 2021
H19
4 
•HR 19 IH
TITLE I—MEDICARE PARTS B 
1
AND D 
2
Subtitle A—Medicare Part B 
3
Provisions 
4
SEC. 101. IMPROVEMENTS TO MEDICARE SITE-OF-SERVICE 
5
TRANSPARENCY. 
6
Section 1834(t) of the Social Security Act (42 U.S.C. 
7
1395m(t)) is amended— 
8
(1) in paragraph (1)— 
9
(A) in the heading, by striking ‘‘IN GEN-
10
ERAL’’ and inserting ‘‘SITE PAYMENT’’; 
11
(B) in the matter preceding subparagraph 
12
(A)— 
13
(i) by striking ‘‘or to’’ and inserting ‘‘, 
14
to’’; 
15
(ii) by inserting ‘‘, or to a physician 
16
for services furnished in a physician’s of-
17
fice’’ after ‘‘surgical center’’; and 
18
(iii) by inserting ‘‘(or 2022 with re-
19
spect to a physician for services furnished 
20
in a physician’s office)’’ after ‘‘2018’’; and 
21
(C) in subparagraph (A)— 
22
(i) by striking ‘‘and the’’ and insert-
23
ing ‘‘, the’’; and 
24
00:26 Apr 24, 2021
H19
5 
•HR 19 IH
(ii) by inserting ‘‘, and the physician 
1
fee schedule under section 1848 (with re-
2
spect to the practice expense component of 
3
such payment amount)’’ after ‘‘such sec-
4
tion’’; 
5
(2) by redesignating paragraphs (2) through 
6
(4) as paragraphs (3) through (5), respectively; and 
7
(3) by inserting after paragraph (1) the fol-
8
lowing new paragraph: 
9
‘‘(2) 
PHYSICIAN
PAYMENT.—Beginning 
in 
10
2022, the Secretary shall expand the information in-
11
cluded on the Internet website described in para-
12
graph (1) to include— 
13
‘‘(A) the amount paid to a physician under 
14
section 1848 for an item or service for the set-
15
tings described in paragraph (1); and 
16
‘‘(B) the estimated amount of beneficiary 
17
liability applicable to the item or service.’’. 
18
00:26 Apr 24, 2021
H19
6 
•HR 19 IH
SEC. 102. REQUIRING MANUFACTURERS OF CERTAIN SIN-
1
GLE-DOSE CONTAINER OR SINGLE-USE PACK-
2
AGE DRUGS PAYABLE UNDER PART B OF THE 
3
MEDICARE PROGRAM TO PROVIDE REFUNDS 
4
WITH RESPECT TO DISCARDED AMOUNTS OF 
5
SUCH DRUGS. 
6
Section 1847A of the Social Security Act (42 U.S.C. 
7
1395w–3a) is amended by adding at the end the following 
8
new subsection: 
9
‘‘(i) REFUND
FOR CERTAIN DISCARDED SINGLE- 
10
DOSE CONTAINER OR SINGLE-USE PACKAGE DRUGS.— 
11
‘‘(1) SECRETARIAL
PROVISION
OF
INFORMA-
12
TION.— 
13
‘‘(A) IN
GENERAL.—For each calendar 
14
quarter beginning on or after January 1, 2022, 
15
the Secretary shall, with respect to a refundable 
16
single-dose container or single-use package drug 
17
(as defined in paragraph (8)), report to each 
18
manufacturer 
(as 
defined 
in 
subsection 
19
(c)(6)(A)) of such refundable single-dose con-
20
tainer or single-use package drug the following 
21
for the calendar quarter: 
22
‘‘(i) Subject to subparagraph (C), in-
23
formation on the total number of units of 
24
the billing and payment code of such drug, 
25
if any, that were discarded during such 
26
00:26 Apr 24, 2021
H19
7 
•HR 19 IH
quarter, as determined using a mechanism 
1
such as the JW modifier used as of the 
2
date of enactment of this subsection (or 
3
any such successor modifier that includes 
4
such data as determined appropriate by 
5
the Secretary). 
6
‘‘(ii) The refund amount that the 
7
manufacturer is liable for pursuant to 
8
paragraph (3). 
9
‘‘(B) 
DETERMINATION
OF
DISCARDED 
10
AMOUNTS.—For 
purposes 
of 
subparagraph 
11
(A)(i), with respect to a refundable single-dose 
12
container or single-use package drug furnished 
13
during a quarter, the amount of such drug that 
14
was discarded shall be determined based on the 
15
amount of such drug that was unused and dis-
16
carded for each drug on the date of service. 
17
‘‘(C) EXCLUSION OF UNITS OF PACKAGED 
18
DRUGS.—The total number of units of the bill-
19
ing and payment code of a refundable single- 
20
dose container or single-use package drug of a 
21
manufacturer furnished during a calendar quar-
22
ter for purposes of subparagraph (A)(i), and 
23
the determination of the estimated total allowed 
24
charges for the drug in the quarter for purposes 
25
00:26 Apr 24, 2021
H19
8 
•HR 19 IH
of paragraph (3)(A)(ii), shall not include such 
1
units that are packaged into the payment 
2
amount for an item or service and are not sepa-
3
rately payable. 
4
‘‘(2) 
MANUFACTURER
REQUIREMENT.—For 
5
each calendar quarter beginning on or after January 
6
1, 2022, the manufacturer of a refundable single- 
7
dose container or single-use package drug shall, for 
8
such drug, provide to the Secretary a refund that is 
9
equal to the amount specified in paragraph (3) for 
10
such drug for such quarter. 
11
‘‘(3) REFUND AMOUNT.— 
12
‘‘(A) IN GENERAL.—The amount of the re-
13
fund specified in this paragraph is, with respect 
14
to a refundable single-dose container or single- 
15
use package drug of a manufacturer assigned to 
16
a billing and payment code for a calendar quar-
17
ter beginning on or after January 1, 2022, an 
18
amount equal to the estimated amount (if any) 
19
by which— 
20
‘‘(i) the product of— 
21
‘‘(I) the total number of units of 
22
the billing and payment code for such 
23
drug that were discarded during such 
24
00:26 Apr 24, 2021
H19
9 
•HR 19 IH
quarter (as determined under para-
1
graph (1)); and 
2
‘‘(II)(aa) in the case of a refund-
3
able single-dose container or single- 
4
use package drug that is a single 
5
source drug or biological, the amount 
6
of payment determined for such drug 
7
or 
biological 
under 
subsection 
8
(b)(1)(B) for such quarter; or 
9
‘‘(bb) in the case of a refundable 
10
single-dose container or single-use 
11
package drug that is a biosimilar bio-
12
logical product, the amount of pay-
13
ment determined for such product 
14
under subsection (b)(1)(C) for such 
15
quarter; exceeds 
16
‘‘(ii) an amount equal to the applica-
17
ble percentage (as defined in subparagraph 
18
(B)) of the estimated total allowed charges 
19
for such drug under this part during the 
20
quarter. 
21
‘‘(B) 
APPLICABLE
PERCENTAGE
DE-
22
FINED.— 
23
00:26 Apr 24, 2021
H19
10 
•HR 19 IH
‘‘(i) IN
GENERAL.—For purposes of 
1
subparagraph (A)(ii), the term ‘applicable 
2
percentage’ means— 
3
‘‘(I) subject to subclause (II), 10 
4
percent; and 
5
‘‘(II) if applicable, in the case of 
6
a refundable single-dose container or 
7
single-use package drug described in 
8
clause (ii), a percentage specified by 
9
the Secretary pursuant to such clause. 
10
‘‘(ii) TREATMENT
OF
DRUGS
THAT 
11
HAVE
UNIQUE
CIRCUMSTANCES.—In the 
12
case of a refundable single-dose container 
13
or single-use package drug that has unique 
14
circumstances involving similar loss of 
15
product as that described in paragraph 
16
(8)(B)(ii), the Secretary, through notice 
17
and comment rulemaking, may increase 
18
the applicable percentage otherwise appli-
19
cable under clause (i)(I) as determined ap-
20
propriate by the Secretary. 
21
‘‘(4) FREQUENCY.—Amounts required to be re-
22
funded pursuant to paragraph (2) shall be paid in 
23
regular intervals (as determined appropriate by the 
24
Secretary). 
25
00:26 Apr 24, 2021
H19
11 
•HR 19 IH
‘‘(5) REFUND DEPOSITS.—Amounts paid as re-
1
funds pursuant to paragraph (2) shall be deposited 
2
into the Federal Supplementary Medical Insurance 
3
Trust Fund established under section 1841. 
4
‘‘(6) ENFORCEMENT.— 
5
‘‘(A) AUDITS.— 
6
‘‘(i) MANUFACTURER AUDITS.—Each 
7
manufacturer of a refundable single-dose 
8
container or single-use package drug that 
9
is required to provide a refund under this 
10
subsection shall be subject to periodic 
11
audit with respect to such drug and such 
12
refunds by the Secretary. 
13
‘‘(ii) PROVIDER
AUDITS.—The Sec-
14
retary shall conduct periodic audits of 
15
claims submitted under this part with re-
16
spect to refundable single-dose container or 
17
single-use package drugs in accordance 
18
with the authority under section 1833(e) to 
19
ensure compliance with the requirements 
20
applicable under this subsection. 
21
‘‘(B) CIVIL MONEY PENALTY.— 
22
‘‘(i) IN
GENERAL.—The Secretary 
23
shall impose a civil money penalty on a 
24
manufacturer of a refundable single-dose 
25
00:26 Apr 24, 2021
H19
12 
•HR 19 IH
container or single-use package drug who 
1
has failed to comply with the requirement 
2
under paragraph (2) for such drug for a 
3
calendar quarter in an amount equal to the 
4
sum of— 
5
‘‘(I) the amount that the manu-
6
facturer would have paid under such 
7
paragraph with respect to such drug 
8
for such quarter; and 
9
‘‘(II) 25 percent of such amount. 
10
‘‘(ii) APPLICATION.—The provisions 
11
of section 1128A (other than subsections 
12
(a) and (b)) shall apply to a civil money 
13
penalty under this subparagraph in the 
14
same manner as such provisions apply to a 
15
penalty 
or 
proceeding 
under 
section 
16
1128A(a). 
17
‘‘(7) IMPLEMENTATION.—The Secretary shall 
18
implement this subsection through notice and com-
19
ment rulemaking. 
20
‘‘(8) DEFINITION
OF
REFUNDABLE
SINGLE- 
21
DOSE CONTAINER OR SINGLE-USE PACKAGE DRUG.— 
22
‘‘(A) IN GENERAL.—Except as provided in 
23
subparagraph (B), in this subsection, the term 
24
‘refundable single-dose container or single-use 
25
00:26 Apr 24, 2021
H19
13 
•HR 19 IH
package drug’ means a single source drug or bi-
1
ological (as defined in section 1847A(c)(6)(D)) 
2
or a biosimilar biological product (as defined in 
3
section 1847A(c)(6)(H)) for which payment is 
4
made under this part and that is furnished 
5
from a single-dose container or single-use pack-
6
age. 
7
‘‘(B) EXCLUSIONS.—The term ‘refundable 
8
single-dose container or single-use package 
9
drug’ does not include— 
10
‘‘(i) a drug or biological that is either 
11
a radiopharmaceutical or an imaging 
12
agent; 
13
‘‘(ii) a drug or biological approved by 
14
the Food and Drug Administration for 
15
which dosage and administration instruc-
16
tions included in the labeling require filtra-
17
tion during the drug preparation process, 
18
prior to dilution and administration, and 
19
require that any unused portion of such 
20
drug after the filtration process be dis-
21
carded after the completion of such filtra-
22
tion process; or 
23
‘‘(iii) a drug or biological approved by 
24
the Food and Drug Administration on or 
25
00:26 Apr 24, 2021
H19
14 
•HR 19 IH
after the date of enactment of this sub-
1
section and with respect to which payment 
2
has been made under this part for fewer 
3
than 18 months. 
4
‘‘(9) REPORT TO CONGRESS.—Not later than 3 
5
years after the date of enactment of this subsection, 
6
the Office of the Inspector General, after consulta-
7
tion with the Centers for Medicare & Medicaid Serv-
8
ices and the Food and Drug Administration, shall 
9
submit to the Committee on Energy and Commerce 
10
and the Committee on Ways and Means of the 
11
House of Representatives and the Committee on Fi-
12
nance in the Senate, a report on any impact this 
13
section is reported to have on the licensure, market 
14
entry, market retention, or marketing of biosimilar 
15
biological products. Such report shall be updated pe-
16
riodically at the direction of the Committee on En-
17
ergy and Commerce and the Committee on Ways 
18
and Means of the House of Representatives and the 
19
Committee on Finance in the Senate.’’. 
20
SEC. 103. PROVIDING FOR VARIATION IN PAYMENT FOR 
21
CERTAIN DRUGS COVERED UNDER PART B 
22
OF THE MEDICARE PROGRAM. 
23
(a) IN GENERAL.—Section 1847A(b) of the Social 
24
Security Act (42 U.S.C. 1395w–3a(b)) is amended— 
25
00:26 Apr 24, 2021
H19
15 
•HR 19 IH
(1) in paragraph (1)— 
1
(A) in subparagraph (A), by inserting after 
2
‘‘or 106 percent’’ the following: ‘‘(or, for a mul-
3
tiple source drug (other than autologous cellular 
4
immunotherapy) furnished on or after January 
5
1, 2022, the applicable percent specified in 
6
paragraph (9)(A) for the drug and quarter in-
7
volved)’’; and 
8
(B) in subparagraph (B) of paragraph (1), 
9
by inserting after ‘‘106 percent’’ the following: 
10
‘‘(or, for a single source drug or biological 
11
(other than autologous cellular immunotherapy) 
12
furnished on or after January 1, 2022, the ap-
13
plicable percent specified in paragraph (9)(A) 
14
for the drug or biological and quarter in-
15
volved)’’; and 
16
(2) by adding at the end the following new 
17
paragraph: 
18
‘‘(9) APPLICATION OF VARIABLE PERCENTAGES 
19
BASED
ON
PERCENTILE
RANKING
OF
PER
BENE-
20
FICIARY ALLOWED CHARGES.— 
21
‘‘(A) APPLICABLE
PERCENT
TO
BE
AP-
22
PLIED.— 
23
‘‘(i) IN GENERAL.—Subject to clauses 
24
(ii), with respect to a drug or biological 
25
00:26 Apr 24, 2021
H19
16 
•HR 19 IH
furnished in a calendar quarter beginning 
1
on or after January 1, 2022, if the Sec-
2
retary determines that the percentile rank 
3
of a drug or biological under subparagraph 
4
(B)(i)(III), with respect to per beneficiary 
5
allowed charges for all such drugs or 
6
biologicals, is— 
7
‘‘(I) at least equal to the 85th 
8
percentile, the applicable percent for 
9
the drug for such quarter under this 
10
subparagraph is 104 percent; 
11
‘‘(II) at least equal to the 70th 
12
percentile, but less than the 85th per-
13
centile, such applicable percent is 106 
14
percent; 
15
‘‘(III) at least equal to the 50th 
16
percentile, but less than the 70th per-
17
centile, such applicable percent is 108 
18
percent; or 
19
‘‘(IV) less than the 50th per-
20
centile, such applicable percent is 110 
21
percent. 
22
‘‘(ii) CASES WHERE DATA NOT SUFFI-
23
CIENTLY
AVAILABLE
TO
COMPUTE
PER 
24
BENEFICIARY
ALLOWED
CHARGES.—Sub-
25
00:26 Apr 24, 2021
H19
17 
•HR 19 IH
ject to clause (iii), in the case of a drug or 
1
biological furnished for which the amount 
2
of payment is determined under subpara-
3
graph (A) or (B) of paragraph (1) and not 
4
under subsection (c)(4), for calendar quar-
5
ters during a period in which data are not 
6
sufficiently available to compute a per ben-
7
eficiary allowed charges for the drug or bi-
8
ological, the applicable percent is 106 per-
9
cent. 
10
‘‘(B) DETERMINATION
OF
PERCENTILE 
11
RANK OF PER BENEFICIARY ALLOWED CHARGES 
12
OF DRUGS.— 
13
‘‘(i) IN GENERAL.—With respect to a 
14
calendar quarter beginning on or after 
15
January 1, 2022, for drugs and biologicals 
16
for which the amount of payment is deter-
17
mined under subparagraph (A) or (B) of 
18
paragraph 
(1), 
except 
for 
drugs 
or 
19
biologicals for which data are not suffi-
20
ciently available, the Secretary shall— 
21
‘‘(I) compute the per beneficiary 
22
allowed charges (as defined in sub-
23
paragraph (C)) for each such drug or 
24
biological; 
25
00:26 Apr 24, 2021
H19
18 
•HR 19 IH
‘‘(II) adjust such per beneficiary 
1
allowed charges for the quarter, to the 
2
extent provided under subparagraph 
3
(D); and 
4
‘‘(III) array such adjusted per 
5
beneficiary allowed charges for all 
6
such drugs or biologicals from high to 
7
low and rank such drugs or biologicals 
8
by percentile of such arrayed per ben-
9
eficiary allowed charges. 
10
‘‘(ii) 
FREQUENCY.—The 
Secretary 
11
shall make the computations under clause 
12
(i)(I) every 6 months (or, if necessary, as 
13
determined by the Secretary, every 9 or 12 
14
months) and such computations shall apply 
15
to succeeding calendar quarters until a 
16
new computation has been made. 
17
‘‘(iii) APPLICABLE
DATA
PERIOD.— 
18
For purposes of this paragraph, the term 
19
‘applicable data period’ means the most re-
20
cent period for which the data necessary 
21
for making the computations under clause 
22
(i) are available, as determined by the Sec-
23
retary. 
24
00:26 Apr 24, 2021
H19
19 
•HR 19 IH
‘‘(C) 
PER
BENEFICIARY
ALLOWED 
1
CHARGES
DEFINED.—In this paragraph, the 
2
term ‘per beneficiary allowed charges’ means, 
3
with respect to a drug or biological for which 
4
the amount of payment is determined under 
5
subparagraph (A) or (B) of paragraph (1)— 
6
‘‘(i) the allowed charges for the drug 
7
or biological for which payment is so made 
8
for the applicable data period, as estimated 
9
by the Secretary; divided by 
10
‘‘(ii) the number of individuals for 
11
whom any payment for the drug or biologi-
12
cal was made under paragraph (1) for the 
13
applicable data period, as estimated by the 
14
Secretary. 
15
‘‘(D) ADJUSTMENT TO REFLECT CHANGES 
16
IN
AVERAGE
SALES
PRICE.—In applying this 
17
paragraph for a particular calendar quarter, the 
18
Secretary shall adjust the per beneficiary al-
19
lowed charges for a drug or biological by multi-
20
plying such per beneficiary allowed charges 
21
under subparagraph (C) for the applicable data 
22
period by the ratio of— 
23
‘‘(i) the average sales price for the 
24
drug or biological for the most recent cal-
25
00:26 Apr 24, 2021
H19
20 
•HR 19 IH
endar quarter used under subsection 
1
(c)(5)(B); to 
2
‘‘(ii) the average sales price for the 
3
drug or biological for the calendar quarter 
4
(or the weighted average for the quarters 
5
involved) included in the applicable data 
6
period.’’. 
7
(b) APPLICATION
OF JUDICIAL REVIEW PROVI-
8
SIONS.—Section 1847A(g) of the Social Security Act is 
9
amended— 
10
(1) by striking ‘‘and’’ at the end of paragraph 
11
(4); 
12
(2) by striking the period at the end of para-
13
graph (5) and inserting ‘‘; and’’; and 
14
(3) by adding at the end the following new 
15
paragraph: 
16
‘‘(6) the determination of per beneficiary al-
17
lowed charges of drugs or biologicals and ranking of 
18
such charges under subsection (b)(9).’’. 
19
SEC. 104. ESTABLISHMENT OF MAXIMUM ADD-ON PAYMENT 
20
FOR DRUGS AND BIOLOGICALS. 
21
(a) IN GENERAL.—Section 1847A of the Social Secu-
22
rity Act (42 U.S.C. 1395w–3a), as amended by section 
23
103, is further amended— 
24
(1) in subsection (b)— 
25
00:26 Apr 24, 2021
H19
21 
•HR 19 IH
(A) in paragraph (1), in the matter pre-
1
ceding subparagraph (A), by striking ‘‘para-
2
graph (7)’’ and inserting ‘‘paragraphs (7) and 
3
(10)’’; and 
4
(B) by adding at the end the following new 
5
paragraph: 
6
‘‘(10) MAXIMUM ADD-ON PAYMENT AMOUNT.— 
7
‘‘(A) IN
GENERAL.—In determining the 
8
payment amount under the provisions of sub-
9
paragraph (A), (B), or (C) of paragraph (1) of 
10
this subsection, subsection (c)(4)(A)(ii), or sub-
11
section (d)(3)(C) for a drug or biological fur-
12
nished on or after January 1, 2022, if the ap-
13
plicable add-on payment (as defined in subpara-
14
graph (B)) for each drug or biological on a 
15
claim for a date of service exceeds the max-
16
imum add-on payment amount specified under 
17
subparagraph (C) for the drug or biological, 
18
then the payment amount otherwise determined 
19
for the drug or biological under those provi-
20
sions, as applicable, shall be reduced by the 
21
amount of such excess. 
22
‘‘(B) APPLICABLE ADD-ON PAYMENT DE-
23
FINED.—In this paragraph, the term ‘applicable 
24
add-on payment’ means the following amounts, 
25
00:26 Apr 24, 2021
H19
22 
•HR 19 IH
determined without regard to the application of 
1
subparagraph (A): 
2
‘‘(i) In the case of a multiple source 
3
drug, an amount equal to the difference 
4
between— 
5
‘‘(I) the amount that would oth-
6
erwise be applied under paragraph 
7
(1)(A); and 
8
‘‘(II) the amount that would be 
9
applied under such paragraph if ‘100 
10
percent’ were substituted for the ap-
11
plicable percent (as defined in para-
12
graph (9)) for such drug. 
13
‘‘(ii) In the case of a single source 
14
drug or biological, an amount equal to the 
15
difference between— 
16
‘‘(I) the amount that would oth-
17
erwise be applied under paragraph 
18
(1)(B); and 
19
‘‘(II) the amount that would be 
20
applied under such paragraph if ‘100 
21
percent’ were substituted for the ap-
22
plicable percent (as defined in para-
23
graph (9)) for such drug or biological. 
24
00:26 Apr 24, 2021
H19
23 
•HR 19 IH
‘‘(iii) In the case of a biosimilar bio-
1
logical product, the amount otherwise de-
2
termined under paragraph (8)(B). 
3
‘‘(iv) In the case of a drug or biologi-
4
cal during the initial period described in 
5
subsection (c)(4)(A), an amount equal to 
6
the difference between— 
7
‘‘(I) the amount that would oth-
8
erwise be applied under subsection 
9
(c)(4)(A)(ii); and 
10
‘‘(II) the amount that would be 
11
applied under such subsection if ‘100 
12
percent’ were substituted, as applica-
13
ble, for— 
14
‘‘(aa) ‘103 percent’ in sub-
15
clause (I) of such subsection; or 
16
‘‘(bb) any percent in excess 
17
of 100 percent applied under 
18
subclause (II) of such subsection. 
19
‘‘(v) In the case of a drug or biologi-
20
cal to which subsection (d)(3)(C) applies, 
21
an amount equal to the difference be-
22
tween— 
23
00:26 Apr 24, 2021
H19
24 
•HR 19 IH
‘‘(I) the amount that would oth-
1
erwise be applied under such sub-
2
section; and 
3
‘‘(II) the amount that would be 
4
applied under such subsection if ‘100 
5
percent’ were substituted, as applica-
6
ble, for— 
7
‘‘(aa) any percent in excess 
8
of 100 percent applied under 
9
clause (i) of such subsection; or 
10
‘‘(bb) ‘103 percent’ in clause 
11
(ii) of such subsection. 
12
‘‘(C) MAXIMUM ADD-ON PAYMENT AMOUNT 
13
SPECIFIED.—For purposes of subparagraph 
14
(A), the maximum add-on payment amount 
15
specified in this subparagraph is— 
16
‘‘(i) with respect to a drug or biologi-
17
cal 
(other 
than 
autologous 
cellular 
18
immunotherapy)— 
19
‘‘(I) for each of 2022 through 
20
2029, $1,000; and 
21
‘‘(II) for a subsequent year, the 
22
amount specified in this subparagraph 
23
for the preceding year increased by 
24
the percentage increase in the con-
25
00:26 Apr 24, 2021
H19
25 
•HR 19 IH
sumer price index for all urban con-
1
sumers (all items; United States city 
2
average) for the 12-month period end-
3
ing with June of the previous year; or 
4
‘‘(ii) with respect to a drug or biologi-
5
cal 
consisting 
of 
autologous 
cellular 
6
immunotherapy— 
7
‘‘(I) for each of 2022 through 
8
2029, $2,000; and 
9
‘‘(II) for a subsequent year, the 
10
amount specified in this subparagraph 
11
for the preceding year increased by 
12
the percentage increase in the con-
13
sumer price index for all urban con-
14
sumers (all items; United States city 
15
average) for the 12-month period end-
16
ing with June of the previous year. 
17
Any amount determined under this subpara-
18
graph that is not a multiple of $10 shall be 
19
rounded to the nearest multiple of $10.’’; and 
20
(2) in subsection (c)(4)(A)(ii), by striking ‘‘in 
21
the case’’ and inserting ‘‘subject to subsection 
22
(b)(10), in the case’’. 
23
(b) CONFORMING AMENDMENTS RELATING TO SEPA-
24
RATELY PAYABLE DRUGS.— 
25
00:26 Apr 24, 2021
H19
26 
•HR 19 IH
(1) OPPS.—Section 1833(t)(14) of the Social 
1
Security Act (42 U.S.C. 1395l(t)(14)) is amended— 
2
(A) in subparagraph (A)(iii)(II), by insert-
3
ing ‘‘, subject to subparagraph (I)’’ after ‘‘are 
4
not available’’; and 
5
(B) by adding at the end the following new 
6
subparagraph: 
7
‘‘(I) APPLICATION
OF
MAXIMUM
ADD-ON 
8
PAYMENT
FOR
SEPARATELY
PAYABLE
DRUGS 
9
AND BIOLOGICALS.—In establishing the amount 
10
of payment under subparagraph (A) for a speci-
11
fied covered outpatient drug that is furnished 
12
as part of a covered OPD service (or group of 
13
services) on or after January 1, 2022, if such 
14
payment is determined based on the average 
15
price for the year established under section 
16
1847A pursuant to clause (iii)(II) of such sub-
17
paragraph, the provisions of subsection (b)(10) 
18
of section 1847A shall apply to the amount of 
19
payment so established in the same manner as 
20
such provisions apply to the amount of payment 
21
under section 1847A.’’. 
22
(2) ASC.—Section 1833(i)(2)(D) of the Social 
23
Security Act (42 U.S.C. 1395l(i)(2)(D)) is amend-
24
ed— 
25
00:26 Apr 24, 2021
H19
27 
•HR 19 IH
(A) by moving clause (v) 6 ems to the left; 
1
(B) by redesignating clause (vi) as clause 
2
(vii); and 
3
(C) by inserting after clause (v) the fol-
4
lowing new clause: 
5
‘‘(vi) If there is a separate payment 
6
under the system described in clause (i) for 
7
a drug or biological furnished on or after 
8
January 1, 2022, the provisions of sub-
9
section (t)(14)(I) shall apply to the estab-
10
lishment of the amount of payment for the 
11
drug or biological under such system in the 
12
same manner in which such provisions 
13
apply to the establishment of the amount 
14
of payment under subsection (t)(14)(A).’’. 
15
SEC. 105. TREATMENT OF DRUG ADMINISTRATION SERV-
16
ICES FURNISHED BY CERTAIN EXCEPTED 
17
OFF-CAMPUS OUTPATIENT DEPARTMENTS OF 
18
A PROVIDER. 
19
Section 1833(t)(16) of the Social Security Act (42 
20
U.S.C. 1395l(t)(16)) is amended by adding at the end the 
21
following new subparagraph: 
22
‘‘(G) SPECIAL PAYMENT RULE FOR DRUG 
23
ADMINISTRATION SERVICES FURNISHED BY AN 
24
EXCEPTED DEPARTMENT OF A PROVIDER.— 
25
00:26 Apr 24, 2021
H19
28 
•HR 19 IH
‘‘(i) IN GENERAL.—In the case of a 
1
covered OPD service that is a drug admin-
2
istration service (as defined by the Sec-
3
retary) furnished by a department of a 
4
provider described in clause (ii) or (iv) of 
5
paragraph (21)(B), the payment amount 
6
for such service furnished on or after Jan-
7
uary 1, 2022, shall be the same payment 
8
amount (as determined in paragraph 
9
(21)(C)) that would apply if the drug ad-
10
ministration service was furnished by an 
11
off-campus outpatient department of a pro-
12
vider (as defined in paragraph (21)(B)). 
13
‘‘(ii) APPLICATION WITHOUT REGARD 
14
TO BUDGET NEUTRALITY.—The reductions 
15
made under this subparagraph— 
16
‘‘(I) shall not be considered an 
17
adjustment under paragraph (2)(E); 
18
and 
19
‘‘(II) shall not be implemented in 
20
a budget neutral manner.’’. 
21
00:26 Apr 24, 2021
H19
29 
•HR 19 IH
Subtitle B—Drug Price 
1
Transparency 
2
SEC. 111. REPORTING ON EXPLANATION FOR DRUG PRICE 
3
INCREASES. 
4
(a) IN GENERAL.—Title III of the Public Health 
5
Service Act (42 U.S.C. 241 et seq.) is amended by adding 
6
at the end the following: 
7
‘‘PART W—DRUG PRICE REPORTING; DRUG 
8
VALUE FUND 
9
‘‘SEC. 399OO. REPORTING ON EXPLANATION FOR DRUG 
10
PRICE INCREASES. 
11
‘‘(a) DEFINITIONS.—In this section: 
12
‘‘(1) MANUFACTURER.—The term ‘manufac-
13
turer’ means the person— 
14
‘‘(A) that holds the application for a drug 
15
approved under section 505 of the Federal 
16
Food, Drug, and Cosmetic Act or licensed 
17
under section 351 of this Act; or 
18
‘‘(B) who is responsible for setting the 
19
wholesale acquisition cost for the drug. 
20
‘‘(2) QUALIFYING DRUG.—The term ‘qualifying 
21
drug’ means any drug that is approved under sub-
22
section (c) or (j) of section 505 of the Federal Food, 
23
Drug, and Cosmetic Act or licensed under subsection 
24
(a) or (k) of section 351 of this Act— 
25
00:26 Apr 24, 2021
H19
30 
•HR 19 IH
‘‘(A) that has a wholesale acquisition cost 
1
of $100 or more, adjusted for inflation occur-
2
ring after the date of enactment of this section, 
3
for a month’s supply or a typical course of 
4
treatment that lasts less than a month, and 
5
is— 
6
‘‘(i) subject to section 503(b)(1) of 
7
the Federal Food, Drug, and Cosmetic 
8
Act; 
9
‘‘(ii) administered or otherwise dis-
10
pensed to treat a disease or condition af-
11
fecting more than 200,000 persons in the 
12
United States; and 
13
‘‘(iii) not a vaccine; and 
14
‘‘(B) for which, during the previous cal-
15
endar year, at least 1 dollar of the total amount 
16
of sales were for individuals enrolled under the 
17
Medicare program under title XVIII of the So-
18
cial Security Act (42 U.S.C. 1395 et seq.) or 
19
under a State Medicaid plan under title XIX of 
20
such Act (42 U.S.C. 1396 et seq.) or under a 
21
waiver of such plan. 
22
‘‘(3) WHOLESALE
ACQUISITION
COST.—The 
23
term ‘wholesale acquisition cost’ has the meaning 
24
00:26 Apr 24, 2021
H19
31 
•HR 19 IH
given that term in section 1847A(c)(6)(B) of the So-
1
cial Security Act (42 U.S.C. 1395w–3a(c)(6)(B)). 
2
‘‘(b) REPORT.— 
3
‘‘(1) REPORT REQUIRED.—The manufacturer of 
4
a qualifying drug shall submit a report to the Sec-
5
retary for each increase in the price of a qualifying 
6
drug that results in an increase in the wholesale ac-
7
quisition cost of that drug that is equal to— 
8
‘‘(A) 10 percent or more within a single 
9
calendar year beginning on or after January 1, 
10
2021; or 
11
‘‘(B) 25 percent or more within three con-
12
secutive calendar years for which the first such 
13
calendar year begins on or after January 1, 
14
2021. 
15
‘‘(2) REPORT
DEADLINE.—Each report de-
16
scribed in paragraph (1) shall be submitted to the 
17
Secretary— 
18
‘‘(A) in the case of a report with respect 
19
to an increase in the price of a qualifying drug 
20
that occurs during the period beginning on Jan-
21
uary 1, 2021, and ending on the day that is 60 
22
days after the date of enactment of this section, 
23
not later than 90 days after such date of enact-
24
ment; and 
25
00:26 Apr 24, 2021
H19
32 
•HR 19 IH
‘‘(B) in the case of a report with respect 
1
to an increase in the price of a qualifying drug 
2
that occurs after the period described in sub-
3
paragraph (A), not later than 30 days prior to 
4
the planned effective date of such price increase 
5
for such qualifying drug. 
6
‘‘(c) CONTENTS.—A report under subsection (b), con-
7
sistent with the standard for disclosures described in sec-
8
tion 213.3(d) of title 12, Code of Federal Regulations (as 
9
in effect on the date of enactment of this section), shall, 
10
at a minimum, include— 
11
‘‘(1) with respect to the qualifying drug— 
12
‘‘(A) the percentage by which the manufac-
13
turer will raise the wholesale acquisition cost of 
14
the drug within the calendar year or three con-
15
secutive calendar years as described in sub-
16
section (b)(1)(A) or (b)(1)(B), if applicable, and 
17
the effective date of such price increase; 
18
‘‘(B) an explanation for, and description 
19
of, each price increase for such drug that will 
20
occur during the calendar year period described 
21
in subsection (b)(1)(A) or the three consecutive 
22
calendar year period described in subsection 
23
(b)(1)(B), as applicable; 
24
00:26 Apr 24, 2021
H19
33 
•HR 19 IH
‘‘(C) if known and different from the man-
1
ufacturer of the qualifying drug, the identity 
2
of— 
3
‘‘(i) the sponsor or sponsors of any in-
4
vestigational new drug applications under 
5
section 505(i) of the Federal Food, Drug, 
6
and Cosmetic Act for clinical investigations 
7
with respect to such drug, for which the 
8
full reports are submitted as part of the 
9
application— 
10
‘‘(I) for approval of the drug 
11
under section 505 of such Act; or 
12
‘‘(II) for licensure of the drug 
13
under section 351 of this Act; and 
14
‘‘(ii) the sponsor of an application for 
15
the drug approved under such section 505 
16
of the Federal Food, Drug, and Cosmetic 
17
Act or licensed under section 351 of this 
18
Act; 
19
‘‘(D) a description of the history of the 
20
manufacturer’s price increases for the drug 
21
since the approval of the application for the 
22
drug under section 505 of the Federal Food, 
23
Drug, and Cosmetic Act or the issuance of the 
24
license for the drug under section 351 of this 
25
00:26 Apr 24, 2021
H19
34 
•HR 19 IH
Act, or since the manufacturer acquired such 
1
approved application or license, if applicable; 
2
‘‘(E) the current wholesale acquisition cost 
3
of the drug; 
4
‘‘(F) the total expenditures of the manu-
5
facturer on— 
6
‘‘(i) materials and manufacturing for 
7
such drug; and 
8
‘‘(ii) acquiring patents and licensing 
9
for such drug; 
10
‘‘(G) the percentage of total expenditures 
11
of the manufacturer on research and develop-
12
ment for such drug that was derived from Fed-
13
eral funds; 
14
‘‘(H) the total expenditures of the manu-
15
facturer on research and development for such 
16
drug that is necessary to demonstrate that it 
17
meets applicable statutory standards for ap-
18
proval under section 505 of the Federal Food, 
19
Drug, and Cosmetic Act or licensure under sec-
20
tion 351 of this Act, as applicable; 
21
‘‘(I) the total expenditures of the manufac-
22
turer on pursuing new or expanded indications 
23
or dosage changes for such drug under section 
24
00:26 Apr 24, 2021
H19
35 
•HR 19 IH
505 of the Federal Food, Drug, and Cosmetic 
1
Act or section 351 of this Act; 
2
‘‘(J) the total expenditures of the manufac-
3
turer on carrying out postmarket requirements 
4
related to such drug, including under section 
5
505(o)(3) of the Federal Food, Drug, and Cos-
6
metic Act; 
7
‘‘(K) the total revenue and the net profit 
8
generated from the qualifying drug for each cal-
9
endar year since the approval of the application 
10
for the drug under section 505 of the Federal 
11
Food, Drug, and Cosmetic Act or the issuance 
12
of the license for the drug under section 351, 
13
or since the manufacturer acquired such ap-
14
proved application or license; and 
15
‘‘(L) the total costs associated with mar-
16
keting and advertising for the qualifying drug; 
17
‘‘(2) with respect to the manufacturer— 
18
‘‘(A) the total revenue and the net profit 
19
of the manufacturer for each of the 1-year pe-
20
riod described in subsection (b)(1)(A) or the 3- 
21
year period described in subsection (b)(1)(B), 
22
as applicable; 
23
‘‘(B) all stock-based performance metrics 
24
used by the manufacturer to determine execu-
25
00:26 Apr 24, 2021
H19
36 
•HR 19 IH
tive compensation for each of the 1-year period 
1
described in subsection (b)(1)(A) or the 3-year 
2
period described in subsection (b)(1)(B), as ap-
3
plicable; and 
4
‘‘(C) any additional information the manu-
5
facturer chooses to provide related to drug pric-
6
ing decisions, such as total expenditures on— 
7
‘‘(i) drug research and development; 
8
or 
9
‘‘(ii) clinical trials, including on drugs 
10
that failed to receive approval by the Food 
11
and Drug Administration; and 
12
‘‘(3) such other related information as the Sec-
13
retary considers appropriate and as specified by the 
14
Secretary through notice-and-comment rulemaking. 
15
‘‘(d) INFORMATION PROVIDED.—The manufacturer 
16
of a qualifying drug that is required to submit a report 
17
under subsection (b), shall ensure that such report and 
18
any explanation for, and description of, each price increase 
19
described in subsection (c)(1)(B) shall be truthful, not 
20
misleading, and accurate. 
21
‘‘(e) CIVIL MONETARY PENALTY.—Any manufac-
22
turer of a qualifying drug that fails to submit a report 
23
for the drug as required by this section, following notifica-
24
tion by the Secretary to the manufacturer that the manu-
25
00:26 Apr 24, 2021
H19
37 
•HR 19 IH
facturer is not in compliance with this section, shall be 
1
subject to a civil monetary penalty of $75,000 for each 
2
day on which the violation continues. 
3
‘‘(f) FALSE INFORMATION.—Any manufacturer that 
4
submits a report for a drug as required by this section 
5
that knowingly provides false information in such report 
6
is subject to a civil monetary penalty in an amount not 
7
to exceed $75,000 for each item of false information. 
8
‘‘(g) PUBLIC POSTING.— 
9
‘‘(1) IN GENERAL.—Subject to paragraph (3), 
10
the Secretary shall post each report submitted under 
11
subsection (b) on the public website of the Depart-
12
ment of Health and Human Services the day the 
13
price increase of a qualifying drug is scheduled to go 
14
into effect. 
15
‘‘(2) FORMAT.—In developing the format in 
16
which reports will be publicly posted under para-
17
graph (1), the Secretary shall consult with stake-
18
holders, including beneficiary groups, and shall seek 
19
feedback from consumer advocates and readability 
20
experts on the format and presentation of the con-
21
tent of such reports to ensure that such reports 
22
are— 
23
‘‘(A) user-friendly to the public; and 
24
00:26 Apr 24, 2021
H19
38 
•HR 19 IH
‘‘(B) written in plain language that con-
1
sumers can readily understand. 
2
‘‘(3) PROTECTED
INFORMATION.—Nothing in 
3
this section shall be construed to authorize the pub-
4
lic disclosure of information submitted by a manu-
5
facturer that is prohibited from disclosure by appli-
6
cable laws concerning the protection of trade secrets, 
7
commercial information, and other information cov-
8
ered under such laws. 
9
‘‘SEC. 399OO–1. ANNUAL REPORT TO CONGRESS. 
10
‘‘(a) IN GENERAL.—Subject to subsection (b), the 
11
Secretary shall submit to Congress, and post on the public 
12
website of the Department of Health and Human Services 
13
in a way that is user-friendly to the public and written 
14
in plain language that consumers can readily understand, 
15
an annual report— 
16
‘‘(1) summarizing the information reported pur-
17
suant to section 399OO; 
18
‘‘(2) including copies of the reports and sup-
19
porting detailed economic analyses submitted pursu-
20
ant to such section; 
21
‘‘(3) detailing the costs and expenditures in-
22
curred by the Department of Health and Human 
23
Services in carrying out section 399OO; and 
24
00:26 Apr 24, 2021
H19
39 
•HR 19 IH
‘‘(4) explaining how the Department of Health 
1
and Human Services is improving consumer and 
2
provider information about drug value and drug 
3
price transparency. 
4
‘‘(b) PROTECTED INFORMATION.—Nothing in this 
5
section shall be construed to authorize the public disclo-
6
sure of information submitted by a manufacturer that is 
7
prohibited from disclosure by applicable laws concerning 
8
the protection of trade secrets, commercial information, 
9
and other information covered under such laws.’’. 
10
(b) EFFECTIVE DATE.—The amendment made by 
11
subsection (a) takes effect on the date of enactment of 
12
this Act. 
13
SEC. 112. PUBLIC DISCLOSURE OF DRUG DISCOUNTS. 
14
Section 1150A of the Social Security Act (42 U.S.C. 
15
1320b–23) is amended— 
16
(1) in subsection (c), in the matter preceding 
17
paragraph (1), by inserting ‘‘(other than as per-
18
mitted under subsection (e))’’ after ‘‘disclosed by the 
19
Secretary’’; and 
20
(2) by adding at the end the following new sub-
21
section: 
22
‘‘(e) PUBLIC AVAILABILITY OF CERTAIN INFORMA-
23
TION.— 
24
00:26 Apr 24, 2021
H19
40 
•HR 19 IH
‘‘(1) IN GENERAL.—In order to allow the com-
1
parison of PBMs’ ability to negotiate rebates, dis-
2
counts, direct and indirect remuneration fees, ad-
3
ministrative fees, and price concessions and the 
4
amount of such rebates, discounts, direct and indi-
5
rect remuneration fees, administrative fees, and 
6
price concessions that are passed through to plan 
7
sponsors, beginning January 1, 2022, the Secretary 
8
shall make available on the Internet website of the 
9
Department of Health and Human Services the in-
10
formation with respect to the second preceding cal-
11
endar year provided to the Secretary on generic dis-
12
pensing rates (as described in paragraph (1) of sub-
13
section (b)) and information provided to the Sec-
14
retary under paragraphs (2) and (3) of such sub-
15
section that, as determined by the Secretary, is with 
16
respect to each PBM. 
17
‘‘(2) AVAILABILITY OF DATA.—In carrying out 
18
paragraph (1), the Secretary shall ensure the fol-
19
lowing: 
20
‘‘(A) CONFIDENTIALITY.—The information 
21
described in such paragraph is displayed in a 
22
manner that prevents the disclosure of informa-
23
tion, with respect to an individual drug or an 
24
individual plan, on rebates, discounts, direct 
25
00:26 Apr 24, 2021
H19
41 
•HR 19 IH
and indirect remuneration fees, administrative 
1
fees, and price concessions. 
2
‘‘(B) CLASS OF DRUG.—The information 
3
described in such paragraph is made available 
4
by class of drug, using an existing classification 
5
system, but only if the class contains such num-
6
ber of drugs, as specified by the Secretary (but 
7
not fewer than three drugs), to ensure confiden-
8
tiality of proprietary information or other infor-
9
mation that is prevented to be disclosed under 
10
subparagraph (A).’’. 
11
SEC. 113. STUDY OF PHARMACEUTICAL SUPPLY CHAIN 
12
INTERMEDIARIES AND MERGER ACTIVITY. 
13
(a) INITIAL REPORT.—Not later than 1 year after 
14
the date of enactment of this Act, the Commission shall 
15
submit to the appropriate committees of Congress a report 
16
that— 
17
(1) addresses at minimum— 
18
(A) whether pharmacy benefit managers— 
19
(i) charge payers a higher price than 
20
the reimbursement rate at which the phar-
21
macy benefit managers reimburse com-
22
peting pharmacies; 
23
(ii) steer patients for anticompetitive 
24
purposes to any pharmacies, including re-
25
00:26 Apr 24, 2021
H19
42 
•HR 19 IH
tail, mail-order, or any other type of phar-
1
macy, in which the pharmacy benefit man-
2
ager has an ownership interest; 
3
(iii) audit or review proprietary data, 
4
including acquisition costs, patient infor-
5
mation, or dispensing information, of com-
6
peting pharmacies that can be used for 
7
anticompetitive purposes; or 
8
(iv) use formulary designs to increase 
9
the market share of higher cost prescrip-
10
tion drugs and depress the market share of 
11
lower cost prescription drugs (each net of 
12
rebates and discounts); 
13
(B) how companies and payers assess the 
14
benefits, costs, and risks of contracting with 
15
intermediaries, including pharmacy services ad-
16
ministrative organizations, and whether more 
17
information about the roles of intermediaries 
18
should be available to consumers and payers; 
19
and 
20
(C) whether there are any specific legal or 
21
regulatory obstacles the Commission currently 
22
faces in ensuring a competitive and transparent 
23
marketplace in the pharmaceutical supply 
24
chain, including the pharmacy benefit manager 
25
00:26 Apr 24, 2021
H19
43 
•HR 19 IH
marketplace and pharmacy services administra-
1
tive organizations; and 
2
(2) provides— 
3
(A) observations or conclusions drawn 
4
from the November 2017 roundtable entitled 
5
‘‘Understanding Competition in Prescription 
6
Drug Markets: Entry and Supply Chain Dy-
7
namics’’, and any similar efforts; 
8
(B) specific actions the Commission in-
9
tends to take as a result of the November 2017 
10
roundtable, and any similar efforts, including a 
11
detailed description of relevant forthcoming ac-
12
tions, additional research or roundtable discus-
13
sions, consumer education efforts, or enforce-
14
ment actions; and 
15
(C) policy or legislative recommendations 
16
to— 
17
(i) improve transparency and competi-
18
tion in the pharmaceutical supply chain; 
19
(ii) prevent and deter anticompetitive 
20
behavior in the pharmaceutical supply 
21
chain; and 
22
(iii) best ensure that consumers ben-
23
efit from any cost savings or efficiencies 
24
00:26 Apr 24, 2021
H19
44 
•HR 19 IH
that may result from mergers and consoli-
1
dations. 
2
(b) INTERIM REPORT.—Not later than 180 days 
3
after the date of enactment of this Act, the Commission 
4
shall submit to the appropriate committees of Congress 
5
an interim report on the progress of the report required 
6
by subsection (a), along with preliminary findings and 
7
conclusions based on information collected to that date. 
8
(c) DEFINITIONS.—In this section: 
9
(1) 
APPROPRIATE
COMMITTEES
OF
CON-
10
GRESS.—The term ‘‘appropriate committees of Con-
11
gress’’ means— 
12
(A) the Committee on Energy and Com-
13
merce of the House of Representatives; 
14
(B) the Committee on the Judiciary of the 
15
Senate; and 
16
(C) the Committee on the Judiciary of the 
17
House of Representatives. 
18
(2) COMMISSION.—The term ‘‘Commission’’ 
19
means the Federal Trade Commission. 
20
00:26 Apr 24, 2021
H19
45 
•HR 19 IH
SEC. 114. MAKING PRESCRIPTION DRUG MARKETING SAM-
1
PLE INFORMATION REPORTED BY MANUFAC-
2
TURERS AVAILABLE TO CERTAIN INDIVID-
3
UALS AND ENTITIES. 
4
(a) IN GENERAL.—Section 1128H of the Social Secu-
5
rity Act (42 U.S.C. 1320a–7i) is amended— 
6
(1) by redesignating subsection (b) as sub-
7
section (e); and 
8
(2) by inserting after subsection (a) the fol-
9
lowing new subsections: 
10
‘‘(b) DATA SHARING AGREEMENTS.— 
11
‘‘(1) IN GENERAL.—The Secretary shall enter 
12
into agreements with the specified data sharing indi-
13
viduals and entities described in paragraph (2) 
14
under which— 
15
‘‘(A) upon request of such an individual or 
16
entity, as applicable, the Secretary makes avail-
17
able to such individual or entity the information 
18
submitted under subsection (a) by manufactur-
19
ers and authorized distributors of record; and 
20
‘‘(B) such individual or entity agrees to 
21
not disclose publicly or to another individual or 
22
entity any information that identifies a par-
23
ticular practitioner or health care facility. 
24
‘‘(2) SPECIFIED
DATA
SHARING
INDIVIDUALS 
25
AND ENTITIES.—For purposes of paragraph (1), the 
26
00:26 Apr 24, 2021
H19
46 
•HR 19 IH
specified data sharing individuals and entities de-
1
scribed in this paragraph are the following: 
2
‘‘(A) OVERSIGHT AGENCIES.—Health over-
3
sight agencies (as defined in section 164.501 of 
4
title 45, Code of Federal Regulations), includ-
5
ing the Centers for Medicare & Medicaid Serv-
6
ices, the Office of the Inspector General of the 
7
Department of Health and Human Services, the 
8
Government Accountability Office, the Congres-
9
sional Budget Office, the Medicare Payment 
10
Advisory Commission, and the Medicaid and 
11
CHIP Payment and Access Commission. 
12
‘‘(B) 
RESEARCHERS.—Individuals 
who 
13
conduct scientific research (as defined in sec-
14
tion 164.501 of title 45, Code of Federal Regu-
15
lations) in relevant areas as determined by the 
16
Secretary. 
17
‘‘(C) PAYERS.—Private and public health 
18
care payers, including group health plans, 
19
health insurance coverage offered by health in-
20
surance issuers, Federal health programs, and 
21
State health programs. 
22
‘‘(3) EXEMPTION FROM FREEDOM OF INFORMA-
23
TION ACT.—Except as described in paragraph (1), 
24
the Secretary may not be compelled to disclose the 
25
00:26 Apr 24, 2021
H19
47 
•HR 19 IH
information submitted under subsection (a) to any 
1
individual or entity. For purposes of section 552 of 
2
title 5, United States Code (commonly referred to as 
3
the Freedom of Information Act), this paragraph 
4
shall be considered a statute described in subsection 
5
(b)(3)(B) of such section. 
6
‘‘(c) PENALTIES.— 
7
‘‘(1) DATA SHARING AGREEMENTS.—Subject to 
8
paragraph (3), any specified data sharing individual 
9
or entity described in subsection (b)(2) that violates 
10
the terms of a data sharing agreement the individual 
11
or entity has with the Secretary under subsection 
12
(b)(1) shall be subject to a civil money penalty of 
13
not less than $1,000, but not more than $10,000, 
14
for each such violation. Such penalty shall be im-
15
posed and collected in the same manner as civil 
16
money penalties under subsection (a) of section 
17
1128A are imposed and collected under that section. 
18
‘‘(2) FAILURE TO REPORT.—Subject to para-
19
graph (3), any manufacturer or authorized dis-
20
tributor of record of an applicable drug under sub-
21
section (a) that fails to submit information required 
22
under such subsection in a timely manner in accord-
23
ance with rules or regulations promulgated to carry 
24
out such subsection shall be subject to a civil money 
25
00:26 Apr 24, 2021
H19
48 
•HR 19 IH
penalty of not less than $1,000, but not more than 
1
$10,000, for each such failure. Such penalty shall be 
2
imposed and collected in the same manner as civil 
3
money penalties under subsection (a) of section 
4
1128A are imposed and collected under that section. 
5
‘‘(3) LIMITATION.—The total amount of civil 
6
money penalties imposed under paragraph (1) or (2) 
7
with respect to a year and an individual or entity de-
8
scribed in paragraph (1) or a manufacturer or dis-
9
tributor described in paragraph (2), respectively, 
10
shall not exceed $150,000. 
11
‘‘(d) DRUG SAMPLE DISTRIBUTION INFORMATION.— 
12
‘‘(1) IN GENERAL.—Not later than January 1 
13
of each year (beginning with 2022), the Secretary 
14
shall maintain a list containing information related 
15
to the distribution of samples of applicable drugs. 
16
Such list shall provide the following information with 
17
respect to the preceding year: 
18
‘‘(A) The name of the manufacturer or au-
19
thorized distributor of record of an applicable 
20
drug for which samples were requested or dis-
21
tributed under this section. 
22
‘‘(B) The quantity and class of drug sam-
23
ples requested. 
24
00:26 Apr 24, 2021
H19
49 
•HR 19 IH
‘‘(C) The quantity and class of drug sam-
1
ples distributed. 
2
‘‘(2) PUBLIC
AVAILABILITY.—The Secretary 
3
shall make the information in such list available to 
4
the public on the Internet website of the Food and 
5
Drug Administration.’’. 
6
(b) FDA MAINTENANCE
OF INFORMATION.—The 
7
Food and Drug Administration shall maintain information 
8
available to affected reporting companies to ensure their 
9
ability to fully comply with the requirements of section 
10
1128H of the Social Security Act. 
11
(c) PROHIBITION ON DISTRIBUTION OF SAMPLES OF 
12
OPIOIDS.—Section 503(d) of the Federal Food, Drug, and 
13
Cosmetic Act (21 U.S.C. 353(d)) is amended— 
14
(1) by moving the margin of paragraph (4) 2 
15
ems to the left; and 
16
(2) by adding at the end the following: 
17
‘‘(5) No person may distribute a drug sample of a 
18
drug that is— 
19
‘‘(A) an applicable drug (as defined in section 
20
1128H(e) of the Social Security Act); 
21
‘‘(B) a controlled substance (as defined in sec-
22
tion 102 of the Controlled Substances Act) for which 
23
the findings required under section 202(b)(2) of 
24
such Act have been made; and 
25
00:26 Apr 24, 2021
H19
50 
•HR 19 IH
‘‘(C) approved under section 505 for use in the 
1
management or treatment of pain (other than for 
2
the management or treatment of a substance use 
3
disorder).’’. 
4
(d) MEDPAC REPORT.—Not later than 3 years after 
5
the date of the enactment of this Act, the Medicare Pay-
6
ment Advisory Commission shall conduct a study on the 
7
impact of drug samples on provider prescribing practices 
8
and health care costs and may, as the Commission deems 
9
appropriate, make recommendations on such study. 
10
SEC. 115. SENSE OF CONGRESS REGARDING THE NEED TO 
11
EXPAND COMMERCIALLY AVAILABLE DRUG 
12
PRICING COMPARISON PLATFORMS. 
13
It is the sense of Congress that— 
14
(1) commercially available drug pricing com-
15
parison platforms can, at no cost, help patients find 
16
the lowest price for their medications at their local 
17
pharmacy; 
18
(2) such platforms should be integrated, to the 
19
maximum extent possible, in the health care delivery 
20
ecosystem; and 
21
(3) pharmacy benefit managers should work to 
22
disclose generic and brand name drug prices to such 
23
platforms to ensure that— 
24
00:26 Apr 24, 2021
H19
51 
•HR 19 IH
(A) patients can benefit from the lowest 
1
possible price available to them; and 
2
(B) overall drug prices can be reduced as 
3
more educated purchasing decisions are made 
4
based on price transparency. 
5
Subtitle C—Medicare Part D 
6
Benefit Redesign 
7
SEC. 121. MEDICARE PART D BENEFIT REDESIGN. 
8
(a) 
BENEFIT
STRUCTURE
REDESIGN.—Section 
9
1860D–2(b) of the Social Security Act (42 U.S.C. 1395w– 
10
102(b)) is amended— 
11
(1) in paragraph (2)— 
12
(A) in subparagraph (A)— 
13
(i) in the matter preceding clause (i), 
14
by inserting ‘‘for a year preceding 2022 
15
and for costs above the annual deductible 
16
specified in paragraph (1) and up to the 
17
annual out-of-pocket threshold specified in 
18
paragraph (4)(B) for 2022 and each subse-
19
quent year’’ after ‘‘paragraph (3)’’; 
20
(ii) in clause (i), by inserting after 
21
‘‘25 percent’’ the following: ‘‘(or, for 2022 
22
and each subsequent year, 15 percent)’’; 
23
and 
24
00:26 Apr 24, 2021
H19
52 
•HR 19 IH
(iii) in clause (ii), by inserting ‘‘(or, 
1
for 2022 and each subsequent year, 15 
2
percent)’’ after ‘‘25 percent’’; 
3
(B) in subparagraph (C)— 
4
(i) in clause (i), in the matter pre-
5
ceding subclause (I), by inserting ‘‘for a 
6
year preceding 2022,’’ after ‘‘paragraph 
7
(4),’’; and 
8
(ii) in clause (ii)(III), by striking 
9
‘‘and each subsequent year’’ and inserting 
10
‘‘and 2021’’; and 
11
(C) in subparagraph (D)— 
12
(i) in clause (i)— 
13
(I) in the matter preceding sub-
14
clause (I), by inserting ‘‘for a year 
15
preceding 2022,’’ after ‘‘paragraph 
16
(4),’’; and 
17
(II) in subclause (I)(bb), by 
18
striking ‘‘a year after 2018’’ and in-
19
serting ‘‘each of years 2018 through 
20
2021’’; and 
21
(ii) in clause (ii)(V), by striking 
22
‘‘2019 and each subsequent year’’ and in-
23
serting ‘‘each of years 2019 through 
24
2021’’; 
25
00:26 Apr 24, 2021
H19
53 
•HR 19 IH
(2) in paragraph (3)(A)— 
1
(A) in the matter preceding clause (i), by 
2
inserting ‘‘for a year preceding 2022,’’ after 
3
‘‘and (4),’’; and 
4
(B) in clause (ii), by striking ‘‘for a subse-
5
quent year’’ and inserting ‘‘for each of years 
6
2007 through 2021’’; 
7
(3) in paragraph (4)— 
8
(A) in subparagraph (A)— 
9
(i) in clause (i)— 
10
(I) by redesignating subclauses 
11
(I) and (II) as items (aa) and (bb), 
12
respectively, and indenting appro-
13
priately; 
14
(II) in the matter preceding item 
15
(aa), as redesignated by subclause (I), 
16
by striking ‘‘is equal to the greater 
17
of—’’ and inserting ‘‘is equal to— 
18
‘‘(I) for a year preceding 2022, 
19
the greater of—’’; 
20
(III) by striking the period at the 
21
end of item (bb), as redesignated by 
22
subclause (I), and inserting ‘‘; and’’; 
23
and 
24
00:26 Apr 24, 2021
H19
54 
•HR 19 IH
(IV) by adding at the end the fol-
1
lowing: 
2
‘‘(II) for 2022 and each suc-
3
ceeding year, $0.’’; and 
4
(ii) in clause (ii)— 
5
(I) by striking ‘‘clause (i)(I)’’ and 
6
inserting ‘‘clause (i)(I)(aa)’’; and 
7
(II) by adding at the end the fol-
8
lowing new sentence: ‘‘The Secretary 
9
shall continue to calculate the dollar 
10
amounts specified in clause (i)(I)(aa), 
11
including with the adjustment under 
12
this clause, after 2021 for purposes of 
13
section 1860D–14(a)(1)(D)(iii).’’; 
14
(B) in subparagraph (B)— 
15
(i) in clause (i)— 
16
(I) in subclause (V), by striking 
17
‘‘or’’ at the end; 
18
(II) in subclause (VI)— 
19
(aa) by striking ‘‘for a sub-
20
sequent year’’ and inserting ‘‘for 
21
2021’’; and 
22
(bb) by striking the period 
23
at the end and inserting a semi-
24
colon; and 
25
00:26 Apr 24, 2021
H19
55 
•HR 19 IH
(III) by adding at the end the 
1
following new subclauses: 
2
‘‘(VII) for 2022, is equal to 
3
$3,100; or 
4
‘‘(VIII) for a subsequent year, is 
5
equal to the amount specified in this 
6
subparagraph for the previous year, 
7
increased by the annual percentage in-
8
crease described in paragraph (6) for 
9
the year involved.’’; and 
10
(ii) in clause (ii), by striking ‘‘clause 
11
(i)(II)’’ and inserting ‘‘clause (i)’’; 
12
(C) in subparagraph (C)(i), by striking 
13
‘‘and for amounts’’ and inserting ‘‘and for a 
14
year preceding 2022 for amounts’’; and 
15
(D) in subparagraph (E), by striking ‘‘In 
16
applying’’ and inserting ‘‘For each of 2011 
17
through 2021, in applying’’. 
18
(b) 
DECREASING
REINSURANCE
PAYMENT 
19
AMOUNT.—Section 1860D–15(b)(1) of the Social Security 
20
Act (42 U.S.C. 1395w–115(b)(1)) is amended— 
21
(1) by striking ‘‘equal to 80 percent’’ and in-
22
serting ‘‘equal to– 
23
‘‘(A) for a year preceding 2022, 80 per-
24
cent’’; 
25
00:26 Apr 24, 2021
H19
56 
•HR 19 IH
(2) in subparagraph (A), as added by para-
1
graph (1), by striking the period at the end and in-
2
serting ‘‘; and’’; and 
3
(3) by adding at the end the following new sub-
4
paragraph: 
5
‘‘(B) for 2022 and each subsequent year, 
6
the sum of— 
7
‘‘(i) an amount equal to 20 percent of 
8
the allowable reinsurance costs (as speci-
9
fied in paragraph (2)) attributable to that 
10
portion of gross covered prescription drug 
11
costs as specified in paragraph (3) in-
12
curred in the coverage year after such indi-
13
vidual has incurred costs that exceed the 
14
annual out-of-pocket threshold specified in 
15
section 1860D–2(b)(4)(B) with respect to 
16
applicable drugs (as defined in section 
17
1860D–14B(g)(2)); and 
18
‘‘(ii) an amount equal to 30 percent of 
19
the allowable reinsurance costs (as speci-
20
fied in paragraph (2)) attributable to that 
21
portion of gross covered prescription drug 
22
costs as specified in paragraph (3) in-
23
curred in the coverage year after such indi-
24
vidual has incurred costs that exceed the 
25
00:26 Apr 24, 2021
H19
57 
•HR 19 IH
annual out-of-pocket threshold specified in 
1
section 1860D–2(b)(4)(B) with respect to 
2
covered part D drugs that are not applica-
3
ble drugs (as so defined).’’. 
4
(c) MANUFACTURER DISCOUNT PROGRAM.— 
5
(1) IN GENERAL.—Part D of title XVIII of the 
6
Social Security Act is amended by inserting after 
7
section 1860D–14A (42 U.S.C. 1495w–114) the fol-
8
lowing new section: 
9
‘‘SEC. 1860D–14B. MANUFACTURER DISCOUNT PROGRAM. 
10
‘‘(a) ESTABLISHMENT.—The Secretary shall estab-
11
lish a manufacturer discount program (in this section re-
12
ferred to as the ‘program’). Under the program, the Sec-
13
retary shall enter into agreements described in subsection 
14
(b) with manufacturers and provide for the performance 
15
of the duties described in subsection (c). The Secretary 
16
shall establish a model agreement for use under the pro-
17
gram by not later than January 1, 2023, in consultation 
18
with manufacturers, and allow for comment on such model 
19
agreement. 
20
‘‘(b) TERMS OF AGREEMENT.— 
21
‘‘(1) IN GENERAL.— 
22
‘‘(A) AGREEMENT.—An agreement under 
23
this section shall require the manufacturer to 
24
provide applicable beneficiaries access to dis-
25
00:26 Apr 24, 2021
H19
58 
•HR 19 IH
counted prices for applicable drugs of the man-
1
ufacturer that are dispensed on or after Janu-
2
ary 1, 2024. 
3
‘‘(B) PROVISION OF DISCOUNTED PRICES 
4
AT THE POINT-OF-SALE.—The discounted prices 
5
described in subparagraph (A) shall be provided 
6
to the applicable beneficiary at the pharmacy or 
7
by the mail order service at the point-of-sale of 
8
an applicable drug. 
9
‘‘(2) PROVISION OF APPROPRIATE DATA.—Each 
10
manufacturer with an agreement in effect under this 
11
section shall collect and have available appropriate 
12
data, as determined by the Secretary, to ensure that 
13
it can demonstrate to the Secretary compliance with 
14
the requirements under the program. 
15
‘‘(3) COMPLIANCE
WITH
REQUIREMENTS
FOR 
16
ADMINISTRATION
OF
PROGRAM.—Each manufac-
17
turer with an agreement in effect under this section 
18
shall comply with requirements imposed by the Sec-
19
retary or a third party with a contract under sub-
20
section (d)(3), as applicable, for purposes of admin-
21
istering the program, including any determination 
22
under subparagraph (A) of subsection (c)(1) or pro-
23
cedures established under such subsection (c)(1). 
24
‘‘(4) LENGTH OF AGREEMENT.— 
25
00:26 Apr 24, 2021
H19
59 
•HR 19 IH
‘‘(A) IN GENERAL.—An agreement under 
1
this section shall be effective for an initial pe-
2
riod of not less than 12 months and shall be 
3
automatically renewed for a period of not less 
4
than 1 year unless terminated under subpara-
5
graph (B). 
6
‘‘(B) TERMINATION.— 
7
‘‘(i) BY THE SECRETARY.—The Sec-
8
retary may provide for termination of an 
9
agreement under this section for a knowing 
10
and willful violation of the requirements of 
11
the agreement or other good cause shown. 
12
Such termination shall not be effective ear-
13
lier than 30 days after the date of notice 
14
to the manufacturer of such termination. 
15
The Secretary shall provide, upon request, 
16
a manufacturer with a hearing concerning 
17
such a termination, and such hearing shall 
18
take place prior to the effective date of the 
19
termination with sufficient time for such 
20
effective date to be repealed if the Sec-
21
retary determines appropriate. 
22
‘‘(ii) BY A MANUFACTURER.—A man-
23
ufacturer may terminate an agreement 
24
under this section for any reason. Any 
25
00:26 Apr 24, 2021
H19
60 
•HR 19 IH
such termination shall be effective, with re-
1
spect to a plan year— 
2
‘‘(I) if the termination occurs be-
3
fore January 30 of a plan year, as of 
4
the day after the end of the plan year; 
5
and 
6
‘‘(II) if the termination occurs on 
7
or after January 30 of a plan year, as 
8
of the day after the end of the suc-
9
ceeding plan year. 
10
‘‘(iii) EFFECTIVENESS
OF
TERMI-
11
NATION.—Any termination under this sub-
12
paragraph shall not affect discounts for 
13
applicable drugs of the manufacturer that 
14
are due under the agreement before the ef-
15
fective date of its termination. 
16
‘‘(iv) NOTICE TO THIRD PARTY.—The 
17
Secretary shall provide notice of such ter-
18
mination to a third party with a contract 
19
under subsection (d)(3) within not less 
20
than 30 days before the effective date of 
21
such termination. 
22
‘‘(5) EFFECTIVE
DATE
OF
AGREEMENT.—An 
23
agreement under this section shall take effect on a 
24
00:26 Apr 24, 2021
H19
61 
•HR 19 IH
date determined appropriate by the Secretary, which 
1
may be at the start of a calendar quarter. 
2
‘‘(c) DUTIES DESCRIBED.—The duties described in 
3
this subsection are the following: 
4
‘‘(1) ADMINISTRATION OF PROGRAM.—Admin-
5
istering the program, including— 
6
‘‘(A) the determination of the amount of 
7
the discounted price of an applicable drug of a 
8
manufacturer; 
9
‘‘(B) the establishment of procedures 
10
under which discounted prices are provided to 
11
applicable beneficiaries at pharmacies or by 
12
mail order service at the point-of-sale of an ap-
13
plicable drug; 
14
‘‘(C) the establishment of procedures to 
15
ensure that, not later than the applicable num-
16
ber of calendar days after the dispensing of an 
17
applicable drug by a pharmacy or mail order 
18
service, the pharmacy or mail order service is 
19
reimbursed for an amount equal to the dif-
20
ference between— 
21
‘‘(i) the negotiated price of the appli-
22
cable drug; and 
23
‘‘(ii) the discounted price of the appli-
24
cable drug; 
25
00:26 Apr 24, 2021
H19
62 
•HR 19 IH
‘‘(D) the establishment of procedures to 
1
ensure that the discounted price for an applica-
2
ble drug under this section is applied before any 
3
coverage or financial assistance under other 
4
health benefit plans or programs that provide 
5
coverage or financial assistance for the pur-
6
chase or provision of prescription drug coverage 
7
on behalf of applicable beneficiaries as the Sec-
8
retary may specify; and 
9
‘‘(E) providing a reasonable dispute resolu-
10
tion mechanism to resolve disagreements be-
11
tween manufacturers, applicable beneficiaries, 
12
and the third party with a contract under sub-
13
section (d)(3). 
14
‘‘(2) MONITORING COMPLIANCE.— 
15
‘‘(A) IN
GENERAL.—The Secretary shall 
16
monitor compliance by a manufacturer with the 
17
terms of an agreement under this section. 
18
‘‘(B) NOTIFICATION.—If a third party 
19
with a contract under subsection (d)(3) deter-
20
mines that the manufacturer is not in compli-
21
ance with such agreement, the third party shall 
22
notify the Secretary of such noncompliance for 
23
appropriate enforcement under subsection (e). 
24
00:26 Apr 24, 2021
H19
63 
•HR 19 IH
‘‘(3) COLLECTION OF DATA FROM PRESCRIP-
1
TION DRUG PLANS AND MA–PD PLANS.—The Sec-
2
retary may collect appropriate data from prescrip-
3
tion drug plans and MA–PD plans in a timeframe 
4
that allows for discounted prices to be provided for 
5
applicable drugs under this section. 
6
‘‘(d) ADMINISTRATION.— 
7
‘‘(1) IN GENERAL.—Subject to paragraph (2), 
8
the Secretary shall provide for the implementation of 
9
this section, including the performance of the duties 
10
described in subsection (c). 
11
‘‘(2) LIMITATION.—In providing for the imple-
12
mentation of this section, the Secretary shall not re-
13
ceive or distribute any funds of a manufacturer 
14
under the program. 
15
‘‘(3) CONTRACT
WITH
THIRD
PARTIES.—The 
16
Secretary shall enter into a contract with 1 or more 
17
third parties to administer the requirements estab-
18
lished by the Secretary in order to carry out this 
19
section. At a minimum, the contract with a third 
20
party under the preceding sentence shall require 
21
that the third party— 
22
‘‘(A) receive and transmit information be-
23
tween the Secretary, manufacturers, and other 
24
00:26 Apr 24, 2021
H19
64 
•HR 19 IH
individuals or entities the Secretary determines 
1
appropriate; 
2
‘‘(B) receive, distribute, or facilitate the 
3
distribution of funds of manufacturers to ap-
4
propriate individuals or entities in order to 
5
meet the obligations of manufacturers under 
6
agreements under this section; 
7
‘‘(C) provide adequate and timely informa-
8
tion to manufacturers, consistent with the 
9
agreement with the manufacturer under this 
10
section, as necessary for the manufacturer to 
11
fulfill its obligations under this section; and 
12
‘‘(D) permit manufacturers to conduct 
13
periodic audits, directly or through contracts, of 
14
the data and information used by the third 
15
party to determine discounts for applicable 
16
drugs of the manufacturer under the program. 
17
‘‘(4) 
PERFORMANCE
REQUIREMENTS.—The 
18
Secretary shall establish performance requirements 
19
for a third party with a contract under paragraph 
20
(3) and safeguards to protect the independence and 
21
integrity of the activities carried out by the third 
22
party under the program under this section. 
23
00:26 Apr 24, 2021
H19
65 
•HR 19 IH
‘‘(5) ADMINISTRATION.—Chapter 35 of title 44, 
1
United States Code, shall not apply to the program 
2
under this section. 
3
‘‘(e) ENFORCEMENT.— 
4
‘‘(1) AUDITS.—Each manufacturer with an 
5
agreement in effect under this section shall be sub-
6
ject to periodic audit by the Secretary. 
7
‘‘(2) CIVIL MONEY PENALTY.— 
8
‘‘(A) IN
GENERAL.—The Secretary shall 
9
impose a civil money penalty on a manufacturer 
10
that fails to provide applicable beneficiaries dis-
11
counts for applicable drugs of the manufacturer 
12
in accordance with such agreement for each 
13
such failure in an amount the Secretary deter-
14
mines is commensurate with the sum of— 
15
‘‘(i) the amount that the manufac-
16
turer would have paid with respect to such 
17
discounts under the agreement, which will 
18
then be used to pay the discounts which 
19
the manufacturer had failed to provide; 
20
and 
21
‘‘(ii) 25 percent of such amount. 
22
‘‘(B) APPLICATION.—The provisions of 
23
section 1128A (other than subsections (a) and 
24
(b)) shall apply to a civil money penalty under 
25
00:26 Apr 24, 2021
H19
66 
•HR 19 IH
this paragraph in the same manner as such 
1
provisions apply to a penalty or proceeding 
2
under section 1128A(a). 
3
‘‘(f) CLARIFICATION REGARDING AVAILABILITY OF 
4
OTHER COVERED PART D DRUGS.—Nothing in this sec-
5
tion shall prevent an applicable beneficiary from pur-
6
chasing a covered part D drug that is not on the formulary 
7
of the prescription drug plan or MA–PD plan that the 
8
applicable beneficiary is enrolled in. 
9
‘‘(g) DEFINITIONS.—In this section: 
10
‘‘(1) APPLICABLE
BENEFICIARY.—The term 
11
‘applicable beneficiary’ means an individual who, on 
12
the date of dispensing a covered part D drug— 
13
‘‘(A) is enrolled in a prescription drug plan 
14
or an MA–PD plan; 
15
‘‘(B) is not enrolled in a qualified retiree 
16
prescription drug plan; and 
17
‘‘(C) has incurred costs for covered part D 
18
drugs in the year that are equal to or exceed 
19
the annual deductible specified in section 
20
1860D–2(b)(1) for such year. 
21
‘‘(2) APPLICABLE DRUG.—The term ‘applicable 
22
drug’ means, with respect to an applicable bene-
23
ficiary, a covered part D drug— 
24
00:26 Apr 24, 2021
H19
67 
•HR 19 IH
‘‘(A) approved under a new drug applica-
1
tion under section 505(c) of the Federal Food, 
2
Drug, and Cosmetic Act or, in the case of a bio-
3
logic product, licensed under section 351 of the 
4
Public Health Service Act (including a product 
5
licensed under subsection (k) of such section); 
6
and 
7
‘‘(B)(i) if the PDP sponsor of the prescrip-
8
tion drug plan or the MA organization offering 
9
the MA–PD plan uses a formulary, which is on 
10
the formulary of the prescription drug plan or 
11
MA–PD plan that the applicable beneficiary is 
12
enrolled in; 
13
‘‘(ii) if the PDP sponsor of the prescrip-
14
tion drug plan or the MA organization offering 
15
the MA–PD plan does not use a formulary, for 
16
which benefits are available under the prescrip-
17
tion drug plan or MA–PD plan that the appli-
18
cable beneficiary is enrolled in; or 
19
‘‘(iii) is provided through an exception or 
20
appeal. 
21
‘‘(3) APPLICABLE
NUMBER
OF
CALENDAR 
22
DAYS.—The term ‘applicable number of calendar 
23
days’ means— 
24
00:26 Apr 24, 2021
H19
68 
•HR 19 IH
‘‘(A) with respect to claims for reimburse-
1
ment submitted electronically, 14 days; and 
2
‘‘(B) with respect to claims for reimburse-
3
ment submitted otherwise, 30 days. 
4
‘‘(4) DISCOUNTED PRICE.— 
5
‘‘(A) IN GENERAL.—The term ‘discounted 
6
price’ means, with respect to an applicable drug 
7
of a manufacturer furnished during a year to 
8
an applicable beneficiary, 90 percent of the ne-
9
gotiated price of such drug. 
10
‘‘(B) CLARIFICATION.—Nothing in this 
11
section shall be construed as affecting the re-
12
sponsibility of an applicable beneficiary for pay-
13
ment of a dispensing fee for an applicable drug. 
14
‘‘(C) SPECIAL CASE FOR CLAIMS SPANNING 
15
DEDUCTIBLE.—In the case where the entire 
16
amount of the negotiated price of an individual 
17
claim for an applicable drug with respect to an 
18
applicable beneficiary does not fall at or above 
19
the annual deductible specified in section 
20
1860D–2(b)(1) for the year, the manufacturer 
21
of the applicable drug shall provide the dis-
22
counted price under this section on only the 
23
portion of the negotiated price of the applicable 
24
00:26 Apr 24, 2021
H19
69 
•HR 19 IH
drug that falls at or above such annual deduct-
1
ible. 
2
‘‘(5) MANUFACTURER.—The term ‘manufac-
3
turer’ means any entity which is engaged in the pro-
4
duction, preparation, propagation, compounding, 
5
conversion, or processing of prescription drug prod-
6
ucts, either directly or indirectly by extraction from 
7
substances of natural origin, or independently by 
8
means of chemical synthesis, or by a combination of 
9
extraction and chemical synthesis. Such term does 
10
not include a wholesale distributor of drugs or a re-
11
tail pharmacy licensed under State law. 
12
‘‘(6) NEGOTIATED
PRICE.—The term ‘nego-
13
tiated price’ has the meaning given such term in sec-
14
tion 1860D–2(d)(1)(B), except that such negotiated 
15
price shall not include any dispensing fee for an ap-
16
plicable drug. 
17
‘‘(7) QUALIFIED RETIREE PRESCRIPTION DRUG 
18
PLAN.—The term ‘qualified retiree prescription drug 
19
plan’ has the meaning given such term in section 
20
11860D–22(a)(2).’’. 
21
(2) SUNSET OF MEDICARE COVERAGE GAP DIS-
22
COUNT PROGRAM.—Section 1860D–14A of the So-
23
cial Security Act (42 U.S.C. 1395–114a) is amend-
24
ed— 
25
00:26 Apr 24, 2021
H19
70 
•HR 19 IH
(A) in subsection (a), in the first sentence, 
1
by striking ‘‘The Secretary’’ and inserting 
2
‘‘Subject to subsection (h), the Secretary’’; and 
3
(B) by adding at the end the following new 
4
subsection: 
5
‘‘(h) SUNSET OF PROGRAM.— 
6
‘‘(1) IN
GENERAL.—The program shall not 
7
apply to applicable drugs dispensed on or after Jan-
8
uary 1, 2024, and, subject to paragraph (2), agree-
9
ments under this section shall be terminated as of 
10
such date. 
11
‘‘(2) CONTINUED APPLICATION FOR APPLICA-
12
BLE
DRUGS
DISPENSED
PRIOR
TO
SUNSET.—The 
13
provisions of this section (including all responsibil-
14
ities and duties) shall continue to apply after Janu-
15
ary 1, 2024, with respect to applicable drugs dis-
16
pensed prior to such date.’’. 
17
(3) INCLUSION OF ACTUARIAL VALUE OF MANU-
18
FACTURER DISCOUNTS IN BIDS.—Section 1860D–11 
19
of the Social Security Act (42 U.S.C. 1395w–111) 
20
is amended— 
21
(A) in subsection (b)(2)(C)(iii)— 
22
(i) by striking ‘‘assumptions regarding 
23
the reinsurance’’ and inserting ‘‘assump-
24
tions regarding— 
25
00:26 Apr 24, 2021
H19
71 
•HR 19 IH
‘‘(I) the reinsurance’’; and 
1
(ii) by adding at the end the fol-
2
lowing: 
3
‘‘(II) for 2024 and each subse-
4
quent year, the manufacturer dis-
5
counts provided under section 1860D– 
6
14B subtracted from the actuarial 
7
value to produce such bid; and’’; and 
8
(B) in subsection (c)(1)(C)— 
9
(i) by striking ‘‘an actuarial valuation 
10
of the reinsurance’’ and inserting ‘‘an ac-
11
tuarial valuation of— 
12
‘‘(i) the reinsurance’’; 
13
(ii) in clause (i), as added by clause 
14
(i) of this subparagraph, by adding ‘‘and’’ 
15
at the end; and 
16
(iii) by adding at the end the fol-
17
lowing: 
18
‘‘(ii) for 2024 and each subsequent 
19
year, the manufacturer discounts provided 
20
under section 1860D–14B;’’. 
21
(4) CLARIFICATION REGARDING EXCLUSION OF 
22
MANUFACTURER DISCOUNTS FROM TROOP.—Section 
23
1860D–2(b)(4) of the Social Security Act (42 
24
U.S.C. 1395w–102(b)(4)) is amended— 
25
00:26 Apr 24, 2021
H19
72 
•HR 19 IH
(A) in subparagraph (C), by inserting ‘‘and 
1
subject to subparagraph (F)’’ after ‘‘subpara-
2
graph (E)’’; and 
3
(B) by adding at the end the following new 
4
subparagraph: 
5
‘‘(F) CLARIFICATION REGARDING EXCLU-
6
SION OF MANUFACTURER DISCOUNTS.—In ap-
7
plying subparagraph (A), incurred costs shall 
8
not include any manufacturer discounts pro-
9
vided under section 1860D–14B.’’. 
10
(d) DETERMINATION OF ALLOWABLE REINSURANCE 
11
COSTS.—Section 1860D–15(b) of the Social Security Act 
12
(42 U.S.C. 1395w–115(b)) is amended— 
13
(1) in paragraph (2)— 
14
(A) by striking ‘‘COSTS.—For purposes’’ 
15
and inserting ‘‘COSTS.— 
16
‘‘(A) IN
GENERAL.—Subject to subpara-
17
graph (B), for purposes’’; and 
18
(B) by adding at the end the following new 
19
subparagraph: 
20
‘‘(B) INCLUSION OF MANUFACTURER DIS-
21
COUNTS ON APPLICABLE DRUGS.—For purposes 
22
of applying subparagraph (A), the term ‘allow-
23
able reinsurance costs’ shall include the portion 
24
of the negotiated price (as defined in section 
25
00:26 Apr 24, 2021
H19
73 
•HR 19 IH
1860D–14B(g)(6)) of an applicable drug (as 
1
defined in section 1860D–14(g)(2)) that was 
2
paid by a manufacturer under the manufacturer 
3
discount program under section 1860D–14B.’’; 
4
and 
5
(2) in paragraph (3)— 
6
(A) in the first sentence, by striking ‘‘For 
7
purposes’’ and inserting ‘‘Subject to paragraph 
8
(2)(B), for purposes’’; and 
9
(B) in the second sentence, by inserting 
10
‘‘or, in the case of an applicable drug, by a 
11
manufacturer’’ after ‘‘by the individual or 
12
under the plan’’. 
13
(e) UPDATING RISK ADJUSTMENT METHODOLOGIES 
14
TO ACCOUNT FOR PART D MODERNIZATION REDESIGN.— 
15
Section 1860D–15(c) of the Social Security Act (42 
16
U.S.C. 1395w–115(c)) is amended by adding at the end 
17
the following new paragraph: 
18
‘‘(3) UPDATING
RISK
ADJUSTMENT
METH-
19
ODOLOGIES TO ACCOUNT FOR PART D MODERNIZA-
20
TION REDESIGN.—The Secretary shall update the 
21
risk adjustment model used to adjust bid amounts 
22
pursuant to this subsection as appropriate to take 
23
into account changes in benefits under this part pur-
24
00:26 Apr 24, 2021
H19
74 
•HR 19 IH
suant to the amendments made by section 121 of 
1
the Lower Costs, More Cures Act of 2021.’’. 
2
(f) CONDITIONS FOR COVERAGE OF DRUGS UNDER 
3
THIS PART.—Section 1860D–43 of the Social Security 
4
Act (42 U.S.C. 1395w–153) is amended— 
5
(1) in subsection (a)— 
6
(A) in paragraph (2), by striking ‘‘and’’ at 
7
the end; 
8
(B) in paragraph (3), by striking the pe-
9
riod at the end and inserting a semicolon; and 
10
(C) by adding at the end the following new 
11
paragraphs: 
12
‘‘(4) participate in the manufacturer discount 
13
program under section 1860D–14B; 
14
‘‘(5) have entered into and have in effect an 
15
agreement described in subsection (b) of such sec-
16
tion 1860D–14B with the Secretary; and 
17
‘‘(6) have entered into and have in effect, under 
18
terms and conditions specified by the Secretary, a 
19
contract with a third party that the Secretary has 
20
entered into a contract with under subsection (d)(3) 
21
of such section 1860D–14B.’’; 
22
(2) by striking subsection (b) and inserting the 
23
following: 
24
00:26 Apr 24, 2021
H19
75 
•HR 19 IH
‘‘(b) EFFECTIVE DATE.—Paragraphs (1) through (3) 
1
of subsection (a) shall apply to covered part D drugs dis-
2
pensed under this part on or after January 1, 2011, and 
3
before January 1, 2024, and paragraphs (4) through (6) 
4
of such subsection shall apply to covered part D drugs 
5
dispensed on or after January 1, 2024.’’; and 
6
(3) in subsection (c), by striking paragraph (2) 
7
and inserting the following: 
8
‘‘(2) the Secretary determines that in the period 
9
beginning on January 1, 2011, and ending on De-
10
cember 31, 2011 (with respect to paragraphs (1) 
11
through (3) of subsection (a)) or the period begin-
12
ning on January 1, 2024, and ending December 31, 
13
2024 (with respect to paragraphs (4) through (6) of 
14
such subsection), there were extenuating cir-
15
cumstances.’’. 
16
(g) CONFORMING AMENDMENTS.— 
17
(1) Section 1860D–2 of the Social Security Act 
18
(42 U.S.C. 1395w–102) is amended— 
19
(A) in subsection (a)(2)(A)(i)(I), by strik-
20
ing ‘‘, or an increase in the initial’’ and insert-
21
ing ‘‘or for a year preceding 2024 an increase 
22
in the initial’’; 
23
(B) in subsection (c)(1)(C)— 
24
00:26 Apr 24, 2021
H19
76 
•HR 19 IH
(i) in the subparagraph heading, by 
1
striking ‘‘AT
INITIAL
COVERAGE
LIMIT’’; 
2
and 
3
(ii) by inserting ‘‘for a year preceding 
4
2024 or the annual out-of-pocket threshold 
5
specified in subsection (b)(4)(B) for the 
6
year for 2024 and each subsequent year’’ 
7
after ‘‘subsection (b)(3) for the year’’ each 
8
place it appears; and 
9
(C) in subsection (d)(1)(A), by striking ‘‘or 
10
an initial’’ and inserting ‘‘or for a year pre-
11
ceding 2024, an initial’’. 
12
(2) Section 1860D–4(a)(4)(B)(i) of the Social 
13
Security Act (42 U.S.C. 1395w–104(a)(4)(B)(i)) is 
14
amended by striking ‘‘the initial’’ and inserting ‘‘for 
15
a year preceding 2024, the initial’’. 
16
(3) Section 1860D–14(a) of the Social Security 
17
Act (42 U.S.C. 1395w–114(a)) is amended— 
18
(A) in paragraph (1)— 
19
(i) in subparagraph (C), by striking 
20
‘‘The continuation’’ and inserting ‘‘For a 
21
year preceding 2024, the continuation’’; 
22
(ii) in subparagraph (D)(iii), by strik-
23
ing ‘‘1860D–2(b)(4)(A)(i)(I)’’ and insert-
24
ing ‘‘1860D–2(b)(4)(A)(i)(I)(aa)’’; and 
25
00:26 Apr 24, 2021
H19
77 
•HR 19 IH
(iii) in subparagraph (E), by striking 
1
‘‘The elimination’’ and inserting ‘‘For a 
2
year preceding 2024, the elimination’’; and 
3
(B) in paragraph (2)— 
4
(i) in subparagraph (C), by striking 
5
‘‘The continuation’’ and inserting ‘‘For a 
6
year preceding 2024, the continuation’’; 
7
and 
8
(ii) in subparagraph (E)— 
9
(I) by inserting ‘‘for a year pre-
10
ceding 2024,’’ after ‘‘subsection (c)’’; 
11
and 
12
(II) 
by 
striking 
‘‘1860D– 
13
2(b)(4)(A)(i)(I)’’ 
and 
inserting 
14
‘‘1860D–2(b)(4)(A)(i)(I)(aa)’’. 
15
(4) Section 1860D–21(d)(7) of the Social Secu-
16
rity Act (42 U.S.C. 1395w–131(d)(7)) is amended 
17
by striking ‘‘section 1860D–2(b)(4)(B)(i)’’ and in-
18
serting ‘‘section 1860D–2(b)(4)(C)(i)’’. 
19
(5) Section 1860D–22(a)(2)(A) of the Social 
20
Security Act (42 U.S.C. 1395w–132(a)(2)(A)) is 
21
amended— 
22
(A) by striking ‘‘the value of any discount’’ 
23
and inserting the following: ‘‘the value of— 
24
00:26 Apr 24, 2021
H19
78 
•HR 19 IH
‘‘(i) for years prior to 2024, any dis-
1
count’’; 
2
(B) in clause (i), as inserted by subpara-
3
graph (A) of this paragraph, by striking the pe-
4
riod at the end and inserting ‘‘; and’’; and 
5
(C) by adding at the end the following new 
6
clause: 
7
‘‘(ii) for 2024 and each subsequent 
8
year, any discount provided pursuant to 
9
section 1860D–14B.’’. 
10
(6) Section 1860D–41(a)(6) of the Social Secu-
11
rity Act (42 U.S.C. 1395w–151(a)(6)) is amended— 
12
(A) by inserting ‘‘for a year before 2024’’ 
13
after ‘‘1860D–2(b)(3)’’; and 
14
(B) by inserting ‘‘for such year’’ before the 
15
period. 
16
(h) EFFECTIVE DATE.—The amendments made by 
17
this section shall apply to plan year 2024 and subsequent 
18
plan years. 
19
00:26 Apr 24, 2021
H19
79 
•HR 19 IH
Subtitle D—Other Medicare Part D 
1
Provisions 
2
SEC. 131. ALLOWING THE OFFERING OF ADDITIONAL PRE-
3
SCRIPTION DRUG PLANS UNDER MEDICARE 
4
PART D. 
5
(a) RESCINDING
AND ISSUANCE
OF NEW GUID-
6
ANCE.—Not later than one year after the date of the en-
7
actment of this Act, the Secretary of Health and Human 
8
Services (in this section referred to as the ‘‘Secretary’’) 
9
shall— 
10
(1) rescind sections of any sub-regulatory guid-
11
ance that limit the number of prescription drug 
12
plans in each PDP region that may be offered by a 
13
PDP sponsor under part D of title XVIII of the So-
14
cial Security Act (42 U.S.C. 1395w–101 et seq.); 
15
and 
16
(2) issue new guidance specifying that a PDP 
17
sponsor may offer up to 4 (or a greater number if 
18
determined appropriate by the Secretary) prescrip-
19
tion drug plans in each PDP region, except in cases 
20
where the PDP sponsor may offer up to 2 additional 
21
plans in a PDP region pursuant to section 1860D– 
22
11(d)(4) of the Social Security Act (42 U.S.C. 
23
1395w–111(d)(4)), as added by subsection (b). 
24
00:26 Apr 24, 2021
H19
80 
•HR 19 IH
(b) OFFERING
OF ADDITIONAL PLANS.—Section 
1
1860D–11(d) of the Social Security Act (42 U.S.C. 
2
1395w–111(d)) is amended by adding at the end the fol-
3
lowing new paragraph: 
4
‘‘(4) OFFERING OF ADDITIONAL PLANS.— 
5
‘‘(A) IN GENERAL.—For plan year 2022 
6
and each subsequent plan year, a PDP sponsor 
7
may offer up to 2 additional prescription drug 
8
plans in a PDP region (in addition to any limit 
9
established by the Secretary under this part) 
10
provided that the PDP sponsor complies with 
11
subparagraph (B) with respect to at least one 
12
such prescription drug plan. 
13
‘‘(B) REQUIREMENTS.—In order to be eli-
14
gible to offer up to 2 additional plans in a PDP 
15
region pursuant to subparagraph (A), a PDP 
16
sponsor must ensure that, with respect to at 
17
least one such prescription drug plan, the spon-
18
sor or any entity that provides pharmacy bene-
19
fits management services under a contract with 
20
any such sponsor or plan does not receive direct 
21
or indirect remuneration, as defined in section 
22
423.308 of title 42, Code of Federal Regula-
23
tions (or any successor regulation), unless at 
24
least 25 percent of the aggregate reductions in 
25
00:26 Apr 24, 2021
H19
81 
•HR 19 IH
price or other remuneration received by the 
1
PDP sponsor or entity from drug manufactur-
2
ers with respect to the plan and plan year— 
3
‘‘(i) are reflected at the point-of-sale 
4
to the enrollee; or 
5
‘‘(ii) are used to reduce total bene-
6
ficiary cost-sharing estimated by the PDP 
7
sponsor for prescription drug coverage 
8
under the plan in the annual bid submitted 
9
by the PDP sponsor under section 1860D– 
10
11(b). 
11
‘‘(C) DEFINITION
OF
REDUCTIONS
IN 
12
PRICE.—For purposes of subparagraph (B), the 
13
term ‘reductions in price’ refers only to collect-
14
ible amounts, as determined by the Secretary, 
15
which excludes amounts which after adjudica-
16
tion and reconciliation with pharmacies and 
17
manufacturers are duplicate in nature, contrary 
18
to other contractual clauses, or otherwise ineli-
19
gible (such as due to beneficiary disenrollment 
20
or coordination of benefits).’’. 
21
(c) RULE OF CONSTRUCTION.—Nothing in the provi-
22
sions of, or amendments made by, this section shall be 
23
construed as limiting the ability of the Secretary to in-
24
crease any limit otherwise applicable on the number of 
25
00:26 Apr 24, 2021
H19
82 
•HR 19 IH
prescription drug plans that a PDP sponsor may offer, 
1
at the discretion of the PDP sponsor, in a PDP region 
2
under part D of title XVIII of the Social Security Act (42 
3
U.S.C. 1395w–101 et seq.). 
4
SEC. 132. ALLOWING CERTAIN ENROLLEES OF PRESCRIP-
5
TION DRUG PLANS AND MA–PD PLANS UNDER 
6
MEDICARE PROGRAM TO SPREAD OUT COST- 
7
SHARING UNDER CERTAIN CIRCUMSTANCES. 
8
(a) STANDARD PRESCRIPTION DRUG COVERAGE.— 
9
Section 1860D–2(b)(2) of the Social Security Act (42 
10
U.S.C. 1395w–102(b)(2)), as amended by section 121, is 
11
further amended— 
12
(1) in subparagraph (A), by striking ‘‘Subject 
13
to subparagraphs (C) and (D)’’ and inserting ‘‘Sub-
14
ject to subparagraphs (C), (D), and (E)’’; and 
15
(2) by adding at the end the following new sub-
16
paragraph: 
17
‘‘(E) 
ENROLLEE
OPTION
REGARDING 
18
SPREADING COST-SHARING.— 
19
‘‘(i) IN
GENERAL.—The Secretary 
20
shall establish by regulation a process 
21
under which, with respect to plan year 
22
2022 and subsequent plan years, a pre-
23
scription drug plan or an MA–PD plan 
24
shall, in the case of a part D eligible indi-
25
00:26 Apr 24, 2021
H19
83 
•HR 19 IH
vidual enrolled with such plan for such 
1
plan year with respect to whom the plan 
2
projects that the dispensing of a covered 
3
part D drug to such individual will result 
4
in the individual incurring costs within a 
5
30-day period that are equal to a signifi-
6
cant percentage (as specified by the Sec-
7
retary pursuant to such regulation) of the 
8
annual out-of-pocket threshold specified in 
9
paragraph (4)(B) for such plan year, pro-
10
vide such individual with the option to 
11
make the coinsurance payment required 
12
under subparagraph (A) for such costs in 
13
the form of equal monthly installments 
14
over the remainder of such plan year. 
15
‘‘(ii) SIGNIFICANT PERCENTAGE LIMI-
16
TATIONS.—In specifying a significant per-
17
centage pursuant to the regulation estab-
18
lished by the Secretary under clause (i), 
19
the Secretary may not specify a percentage 
20
that is less than 30 percent or greater 
21
than 100 percent.’’. 
22
(b) 
ALTERNATIVE
PRESCRIPTION
DRUG
COV-
23
ERAGE.—Section 1860D–2(c) of the Social Security Act 
24
00:26 Apr 24, 2021
H19
84 
•HR 19 IH
(42 U.S.C. 1395w–102(c)) is amended by adding at the 
1
end the following new paragraph: 
2
‘‘(4) SAME
ENROLLEE
OPTION
REGARDING 
3
SPREADING
COST-SHARING.—For plan year 2022 
4
and subsequent plan years, the coverage provides the 
5
enrollee option regarding spreading cost-sharing de-
6
scribed 
in 
and 
required 
under 
subsection 
7
(b)(2)(E).’’. 
8
SEC. 133. ESTABLISHING A MONTHLY CAP ON BENEFICIARY 
9
INCURRED COSTS FOR INSULIN PRODUCTS 
10
AND 
SUPPLIES 
UNDER 
A 
PRESCRIPTION 
11
DRUG PLAN OR MA–PD PLAN. 
12
(a) IN GENERAL.—Section 1860D–2 of the Social 
13
Security Act (42 U.S.C. 1395w–102), as amended by sec-
14
tions 121 and 133, is further amended— 
15
(1) in subsection (b)(2)— 
16
(A) in subparagraph (A), by striking ‘‘and 
17
(E)’’ and inserting ‘‘(E), and (F)’’; 
18
(B) in subparagraph (B), by striking ‘‘and 
19
(D)’’ and inserting ‘‘(D), and (F)’’; and 
20
(C) by adding at the end the following new 
21
subparagraph: 
22
‘‘(F) CAP ON INCURRED COSTS FOR INSU-
23
LIN PRODUCTS AND SUPPLIES.— 
24
00:26 Apr 24, 2021
H19
85 
•HR 19 IH
‘‘(i) IN GENERAL.—The coverage pro-
1
vides benefits, for costs above the annual 
2
deductible specified in paragraph (1) and 
3
up to the annual out-of-pocket threshold 
4
described in paragraph (4)(B) and with re-
5
spect to a month (beginning with January 
6
of 2022), with cost sharing that is equal to 
7
$0 for a specified covered part D drug (as 
8
defined in clause (iii)) furnished to an indi-
9
vidual who has incurred costs during such 
10
month with respect to specified covered 
11
part D drugs equal to— 
12
‘‘(I) for months occurring in 
13
2022, $50; or 
14
‘‘(II) for months occurring in a 
15
subsequent year, the amount applica-
16
ble under this clause for months oc-
17
curring in the year preceding such 
18
subsequent year, increased by the an-
19
nual percentage increase specified in 
20
paragraph (6) for such subsequent 
21
year and rounded to the nearest dol-
22
lar. 
23
‘‘(ii) APPLICATION.—The provisions 
24
of clauses (i) through (iii) of paragraph 
25
00:26 Apr 24, 2021
H19
86 
•HR 19 IH
(4)(C) shall apply with respect to the de-
1
termination of the incurred costs for speci-
2
fied covered part D drugs for purposes of 
3
clause (i) in the same manner as such pro-
4
visions apply with respect to the deter-
5
mination of incurred costs for covered part 
6
D drugs for purposes of paragraph (4)(A). 
7
‘‘(iii) SPECIFIED
COVERED
PART
D 
8
DRUG.—For purposes of this subpara-
9
graph, the term ‘specified covered part D 
10
drug’ means a covered part D drug that 
11
is— 
12
‘‘(I) insulin; or 
13
‘‘(II) a medical supply associated 
14
with the injection of insulin (as de-
15
fined in regulations of the Secretary 
16
promulgated pursuant to subsection 
17
(e)(1)(B)).’’; and 
18
(2) in subsection (c), by adding at the end the 
19
following new paragraph: 
20
‘‘(5) SAME PROTECTION WITH RESPECT TO EX-
21
PENDITURES FOR INSULIN AND CERTAIN MEDICAL 
22
SUPPLIES.—The coverage provides the coverage re-
23
quired under subsection (b)(2)(F).’’. 
24
(b) CONFORMING AMENDMENTS.— 
25
00:26 Apr 24, 2021
H19
87 
•HR 19 IH
(1) IN GENERAL.—Section 1860D–14(a)(1)(D) 
1
of the Social Security Act (42 U.S.C. 1395w– 
2
114(a)(1)(D)), as amended by section 121, is fur-
3
ther amended— 
4
(A) in clause (ii), by striking ‘‘section 
5
1860D–2(b)(2)’’ and inserting ‘‘section 1860D– 
6
2(b)(2)(A)’’; and 
7
(B) in clause (iii), by striking ‘‘section 
8
1860D–2(b)(2)’’ and inserting ‘‘section 1860D– 
9
2(b)(2)(A)’’. 
10
(2) EFFECTIVE DATE.—The amendments made 
11
by paragraph (1) shall apply with respect to plan 
12
year 2022 and each subsequent plan year. 
13
SEC. 134. GROWTH RATE OF MEDICARE PART D OUT-OF- 
14
15
(a) PROVIDING MEDICARE PART D BENEFICIARIES 
16
WITH
CERTAIN
2020 OFFSET
PAYMENTS.—Section 
17
1860D–2(b)(4) of the Social Security Act (42 U.S.C. 
18
1395w–102(b)(4)) is amended by adding at the end the 
19
following new subparagraph: 
20
‘‘(F) 2020 OFFSET PAYMENTS.— 
21
‘‘(i) IN GENERAL.—Subject to clause 
22
(iv), the Secretary shall provide for pay-
23
ment from the Medicare Prescription Drug 
24
Account as follows: 
25
00:26 Apr 24, 2021
H19
88 
•HR 19 IH
‘‘(I) In the case of a specified in-
1
dividual (as defined in clause (ii)(I)) 
2
who as of the last day of a calendar 
3
quarter in 2020 has incurred costs for 
4
covered part D drugs so that the indi-
5
vidual has exceeded the annual out-of- 
6
pocket threshold applied under sub-
7
paragraph (B)(i)(V) for 2020, pay-
8
ment to the individual by not later 
9
than 15th day of the third month fol-
10
lowing the end of such quarter of the 
11
amount by which such threshold so 
12
applied exceeded the target threshold 
13
for 2020. 
14
‘‘(II) In the case of a specified 
15
individual who is not described in sub-
16
clause (I) and who as of the last day 
17
of 2020 has incurred costs for covered 
18
part D drugs so that the individual 
19
has exceeded the target threshold for 
20
2020, payment to the individual by 
21
not later than December 31, 2021, of 
22
the amount by which such incurred 
23
costs exceeded the target threshold for 
24
2020. 
25
00:26 Apr 24, 2021
H19
89 
•HR 19 IH
‘‘(ii) DEFINITIONS.—For purposes of 
1
this subparagraph: 
2
‘‘(I) SPECIFIED
INDIVIDUAL.— 
3
The term ‘specified individual’ means 
4
an individual who— 
5
‘‘(aa) is enrolled in a pre-
6
scription drug plan or an MA– 
7
PD plan; 
8
‘‘(bb) is not enrolled in a 
9
qualified retiree prescription drug 
10
plan; and 
11
‘‘(cc) is not entitled to an in-
12
come-related subsidy under sec-
13
tion 1860D–14(a). 
14
‘‘(II) TARGET
THRESHOLD
FOR 
15
2020.—The term ‘target threshold for 
16
2020’ means the annual out-of-pocket 
17
threshold that would have been ap-
18
plied under subparagraph (B)(i) for 
19
2020 if such threshold had been de-
20
termined in accordance with subclause 
21
(IV) of such subparagraph instead of 
22
subclause (V) of such subparagraph. 
23
‘‘(iii) NOTIFICATION.—In the case of 
24
any specified individual who during 2020 
25
00:26 Apr 24, 2021
H19
90 
•HR 19 IH
has incurred costs for covered part D 
1
drugs so that the individual has exceeded 
2
the target threshold for 2020, the Sec-
3
retary shall, not later than September 30, 
4
2021, provide to such individual a notifica-
5
tion informing such individual of such indi-
6
vidual’s right to a payment described in 
7
clause (i) and the estimated timing of such 
8
payment. 
9
‘‘(iv) CLARIFICATION.—The Secretary 
10
shall provide only 1 payment under this 
11
subparagraph with respect to any indi-
12
vidual. 
13
‘‘(v) 
IMPLEMENTATION.—The 
Sec-
14
retary may implement this subparagraph 
15
by program instruction or otherwise.’’. 
16
(b) REDUCED GROWTH RATE FOR 2021 OF MEDI-
17
CARE PART D OUT-OF-POCKET COST THRESHOLD.—Sec-
18
tion 1860D–2(b)(4)(B)(i) of the Social Security Act (42 
19
U.S.C. 1395w–102(b)(4)(B)(i)) is amended— 
20
(1) in subclause (V), by striking at the end 
21
‘‘or’’; 
22
(2) by redesignating subclause (VI) as sub-
23
clause (VIII); and 
24
00:26 Apr 24, 2021
H19
91 
•HR 19 IH
(3) by inserting after subclause (V) the fol-
1
lowing new subclauses: 
2
‘‘(VI) for 2021, is equal to the 
3
amount that would have been applied 
4
under this subparagraph for 2020 if 
5
such amount had been determined in 
6
accordance with subclause (IV) in-
7
stead of subclause (V), increased by 
8
the lesser of— 
9
‘‘(aa) the annual percentage 
10
increase described in paragraph 
11
(7) for 2021, plus 2 percentage 
12
points; or 
13
‘‘(bb) the annual percentage 
14
increase described in paragraph 
15
(6) for 2021; 
16
‘‘(VII) for 2022, is equal to the 
17
amount that would have been applied 
18
under this subparagraph for 2022 if 
19
the amendments made by section 
20
1101(d)(1) of the Health Care and 
21
Education Reconciliation Act of 2010 
22
and by section 134 of the Lower 
23
Costs, More Cures Act of 2021 had 
24
not been enacted; or’’. 
25
00:26 Apr 24, 2021
H19
92 
•HR 19 IH
TITLE II—MEDICAID 
1
SEC. 201. MEDICAID PHARMACY AND THERAPEUTICS COM-
2
MITTEE IMPROVEMENTS. 
3
(a) IN GENERAL.—Subparagraph (A) of section 
4
1927(d)(4) of the Social Security Act (42 U.S.C. 1396r– 
5
8(d)(4)) is amended to read as follows: 
6
‘‘(A)(i) The formulary is developed and re-
7
viewed by a pharmacy and therapeutics com-
8
mittee consisting of physicians, pharmacists, 
9
and other appropriate individuals appointed by 
10
the Governor of the State. 
11
‘‘(ii) Subject to clause (vi), the State estab-
12
lishes and implements a conflict of interest pol-
13
icy for the pharmacy and therapeutics com-
14
mittee that— 
15
‘‘(I) is publicly accessible; 
16
‘‘(II) requires all committee members 
17
to complete, on at least an annual basis, a 
18
disclosure of relationships, associations, 
19
and financial dealings that may affect their 
20
independence of judgement in committee 
21
matters; and 
22
‘‘(III) contains clear processes, such 
23
as recusal from voting or discussion, for 
24
those members who report a conflict of in-
25
00:26 Apr 24, 2021
H19
93 
•HR 19 IH
terest, along with appropriate processes to 
1
address any instance where a member fails 
2
to report a conflict of interest. 
3
‘‘(iii) The membership of the pharmacy 
4
and therapeutics committee— 
5
‘‘(I) includes at least 1 actively prac-
6
ticing physician and at least 1 actively 
7
practicing pharmacist, each of whom— 
8
‘‘(aa) is independent and free of 
9
conflict with respect to manufacturers 
10
and Medicaid participating plans or 
11
subcontractors, including pharmacy 
12
benefit managers; and 
13
‘‘(bb) has expertise in the care of 
14
1 or more Medicaid-specific popu-
15
lations such as elderly or disabled in-
16
dividuals, children with complex med-
17
ical needs, or low-income individuals 
18
with chronic illnesses; and 
19
‘‘(II) is made publicly available. 
20
‘‘(iv) At the option of the State, the 
21
State’s drug use review board established under 
22
subsection (g)(3) may serve as the pharmacy 
23
and therapeutics committee provided the State 
24
00:26 Apr 24, 2021
H19
94 
•HR 19 IH
ensures that such board meets the requirements 
1
of clauses (ii) and (iii). 
2
‘‘(v) The State reviews and has final ap-
3
proval of the formulary established by the phar-
4
macy and therapeutics committee. 
5
‘‘(vi) If the Secretary determines it appro-
6
priate or necessary based on the findings and 
7
recommendations of the Comptroller General of 
8
the United States in the report submitted to 
9
Congress under section 203 of the Lower Costs, 
10
More Cures Act of 2021, the Secretary shall 
11
issue guidance that States must follow for es-
12
tablishing conflict of interest policies for the 
13
pharmacy and therapeutics committee in ac-
14
cordance with the requirements of clause (ii), 
15
including appropriate standards and require-
16
ments for identifying, addressing, and reporting 
17
on conflicts of interest.’’. 
18
(b) APPLICATION TO MEDICAID MANAGED CARE OR-
19
GANIZATIONS.—Clause (xiii) of section 1903(m)(2)(A) of 
20
the Social Security Act (42 U.S.C. 1396b(m)(2)(A)) is 
21
amended— 
22
(1) by striking ‘‘and (III)’’ and inserting 
23
‘‘(III)’’; 
24
00:26 Apr 24, 2021
H19
95 
•HR 19 IH
(2) by striking the period at the end and insert-
1
ing ‘‘, and (IV) any formulary used by the entity for 
2
covered outpatient drugs dispensed to individuals eli-
3
gible for medical assistance who are enrolled with 
4
the entity is developed and reviewed by a pharmacy 
5
and therapeutics committee that meets the require-
6
ments 
of 
clauses 
(ii) 
and 
(iii) 
of 
section 
7
1927(d)(4)(A).’’; and 
8
(3) by moving the left margin 2 ems to the left. 
9
(c) EFFECTIVE DATE.—The amendments made by 
10
this section shall take effect on the date that is 1 year 
11
after the date of enactment of this Act. 
12
SEC. 202. GAO REPORT ON CONFLICTS OF INTEREST IN 
13
STATE MEDICAID PROGRAM DRUG USE RE-
14
VIEW BOARDS AND PHARMACY AND THERA-
15
PEUTICS (P&T) COMMITTEES. 
16
(a) INVESTIGATION.—The Comptroller General of the 
17
United States shall conduct an investigation of potential 
18
or existing conflicts of interest among members of State 
19
Medicaid program State drug use review boards (in this 
20
section referred to as ‘‘DUR Boards’’) and pharmacy and 
21
therapeutics committees (in this section referred to as 
22
‘‘P&T Committees’’). 
23
(b) REPORT.—Not later than 24 months after the 
24
date of enactment of this Act, the Comptroller General 
25
00:26 Apr 24, 2021
H19
96 
•HR 19 IH
shall submit to Congress a report on the investigation con-
1
ducted under subsection (a) that includes the following: 
2
(1) A description outlining how DUR Boards 
3
and P&T Committees operate in States, including 
4
details with respect to— 
5
(A) the structure and operation of DUR 
6
Boards and statewide P&T Committees; 
7
(B) States that operate separate P&T 
8
Committees for their fee-for-service Medicaid 
9
program and their Medicaid managed care or-
10
ganizations or other Medicaid managed care ar-
11
rangements (collectively referred to in this sec-
12
tion as ‘‘Medicaid MCOs)’’; and 
13
(C) States that allow Medicaid MCOs to 
14
have their own P&T Committees and the extent 
15
to which pharmacy benefit managers administer 
16
or participate in such P&T Committees. 
17
(2) A description outlining the differences be-
18
tween DUR Boards established in accordance with 
19
section 1927(g)(3) of the Social Security Act (42 
20
U.S.C. 1396r(g)(3)) and P&T Committees. 
21
(3) A description outlining the tools P&T Com-
22
mittees may use to determine Medicaid drug cov-
23
erage and utilization management policies. 
24
00:26 Apr 24, 2021
H19
97 
•HR 19 IH
(4) An analysis of whether and how States or 
1
P&T Committees establish participation and inde-
2
pendence requirements for DUR Boards and P&T 
3
Committees, including with respect to entities with 
4
connections with drug manufacturers, State Med-
5
icaid programs, managed care organizations, and 
6
other entities or individuals in the pharmaceutical 
7
industry. 
8
(5) A description outlining how States, DUR 
9
Boards, or P&T Committees define conflicts of inter-
10
est. 
11
(6) A description of how DUR Boards and P&T 
12
Committees address conflicts of interest, including 
13
who is responsible for implementing such policies. 
14
(7) A description of the tools, if any, States use 
15
to ensure that there are no conflicts of interest on 
16
DUR Boards and P&T Committees. 
17
(8) An analysis of the effectiveness of tools 
18
States use to ensure that there are no conflicts of 
19
interest on DUR Boards and P&T Committees and, 
20
if applicable, recommendations as to how such tools 
21
could be improved. 
22
(9) A review of strategies States may use to 
23
guard against conflicts of interest on DUR Boards 
24
and P&T Committees and to ensure compliance with 
25
00:26 Apr 24, 2021
H19
98 
•HR 19 IH
the requirements of titles XI and XIX of the Social 
1
Security Act (42 U.S.C. 1301 et seq., 1396 et seq.) 
2
and access to effective, clinically appropriate, and 
3
medically necessary drug treatments for Medicaid 
4
beneficiaries, including recommendations for such 
5
legislative and administrative actions as the Comp-
6
troller General determines appropriate. 
7
SEC. 203. ENSURING THE ACCURACY OF MANUFACTURER 
8
PRICE AND DRUG PRODUCT INFORMATION 
9
UNDER THE MEDICAID DRUG REBATE PRO-
10
GRAM. 
11
(a) AUDIT OF MANUFACTURER PRICE AND DRUG 
12
PRODUCT INFORMATION.— 
13
(1) IN GENERAL.—Subparagraph (B) of section 
14
1927(b)(3) of the Social Security Act (42 U.S.C. 
15
1396r–8(b)(3)) is amended to read as follows: 
16
‘‘(B) AUDITS AND SURVEYS OF MANUFAC-
17
TURER PRICE AND DRUG PRODUCT INFORMA-
18
TION.— 
19
‘‘(i) AUDITS.—The Secretary shall 
20
conduct ongoing audits of the price and 
21
drug product information reported by man-
22
ufacturers under subparagraph (A) for the 
23
most recently ended rebate period to en-
24
sure the accuracy and timeliness of such 
25
00:26 Apr 24, 2021
H19
99 
•HR 19 IH
information. In conducting such audits, the 
1
Secretary may employ evaluations, surveys, 
2
statistical sampling, predictive analytics 
3
and other relevant tools and methods. 
4
‘‘(ii) VERIFICATIONS SURVEYS OF AV-
5
ERAGE MANUFACTURER PRICE AND MANU-
6
FACTURER’S
AVERAGE
SALES
PRICE.—In 
7
addition to the audits required under 
8
clause (i), the Secretary may survey whole-
9
salers and manufacturers (including manu-
10
facturers that directly distribute their cov-
11
ered outpatient drugs (in this subpara-
12
graph referred to as ‘direct sellers’)), when 
13
necessary, to verify manufacturer prices 
14
and manufacturer’s average sales prices 
15
(including wholesale acquisition cost) to 
16
make payment reported under subpara-
17
graph (A). 
18
‘‘(iii) PENALTIES.—In addition to 
19
other penalties as may be prescribed by 
20
law, including under subparagraph (C) of 
21
this paragraph, the Secretary may impose 
22
a civil monetary penalty in an amount not 
23
to exceed $185,000 on an annual basis on 
24
a wholesaler, manufacturer, or direct sell-
25
00:26 Apr 24, 2021
H19
100 
•HR 19 IH
er, if the wholesaler, manufacturer, or di-
1
rect seller of a covered outpatient drug re-
2
fuses a request for information about 
3
charges or prices by the Secretary in con-
4
nection with an audit or survey under this 
5
subparagraph or knowingly provides false 
6
information. The provisions of section 
7
1128A (other than subsections (a) (with 
8
respect to amounts of penalties or addi-
9
tional assessments) and (b)) shall apply to 
10
a civil money penalty under this clause in 
11
the same manner as such provisions apply 
12
to a penalty or proceeding under section 
13
1128A(a). 
14
‘‘(iv) REPORTS.— 
15
‘‘(I) REPORT
TO
CONGRESS.— 
16
The Secretary shall, not later than 18 
17
months after date of enactment of 
18
this subparagraph, submit a report to 
19
the Committee on Energy and Com-
20
merce of the House of Representatives 
21
and the Committee on Finance of the 
22
Senate regarding additional regulatory 
23
or statutory changes that may be re-
24
quired in order to ensure accurate and 
25
00:26 Apr 24, 2021
H19
101 
•HR 19 IH
timely reporting and oversight of 
1
manufacturer price and drug product 
2
information, 
including 
whether 
3
changes should be made to reasonable 
4
assumption requirements to ensure 
5
such assumptions are reasonable and 
6
accurate or whether another method-
7
ology for ensuring accurate and timely 
8
reporting of price and drug product 
9
information should be considered to 
10
ensure the integrity of the drug rebate 
11
program under this section. 
12
‘‘(II) ANNUAL
REPORTS.—The 
13
Secretary shall, on at least an annual 
14
basis, submit a report to the Com-
15
mittee on Energy and Commerce of 
16
the House of Representatives and the 
17
Committee on Finance of the Senate 
18
summarizing the results of the audits 
19
and surveys conducted under this sub-
20
paragraph during the period that is 
21
the subject of the report. 
22
‘‘(III) CONTENT.—Each report 
23
submitted under subclause (II) shall, 
24
with respect to the period that is the 
25
00:26 Apr 24, 2021
H19
102 
•HR 19 IH
subject of the report, include sum-
1
maries of— 
2
‘‘(aa) error rates in the 
3
price, drug product, and other 
4
relevant information supplied by 
5
manufacturers under subpara-
6
graph (A); 
7
‘‘(bb) the timeliness with 
8
which 
manufacturers, 
whole-
9
salers, and direct sellers provide 
10
information required under sub-
11
paragraph (A) or under clause (i) 
12
or (ii) of this subparagraph; 
13
‘‘(cc) the number of manu-
14
facturers, wholesalers, and direct 
15
sellers and drug products audited 
16
under this subparagraph; 
17
‘‘(dd) the types of price and 
18
drug product information re-
19
viewed under the audits con-
20
ducted under this subparagraph; 
21
‘‘(ee) the tools and meth-
22
odologies employed in such au-
23
dits; 
24
00:26 Apr 24, 2021
H19
103 
•HR 19 IH
‘‘(ff) the findings of such 
1
audits, including which manufac-
2
turers, if any, were penalized 
3
under this subparagraph; and 
4
‘‘(gg) such other relevant in-
5
formation as the Secretary shall 
6
deem appropriate. 
7
‘‘(IV) PROTECTION OF INFORMA-
8
TION.—In preparing a report required 
9
under subclause (II), the Secretary 
10
shall redact such proprietary informa-
11
tion as the Secretary determines ap-
12
propriate to prevent disclosure of, and 
13
to safeguard, such information. 
14
‘‘(v) APPROPRIATIONS.—Out of any 
15
funds in the Treasury not otherwise appro-
16
priated, there is appropriated to the Sec-
17
retary $2,000,000 for fiscal year 2022 and 
18
each fiscal year thereafter to carry out this 
19
subparagraph.’’. 
20
(2) EFFECTIVE DATE.—The amendments made 
21
by this subsection shall take effect on the first day 
22
of the first fiscal quarter that begins after the date 
23
of enactment of this Act. 
24
00:26 Apr 24, 2021
H19
104 
•HR 19 IH
(b) INCREASED PENALTIES
FOR NONCOMPLIANCE 
1
WITH REPORTING REQUIREMENTS.— 
2
(1) INCREASED PENALTY FOR LATE REPORTING 
3
OF INFORMATION.—Section 1927(b)(3)(C)(i) of the 
4
Social Security Act (42 U.S.C. 1396r–8(b)(3)(C)(i)) 
5
is amended by striking ‘‘increased by $10,000 for 
6
each day in which such information has not been 
7
provided and such amount shall be paid to the 
8
Treasury’’ and inserting ‘‘, for each covered out-
9
patient drug with respect to which such information 
10
is not provided, $50,000 for the first day that such 
11
information is not provided on a timely basis and 
12
$19,000 for each subsequent day that such informa-
13
tion is not provided’’. 
14
(2) INCREASED PENALTY FOR KNOWINGLY RE-
15
FALSE
INFORMATION.—Section 
16
1927(b)(3)(C)(ii) of the Social Security Act (42 
17
U.S.C. 1396r–8(b)(3)(C)(ii)) is amended by striking 
18
‘‘$100,000’’ and inserting ‘‘$500,000’’. 
19
(3) EFFECTIVE DATE.—The amendments made 
20
by this subsection shall take effect on the first day 
21
of the first fiscal quarter that begins after the date 
22
of enactment of this Act. 
23
00:26 Apr 24, 2021
H19
105 
•HR 19 IH
SEC. 204. IMPROVING TRANSPARENCY AND PREVENTING 
1
THE USE OF ABUSIVE SPREAD PRICING AND 
2
RELATED PRACTICES IN MEDICAID. 
3
(a) PASS-THROUGH PRICING REQUIRED.— 
4
(1) IN GENERAL.—Section 1927(e) of the So-
5
cial Security Act (42 U.S.C. 1396r–8(e)) is amended 
6
by adding at the end the following: 
7
‘‘(6) PASS-THROUGH
PRICING
REQUIRED.—A 
8
contract between the State and a pharmacy benefit 
9
manager (referred to in this paragraph as a ‘PBM’), 
10
or a contract between the State and a managed care 
11
entity or other specified entity (as such terms are 
12
defined in section 1903(m)(9)(D)) that includes pro-
13
visions making the entity responsible for coverage of 
14
covered outpatient drugs dispensed to individuals en-
15
rolled with the entity, shall require that payment for 
16
such drugs and related administrative services (as 
17
applicable), including payments made by a PBM on 
18
behalf of the State or entity, is based on a pass- 
19
through pricing model under which— 
20
‘‘(A) any payment made by the entity of 
21
the PBM (as applicable) for such a drug— 
22
‘‘(i) is limited to— 
23
‘‘(I) ingredient cost; and 
24
‘‘(II) a professional dispensing 
25
fee that is not less than the profes-
26
00:26 Apr 24, 2021
H19
106 
•HR 19 IH
sional dispensing fee that the State 
1
plan or waiver would pay if the plan 
2
or waiver was making the payment di-
3
rectly; 
4
‘‘(ii) is passed through in its entirety 
5
by the entity or PBM to the pharmacy 
6
that dispenses the drug; and 
7
‘‘(iii) is made in a manner that is con-
8
sistent with section 1902(a)(30)(A) and 
9
sections 447.512, 447.514, and 447.518 of 
10
title 42, Code of Federal Regulations (or 
11
any successor regulation), as if such re-
12
quirements applied directly to the entity or 
13
the PBM; 
14
‘‘(B) payment to the entity or the PBM 
15
(as applicable) for administrative services per-
16
formed by the entity or PBM is limited to a 
17
reasonable administrative fee that covers the 
18
reasonable cost of providing such services; 
19
‘‘(C) the entity or the PBM (as applicable) 
20
shall make available to the State, and the Sec-
21
retary upon request, all costs and payments re-
22
lated to covered outpatient drugs and accom-
23
panying administrative services incurred, re-
24
ceived, or made by the entity or the PBM, in-
25
00:26 Apr 24, 2021
H19
107 
•HR 19 IH
cluding ingredient costs, professional dispensing 
1
fees, administrative fees, post-sale and post-in- 
2
voice fees. Discounts, or related adjustments 
3
such as direct and indirect remuneration fees, 
4
and any and all remuneration; and 
5
‘‘(D) any form of spread pricing whereby 
6
any amount charged or claimed by the entity or 
7
the PBM (as applicable) is in excess of the 
8
amount paid to the pharmacies on behalf of the 
9
entity, including any post-sale or post-invoice 
10
fees, discounts, or related adjustments such as 
11
direct and indirect remuneration fees or assess-
12
ments (after allowing for a reasonable adminis-
13
trative fee as described in subparagraph (B)) is 
14
not allowable for purposes of claiming Federal 
15
matching payments under this title.’’. 
16
(2) CONFORMING
AMENDMENT.—Clause (xiii) 
17
of section 1903(m)(2)(A) of such Act (42 U.S.C. 
18
1396b(m)(2)(A)), as amended by section 202, is fur-
19
ther amended— 
20
(A) by striking ‘‘and (IV)’’ and inserting 
21
‘‘(IV)’’; and 
22
(B) by inserting before the period at the 
23
end the following: ‘‘, and (V) pharmacy benefit 
24
management services provided by the entity, or 
25
00:26 Apr 24, 2021
H19
108 
•HR 19 IH
provided by a pharmacy benefit manager on be-
1
half of the entity under a contract or other ar-
2
rangement between the entity and the phar-
3
macy benefit manager, shall comply with the re-
4
quirements of section 1927(e)(6)’’. 
5
(3) EFFECTIVE DATE.—The amendments made 
6
by this subsection apply to contracts between States 
7
and managed care entities, other specified entities, 
8
or pharmacy benefits managers that are entered into 
9
or renewed on or after the date that is 18 months 
10
after the date of enactment of this Act. 
11
(b) SURVEY OF RETAIL PRICES.— 
12
(1) IN GENERAL.—Section 1927(f) of the Social 
13
Security Act (42 U.S.C. 1396r–8(f)) is amended— 
14
(A) by striking ‘‘and’’ after the semicolon 
15
at the end of paragraph (1)(A)(i) and all that 
16
precedes it through ‘‘(1)’’ and inserting the fol-
17
lowing: 
18
‘‘(1) SURVEY
OF
RETAIL
PRICES.—The Sec-
19
retary shall conduct a survey of retail community 
20
drug prices, to include at least the national average 
21
drug acquisition cost, as follows: 
22
‘‘(A) USE
OF
VENDOR.—The Secretary 
23
may contract services for— 
24
00:26 Apr 24, 2021
H19
109 
•HR 19 IH
‘‘(i) with respect to retail community 
1
pharmacies, the determination on a month-
2
ly basis of retail survey prices of the na-
3
tional average drug acquisition cost for 
4
covered outpatient drugs for such phar-
5
macies, net of all discounts and rebates (to 
6
the extent any information with respect to 
7
such discounts and rebates is available), 
8
the average reimbursement received for 
9
such drugs by such pharmacies from all 
10
sources of payment, including third par-
11
ties, and, to the extent available, the usual 
12
and customary charges to consumers for 
13
such drugs; and’’; 
14
(B) by adding at the end of paragraph (1) 
15
the following: 
16
‘‘(F) SURVEY
REPORTING.—In order to 
17
meet the requirement of section 1902(a)(54), a 
18
State shall require that any retail community 
19
pharmacy in the State that receives any pay-
20
ment, administrative fee, discount, or rebate re-
21
lated to the dispensing of covered outpatient 
22
drugs to individuals receiving benefits under 
23
this title, regardless of whether such payment, 
24
fee, discount, or rebate is received from the 
25
00:26 Apr 24, 2021
H19
110 
•HR 19 IH
State or a managed care entity directly or from 
1
a pharmacy benefit manager or another entity 
2
that has a contract with the State or a man-
3
aged care entity, shall respond to surveys of re-
4
tail prices conducted under this subsection. 
5
‘‘(G) SURVEY INFORMATION.—Information 
6
on retail community prices obtained under this 
7
paragraph shall be made publicly available and 
8
shall include at least the following: 
9
‘‘(i) The monthly response rate of the 
10
survey including a list of pharmacies not in 
11
compliance with subparagraph (F). 
12
‘‘(ii) The sampling frame and number 
13
of pharmacies sampled monthly. 
14
‘‘(iii) 
Characteristics 
of 
reporting 
15
pharmacies, including type (such as inde-
16
pendent or chain), geographic or regional 
17
location, and dispensing volume. 
18
‘‘(iv) Reporting of a separate national 
19
average drug acquisition cost for each drug 
20
for independent retail pharmacies and 
21
chain operated pharmacies. 
22
‘‘(v) Information on price concessions 
23
including on and off invoice discounts, re-
24
bates, and other price concessions. 
25
00:26 Apr 24, 2021
H19
111 
•HR 19 IH
‘‘(vi) Information on average profes-
1
sional dispensing fees paid. 
2
‘‘(H) PENALTIES.— 
3
‘‘(i) FAILURE TO PROVIDE TIMELY IN-
4
FORMATION.—A retail community phar-
5
macy that fails to respond to a survey con-
6
ducted under this subsection on a timely 
7
basis may be subject to a civil monetary 
8
penalty in the amount of $10,000 for each 
9
day in which such information has not 
10
been provided. 
11
‘‘(ii) FALSE INFORMATION.—A retail 
12
community pharmacy that knowingly pro-
13
vides false information in response to a 
14
survey conducted under this subsection 
15
may be subject to a civil money penalty in 
16
an amount not to exceed $100,000 for 
17
each item of false information. 
18
‘‘(iii) OTHER
PENALTIES.—Any civil 
19
money penalties imposed under this sub-
20
paragraph shall be in addition to other 
21
penalties as may be prescribed by law. The 
22
provisions of section 1128A (other than 
23
subsections (a) and (b)) shall apply to a 
24
civil money penalty under this subpara-
25
00:26 Apr 24, 2021
H19
112 
•HR 19 IH
graph in the same manner as such provi-
1
sions apply to a penalty or proceedings 
2
under section 1128A(a). 
3
‘‘(I) 
REPORT
ON
SPECIALTY
PHAR-
4
MACIES.— 
5
‘‘(i) IN GENERAL.—Not later than 1 
6
year after the effective date of this sub-
7
paragraph, the Secretary shall submit a re-
8
port to Congress examining specialty drug 
9
coverage and reimbursement under this 
10
title. 
11
‘‘(ii) CONTENT OF REPORT.—Such re-
12
port shall include a description of how 
13
State Medicaid programs define specialty 
14
drugs, how much State Medicaid programs 
15
pay for specialty drugs, how States and 
16
managed care plans determine payment for 
17
specialty drugs, the settings in which spe-
18
cialty drugs are dispensed (such as retail 
19
community pharmacies or specialty phar-
20
macies), whether acquisition costs for spe-
21
cialty drugs are captured in the national 
22
average drug acquisition cost survey, and 
23
recommendations as to whether specialty 
24
pharmacies should be included in the sur-
25
00:26 Apr 24, 2021
H19
113 
•HR 19 IH
vey of retail prices to ensure national aver-
1
age drug acquisition costs capture drugs 
2
sold at specialty pharmacies and how such 
3
specialty pharmacies should be defined.’’; 
4
(C) in paragraph (2)— 
5
(i) in subparagraph (A), by inserting 
6
‘‘, including payments rates under Med-
7
icaid managed care plans,’’ after ‘‘under 
8
this title’’; and 
9
(ii) in subparagraph (B), by inserting 
10
‘‘and the basis for such dispensing fees’’ 
11
before the semicolon; and 
12
(D) in paragraph (4), by inserting ‘‘, and 
13
$5,000,000 for fiscal year 2022 and each fiscal 
14
year thereafter,’’ after ‘‘2010’’. 
15
(2) EFFECTIVE DATE.—The amendments made 
16
by this subsection take effect on the 1st day of the 
17
1st quarter that begins on or after the date that is 
18
18 months after the date of enactment of this Act. 
19
(c) MANUFACTURER REPORTING
OF WHOLESALE 
20
ACQUISITION COST.—Section 1927(b)(3) of such Act (42 
21
U.S.C. 1396r–8(b)(3)), as amended by section 141, is fur-
22
ther amended— 
23
(1) in subparagraph (A)(i)— 
24
00:26 Apr 24, 2021
H19
114 
•HR 19 IH
(A) in subclause (I), by striking ‘‘and’’ 
1
after the semicolon; 
2
(B) in subclause (II), by adding ‘‘and’’ 
3
after the semicolon; 
4
(C) by moving the left margins of sub-
5
clauses (I) and (II) 2 ems to the right; and 
6
(D) by adding at the end the following: 
7
‘‘(III) in the case of rebate peri-
8
ods that begin on or after the date of 
9
enactment of this subclause, on the 
10
wholesale acquisition cost (as defined 
11
in section 1847A(c)(6)(B)) for cov-
12
ered outpatient drugs for the rebate 
13
period under the agreement (including 
14
for all such drugs that are sold under 
15
a new drug application approved 
16
under section 505(c) of the Federal 
17
Food, Drug, and Cosmetic Act);’’; and 
18
(2) in subparagraph (D)— 
19
(A) in the matter preceding clause (i), by 
20
inserting ‘‘and clause (vii) of this subpara-
21
graph’’ after ‘‘1847A’’; 
22
(B) in clause (vi), by striking ‘‘and’’ after 
23
the comma; 
24
00:26 Apr 24, 2021
H19
115 
•HR 19 IH
(C) in clause (vii), by striking the period 
1
and inserting ‘‘, and’’; and 
2
(D) by inserting after clause (vii) the fol-
3
lowing: 
4
‘‘(viii) to the Secretary to disclose 
5
(through a website accessible to the public) 
6
the most recently reported wholesale acqui-
7
sition 
cost 
(as 
defined 
in 
section 
8
1847A(c)(6)(B)) for each covered out-
9
patient drug (including for all such drugs 
10
that are sold under a new drug application 
11
approved under section 505(c) of the Fed-
12
eral Food, Drug, and Cosmetic Act), as re-
13
ported under subparagraph (A)(i)(III).’’. 
14
SEC. 205. T–MSIS DRUG DATA ANALYTICS REPORTS. 
15
(a) IN GENERAL.—Not later than May 1 of each cal-
16
endar year beginning with calendar year 2023, the Sec-
17
retary of Health and Human Services (in this section re-
18
ferred to as the ‘‘Secretary’’) shall publish on a website 
19
of the Centers for Medicare & Medicaid Services that is 
20
accessible to the public a report of the most recently avail-
21
able data on provider prescribing patterns under the Med-
22
icaid program. 
23
(b) CONTENT OF REPORT.— 
24
00:26 Apr 24, 2021
H19
116 
•HR 19 IH
(1) REQUIRED
CONTENT.—Each report re-
1
quired under subsection (a) for a calendar year shall 
2
include the following information with respect to 
3
each State (and, to the extent available, with respect 
4
to Puerto Rico, the United States Virgin Islands, 
5
Guam, the Northern Mariana Islands, and American 
6
Samoa): 
7
(A) A comparison of covered outpatient 
8
drug (as defined in section 1927(k)(2) of the 
9
Social Security Act (42 U.S.C. 1396r–8(k)(2))) 
10
prescribing patterns under the State Medicaid 
11
plan or waiver of such plan (including drugs 
12
prescribed on a fee-for-service basis and drugs 
13
prescribed under managed care arrangements 
14
under such plan or waiver)— 
15
(i) across all forms or models of reim-
16
bursement used under the plan or waiver; 
17
(ii) within specialties and subspecial-
18
ties, as defined by the Secretary; 
19
(iii) by episodes of care for— 
20
(I) each chronic disease category, 
21
as defined by the Secretary, that is 
22
represented in the 10 conditions that 
23
accounted for the greatest share of 
24
total spending under the plan or waiv-
25
00:26 Apr 24, 2021
H19
117 
•HR 19 IH
er during the year that is the subject 
1
of the report; 
2
(II) procedural groupings; and 
3
(III) rare disease diagnosis codes; 
4
(iv) by patient demographic character-
5
istics, including race (to the extent that 
6
the Secretary determines that there is suf-
7
ficient data available with respect to such 
8
characteristic in a majority of States), gen-
9
der, and age; 
10
(v) by patient high-utilizer or risk sta-
11
tus; and 
12
(vi) by high and low resource settings 
13
by facility and place of service categories, 
14
as determined by the Secretary. 
15
(B) In the case of medical assistance for 
16
covered outpatient drugs (as so defined) pro-
17
vided under a State Medicaid plan or waiver of 
18
such plan in a managed care setting, an anal-
19
ysis of the differences in managed care pre-
20
scribing patterns when a covered outpatient 
21
drug is prescribed in a managed care setting as 
22
compared to when the drug is prescribed in a 
23
fee-for-service setting. 
24
00:26 Apr 24, 2021
H19
118 
•HR 19 IH
(2) ADDITIONAL CONTENT.—A report required 
1
under subsection (a) for a calendar year may include 
2
State-specific information about prescription utiliza-
3
tion management tools under State Medicaid plans 
4
or waivers of such plans, including— 
5
(A) a description of prescription utilization 
6
management tools under State programs to pro-
7
vide long-term services and supports under a 
8
State Medicaid plan or a waiver of such plan; 
9
(B) a comparison of prescription utilization 
10
management tools applicable to populations cov-
11
ered under a State Medicaid plan waiver under 
12
section 1115 of the Social Security Act (42 
13
U.S.C. 1315) and the models applicable to pop-
14
ulations that are not covered under the waiver; 
15
(C) a comparison of the prescription utili-
16
zation management tools employed by different 
17
Medicaid managed care organizations, phar-
18
macy benefit managers, and related entities 
19
within the State; 
20
(D) a comparison of the prescription utili-
21
zation management tools applicable to each en-
22
rollment category under a State Medicaid plan 
23
or waiver; and 
24
00:26 Apr 24, 2021
H19
119 
•HR 19 IH
(E) a comparison of the prescription utili-
1
zation management tools applicable under the 
2
State Medicaid plan or waiver by patient high- 
3
utilizer or risk status. 
4
(3) ADDITIONAL
ANALYSIS.—To the extent 
5
practicable, the Secretary shall include in each re-
6
port published under subsection (a)— 
7
(A) analyses of national, State, and local 
8
patterns of Medicaid population-based pre-
9
scribing behaviors; and 
10
(B) recommendations for administrative or 
11
legislative action to improve the effectiveness of, 
12
and reduce costs for, covered outpatient drugs 
13
under Medicaid while ensuring timely bene-
14
ficiary access to medically necessary covered 
15
outpatient drugs. 
16
(c) USE OF T–MSIS DATA.—Each report required 
17
under subsection (a) shall— 
18
(1) be prepared using data and definitions from 
19
the Transformed Medicaid Statistical Information 
20
System (T–MSIS) data set (or a successor data set) 
21
that is not more than 24 months old on the date 
22
that the report is published; and 
23
(2) as appropriate, include a description with 
24
respect to each State of the quality and complete-
25
00:26 Apr 24, 2021
H19
120 
•HR 19 IH
ness of the data, as well as any necessary caveats 
1
describing the limitations of the data reported to the 
2
Secretary by the State that are sufficient to commu-
3
nicate the appropriate uses for the information. 
4
(d) PREPARATION
OF REPORT.—Each report re-
5
quired under subsection (a) shall be prepared by the Ad-
6
ministrator for the Centers for Medicare & Medicaid Serv-
7
ices. 
8
(e) APPROPRIATION.—For fiscal year 2022 and each 
9
fiscal year thereafter, there is appropriated to the Sec-
10
retary $2,000,000 to carry out this section. 
11
SEC. 206. RISK-SHARING VALUE-BASED PAYMENT AGREE-
12
MENTS FOR COVERED OUTPATIENT DRUGS 
13
UNDER MEDICAID. 
14
(a) IN GENERAL.—Section 1927 of the Social Secu-
15
rity Act (42 U.S.C. 1396r–8) is amended by adding at 
16
the end the following new subsection: 
17
‘‘(l) STATE OPTION TO PAY FOR COVERED OUT-
18
PATIENT DRUGS THROUGH RISK-SHARING VALUE-BASED 
19
AGREEMENTS.— 
20
‘‘(1) IN
GENERAL.—Beginning January 1, 
21
2022, a State shall have the option to pay (whether 
22
on a fee-for-service or managed care basis) for cov-
23
ered outpatient drugs that are potentially curative 
24
treatments intended for one-time use that are ad-
25
00:26 Apr 24, 2021
H19
121 
•HR 19 IH
ministered to individuals under this title by entering 
1
into a risk-sharing value-based payment agreement 
2
with the manufacturer of the drug in accordance 
3
with the requirements of this subsection. 
4
‘‘(2) SECRETARIAL APPROVAL.— 
5
‘‘(A) IN GENERAL.—A State shall submit a 
6
request to the Secretary to enter into a risk- 
7
sharing value based payment agreement, and 
8
the Secretary shall not approve a proposed risk- 
9
sharing value-based payment agreement be-
10
tween a State and a manufacturer for payment 
11
for a covered outpatient drug of the manufac-
12
turer unless the following requirements are met: 
13
‘‘(i) MANUFACTURER IS PARTY TO RE-
14
BATE
AGREEMENT
AND
IN
COMPLIANCE 
15
WITH REQUIREMENTS.—The manufacturer 
16
has a rebate agreement in effect as re-
17
quired under subsections (a) and (b) of 
18
this section and is in compliance with all 
19
applicable requirements under this title. 
20
‘‘(ii) NO
INCREASE
TO
PROJECTED 
21
NET FEDERAL SPENDING.— 
22
‘‘(I) IN
GENERAL.—The Chief 
23
Actuary certifies that the projected 
24
payments for each covered outpatient 
25
00:26 Apr 24, 2021
H19
122 
•HR 19 IH
drug under such proposed agreement 
1
would not result in greater estimated 
2
Federal spending under this title than 
3
the net Federal spending that would 
4
result in the absence of the agree-
5
ment. 
6
‘‘(II) NET
FEDERAL
SPENDING 
7
DEFINED.—For purposes of this sub-
8
section, the term ‘net Federal spend-
9
ing’ means the amount of Federal 
10
payments the Chief Actuary estimates 
11
would be made under this title for ad-
12
ministering a covered outpatient drug 
13
to an individual eligible for medical 
14
assistance under a State plan or a 
15
waiver of such plan, reduced by the 
16
amount of all rebates the Chief Actu-
17
ary estimates would be paid with re-
18
spect to the administering of such 
19
drug, including all rebates under this 
20
title and any supplemental or other 
21
additional rebates, in the absence of 
22
such an agreement. 
23
‘‘(III) INFORMATION.—The Chief 
24
Actuary shall make the certifications 
25
00:26 Apr 24, 2021
H19
123 
•HR 19 IH
required under this clause based on 
1
the most recently available and reli-
2
able drug pricing and product infor-
3
mation. The State and manufacturer 
4
shall provide the Secretary and the 
5
Chief Actuary with all necessary infor-
6
mation required to make the estimates 
7
needed for such certifications. 
8
‘‘(iii) LAUNCH AND LIST PRICE JUS-
9
TIFICATIONS.—The manufacturer submits 
10
all relevant information and supporting 
11
documentation necessary for pricing deci-
12
sions as deemed appropriate by the Sec-
13
retary, which shall be truthful and non- 
14
misleading, including manufacturer infor-
15
mation and supporting documentation for 
16
launch price or list price increases, and 
17
any applicable justification required under 
18
section 1128L. 
19
‘‘(iv) CONFIDENTIALITY OF INFORMA-
20
TION; PENALTIES.—The provisions of sub-
21
paragraphs (C) and (D) of subsection 
22
(b)(3) shall apply to a manufacturer that 
23
fails to submit the information and docu-
24
mentation required under clauses (ii) and 
25
00:26 Apr 24, 2021
H19
124 
•HR 19 IH
(iii) on a timely basis, or that knowingly 
1
provides false or misleading information, in 
2
the same manner as such provisions apply 
3
to a manufacturer with a rebate agreement 
4
under this section. 
5
‘‘(B) CONSIDERATION OF STATE REQUEST 
6
FOR APPROVAL.— 
7
‘‘(i) IN
GENERAL.—The Secretary 
8
shall treat a State request for approval of 
9
a risk-sharing value-based payment agree-
10
ment in the same manner that the Sec-
11
retary treats a State plan amendment, and 
12
subpart B of part 430 of title 42, Code of 
13
Federal Regulations, including, subject to 
14
clause (ii), the timing requirements of sec-
15
tion 430.16 of such title (as in effect on 
16
the date of enactment of this subsection), 
17
shall apply to a request for approval of a 
18
risk-sharing value-based payment agree-
19
ment in the same manner as such subpart 
20
applies to a State plan amendment. 
21
‘‘(ii) TIMING.—The Secretary shall 
22
consult with the Commissioner of Food 
23
and Drugs as required under subpara-
24
graph (C) and make a determination on 
25
00:26 Apr 24, 2021
H19
125 
•HR 19 IH
whether to approve a request from a State 
1
for approval of a proposed risk-sharing 
2
value-based payment agreement (or request 
3
additional information necessary to allow 
4
the Secretary to make a determination 
5
with respect to such request for approval) 
6
within the time period, to the extent prac-
7
ticable, specified in section 430.16 of title 
8
42, Code of Federal Regulations (as in ef-
9
fect on the date of enactment of this sub-
10
section), but in no case shall the Secretary 
11
take more than 180 days after the receipt 
12
of such request for approval or response to 
13
such request for additional information to 
14
make such a determination (or request ad-
15
ditional information). 
16
‘‘(C) CONSULTATION WITH THE COMMIS-
17
SIONER OF FOOD AND DRUGS.—In considering 
18
whether to approve a risk-sharing value-based 
19
payment agreement, the Secretary, to the ex-
20
tent necessary, shall consult with the Commis-
21
sioner of Food and Drugs to determine whether 
22
the relevant clinical parameters specified in 
23
such agreement are appropriate. 
24
00:26 Apr 24, 2021
H19
126 
•HR 19 IH
‘‘(3) INSTALLMENT-BASED
PAYMENT
STRUC-
1
TURE.— 
2
‘‘(A) IN GENERAL.—A risk-sharing value- 
3
based payment agreement shall provide for a 
4
payment structure under which, for every in-
5
stallment year of the agreement (subject to sub-
6
paragraph (B)), the State shall pay the total in-
7
stallment year amount in equal installments to 
8
be paid at regular intervals over a period of 
9
time that shall be specified in the agreement. 
10
‘‘(B) REQUIREMENTS
FOR
INSTALLMENT 
11
PAYMENTS.— 
12
‘‘(i) TIMING
OF
FIRST
PAYMENT.— 
13
The State shall make the first of the in-
14
stallment payments described in subpara-
15
graph (A) for an installment year not later 
16
than 30 days after the end of such year. 
17
‘‘(ii) LENGTH OF INSTALLMENT PE-
18
RIOD.—The period of time over which the 
19
State shall make the installment payments 
20
described in subparagraph (A) for an in-
21
stallment year shall not be longer than 5 
22
years. 
23
‘‘(iii) NONPAYMENT
OR
REDUCED 
24
PAYMENT OF INSTALLMENTS FOLLOWING 
25
00:26 Apr 24, 2021
H19
127 
•HR 19 IH
A
FAILURE
TO
MEET
CLINICAL
PARAM-
1
ETER.—If, prior to the payment date (as 
2
specified in the agreement) of any install-
3
ment payment described in subparagraph 
4
(A) or any other alternative date or time 
5
frame (as otherwise specified in the agree-
6
ment), the covered outpatient drug which 
7
is subject to the agreement fails to meet a 
8
relevant clinical parameter of the agree-
9
ment, the agreement shall provide that— 
10
‘‘(I) the installment payment 
11
shall not be made; or 
12
‘‘(II) the installment payment 
13
shall be reduced by a percentage spec-
14
ified in the agreement that is based 
15
on the outcome achieved by the drug 
16
relative to the relevant clinical param-
17
eter. 
18
‘‘(4) NOTICE OF INTENT.— 
19
‘‘(A) IN
GENERAL.—Subject to subpara-
20
graph (B), a manufacturer of a covered out-
21
patient drug shall not be eligible to enter into 
22
a risk-sharing value-based payment agreement 
23
under this subsection with respect to such drug 
24
unless the manufacturer notifies the Secretary 
25
00:26 Apr 24, 2021
H19
128 
•HR 19 IH
that the manufacturer is interested in entering 
1
into such an agreement with respect to such 
2
drug. The decision to submit and timing of a 
3
request to enter into a proposed risk-sharing 
4
value-based payment agreement shall remain 
5
solely within the discretion of the State and 
6
shall only be effective upon Secretarial approval 
7
as required under this subsection. 
8
‘‘(B) TREATMENT OF SUBSEQUENTLY AP-
9
PROVED DRUGS.— 
10
‘‘(i) IN GENERAL.—In the case of a 
11
manufacturer of a covered outpatient drug 
12
approved under section 505 of the Federal 
13
Food, Drug, and Cosmetic Act or licensed 
14
under section 351 of the Public Health 
15
Service Act after the date of enactment of 
16
this subsection, not more than 90 days 
17
after meeting with the Food and Drug Ad-
18
ministration following phase II clinical 
19
trials for such drug (or, in the case of a 
20
drug described in clause (ii), not later than 
21
March 31, 2022), the manufacturer must 
22
notify the Secretary of the manufacturer’s 
23
intent to enter into a risk-sharing value- 
24
based payment agreement under this sub-
25
00:26 Apr 24, 2021
H19
129 
•HR 19 IH
section with respect to such drug. If no 
1
such meeting has occurred, the Secretary 
2
may use discretion as to whether a poten-
3
tially curative treatment intended for one- 
4
time use may qualify for a risk-sharing 
5
value-based payment agreement under this 
6
section. A manufacturer notification of in-
7
terest shall not have any influence on a de-
8
cision for approval by the Food and Drug 
9
Administration. 
10
‘‘(ii) APPLICATION TO CERTAIN SUB-
11
SEQUENTLY
APPROVED
DRUGS.—A drug 
12
described in this clause is a covered out-
13
patient drug of a manufacturer— 
14
‘‘(I) that is approved under sec-
15
tion 505 of the Federal Food, Drug, 
16
and Cosmetic Act or licensed under 
17
section 351 of the Public Health Serv-
18
ice Act after the date of enactment of 
19
this subsection; and 
20
‘‘(II) with respect to which, as of 
21
January 1, 2022, more than 90 days 
22
have passed after the manufacturer’s 
23
meeting with the Food and Drug Ad-
24
00:26 Apr 24, 2021
H19
130 
•HR 19 IH
ministration following phase II clinical 
1
trials for such drug. 
2
‘‘(iii) 
PARALLEL
APPROVAL.—The 
3
Secretary, in coordination with the Admin-
4
istrator of the Centers for Medicare & 
5
Medicaid Services and the Commissioner of 
6
Food and Drugs, shall, to the extent prac-
7
ticable, approve a State’s request to enter 
8
into a proposed risk-sharing value-based 
9
payment agreement that otherwise meets 
10
the requirements of this subsection at the 
11
time that such a drug is approved by the 
12
Food and Drug Administration to help 
13
provide that no State that wishes to enter 
14
into such an agreement is required to pay 
15
for the drug in full at one time if the State 
16
is seeking to pay over a period of time as 
17
outlined in the proposed agreement. 
18
‘‘(iv) RULE
OF
CONSTRUCTION.— 
19
Nothing in this paragraph shall be applied 
20
or construed to modify or affect the time-
21
frames or factors involved in the Sec-
22
retary’s determination of whether to ap-
23
prove or license a drug under section 505 
24
of the Federal Food, Drug, and Cosmetic 
25
00:26 Apr 24, 2021
H19
131 
•HR 19 IH
Act or section 351 of the Public Health 
1
Service Act. 
2
‘‘(5) SPECIAL PAYMENT RULES.— 
3
‘‘(A) IN GENERAL.—Except as otherwise 
4
provided in this paragraph, with respect to an 
5
individual who is administered a unit of a cov-
6
ered outpatient drug that is purchased under a 
7
State plan by a State Medicaid agency under a 
8
risk-sharing value-based payment agreement in 
9
an installment year, the State shall remain lia-
10
ble to the manufacturer of such drug for pay-
11
ment for such unit without regard to whether 
12
the individual remains enrolled in the State 
13
plan under this title (or a waiver of such plan) 
14
for each installment year for which the State is 
15
to make installment payments for covered out-
16
patient drugs purchased under the agreement 
17
in such year. 
18
‘‘(B) DEATH.—In the case of an individual 
19
described in subparagraph (A) who dies during 
20
the period described in such subparagraph, the 
21
State plan shall not be liable for any remaining 
22
payment for the unit of the covered outpatient 
23
drug administered to the individual which is 
24
00:26 Apr 24, 2021
H19
132 
•HR 19 IH
owed under the agreement described in such 
1
subparagraph. 
2
‘‘(C) WITHDRAWAL OF APPROVAL.—In the 
3
case of a covered outpatient drug that is the 
4
subject of a risk-sharing value-based agreement 
5
between a State and a manufacturer under this 
6
subsection, including a drug approved in ac-
7
cordance with section 506(c) of the Federal 
8
Food, Drug, and Cosmetic Act, and such drug 
9
is the subject of an application that has been 
10
withdrawn by the Secretary, the State plan 
11
shall not be liable for any remaining payment 
12
that is owed under the agreement. 
13
‘‘(D) ALTERNATIVE ARRANGEMENT UNDER 
14
AGREEMENT.—Subject to approval by the Sec-
15
retary, the terms of a proposed risk-sharing 
16
value-based payment agreement submitted for 
17
approval by a State may provide that subpara-
18
graph (A) shall not apply. 
19
‘‘(E) GUIDANCE.—Not later than January 
20
1, 2022, the Secretary shall issue guidance to 
21
States establishing a process for States to no-
22
tify the Secretary when an individual who is ad-
23
ministered a unit of a covered outpatient drug 
24
that is purchased by a State plan under a risk- 
25
00:26 Apr 24, 2021
H19
133 
•HR 19 IH
sharing value-based payment agreement ceases 
1
to be enrolled under the State plan under this 
2
title (or a waiver of such plan) or dies before 
3
the end of the installment period applicable to 
4
such unit under the agreement. 
5
‘‘(6) TREATMENT OF PAYMENTS UNDER RISK- 
6
SHARING
VALUE-BASED
AGREEMENTS
FOR
PUR-
7
8
PRICE.—The Secretary shall treat any payments 
9
made to the manufacturer of a covered outpatient 
10
drug under a risk-sharing value-based payment 
11
agreement under this subsection during a rebate pe-
12
riod in the same manner that the Secretary treats 
13
payments made under a State supplemental rebate 
14
agreement 
under 
sections 
447.504(c)(19) 
and 
15
447.505(c)(7) of title 42, Code of Federal Regula-
16
tions (or any successor regulations), for purposes of 
17
determining average manufacturer price and best 
18
price under this section with respect to the covered 
19
outpatient drug and a rebate period and for pur-
20
poses of offsets required under subsection (b)(1)(B). 
21
‘‘(7) ASSESSMENTS
AND
REPORT
TO
CON-
22
GRESS.— 
23
‘‘(A) ASSESSMENTS.— 
24
00:26 Apr 24, 2021
H19
134 
•HR 19 IH
‘‘(i) IN
GENERAL.—Not later than 
1
180 days after the end of each assessment 
2
period of any risk-sharing value-based pay-
3
ment agreement for a State approved 
4
under this subsection, the Secretary shall 
5
conduct an evaluation of such agreement 
6
which shall include an evaluation by the 
7
Chief Actuary to determine whether pro-
8
gram spending under the risk-sharing 
9
value-based payment agreement aligned 
10
with the projections for the agreement 
11
made under paragraph (2)(A)(ii), including 
12
an assessment of whether actual Federal 
13
spending under this title under the agree-
14
ment was less or more than net Federal 
15
spending would have been in the absence 
16
of the agreement. 
17
‘‘(ii) ASSESSMENT PERIOD.—For pur-
18
poses of clause (i)— 
19
‘‘(I) the first assessment period 
20
for a risk-sharing value-based pay-
21
ment agreement shall be the period of 
22
time over which payments are sched-
23
uled to be made under the agreement 
24
for the first 10 individuals who are 
25
00:26 Apr 24, 2021
H19
135 
•HR 19 IH
administered covered outpatient drugs 
1
under the agreement except that such 
2
period shall not exceed the 5-year pe-
3
riod after the date on which the Sec-
4
retary approves the agreement; and 
5
‘‘(II) each subsequent assessment 
6
period for a risk-sharing value-based 
7
payment agreement shall be the 5- 
8
year period following the end of the 
9
previous assessment period. 
10
‘‘(B) RESULTS OF ASSESSMENTS.— 
11
‘‘(i) TERMINATION
OPTION.—If the 
12
Secretary determines as a result of the as-
13
sessment by the Chief Actuary under sub-
14
paragraph (A) that the actual Federal 
15
spending under this title for any covered 
16
outpatient drug that was the subject of the 
17
State’s risk-sharing value-based payment 
18
agreement was greater than the net Fed-
19
eral spending that would have resulted in 
20
the absence of the agreement, the Sec-
21
retary may terminate approval of such 
22
agreement and shall immediately conduct 
23
an assessment under this paragraph of any 
24
other ongoing risk-sharing value-based 
25
00:26 Apr 24, 2021
H19
136 
•HR 19 IH
payment agreement to which the same 
1
manufacturer is a party. 
2
‘‘(ii) REPAYMENT REQUIRED.— 
3
‘‘(I) IN
GENERAL.—If the Sec-
4
retary determines as a result of the 
5
assessment by the Chief Actuary 
6
under subparagraph (A) that the Fed-
7
eral spending under the risk-sharing 
8
value-based agreement for a covered 
9
outpatient drug that was subject to 
10
such agreement was greater than the 
11
net Federal spending that would have 
12
resulted in the absence of the agree-
13
ment, the manufacturer shall repay 
14
the difference to the State and Fed-
15
eral governments in a timely manner 
16
as determined by the Secretary. 
17
‘‘(II) TERMINATION
FOR
FAIL-
18
URE TO PAY.—The failure of a manu-
19
facturer to make repayments required 
20
under subclause (I) in a timely man-
21
ner shall result in immediate termi-
22
nation of all risk-sharing value-based 
23
agreements to which the manufacturer 
24
is a party. 
25
00:26 Apr 24, 2021
H19
137 
•HR 19 IH
‘‘(III) 
ADDITIONAL
PEN-
1
ALTIES.—In the case of a manufac-
2
turer that fails to make repayments 
3
required under subclause (I), the Sec-
4
retary may treat such manufacturer 
5
in the same manner as a manufac-
6
turer that fails to pay required re-
7
bates under this section, and the Sec-
8
retary may— 
9
‘‘(aa) suspend or terminate 
10
the manufacturer’s rebate agree-
11
ment under this section; and 
12
‘‘(bb) pursue any other rem-
13
edy that would be available if the 
14
manufacturer had failed to pay 
15
required rebates under this sec-
16
tion. 
17
‘‘(C) REPORT
TO
CONGRESS.—Not later 
18
than 5 years after the first risk-sharing value- 
19
based payment agreement is approved under 
20
this subsection, the Secretary shall submit to 
21
Congress and make available to the public a re-
22
port that includes— 
23
‘‘(i) an assessment of the impact of 
24
risk-sharing value-based payment agree-
25
00:26 Apr 24, 2021
H19
138 
•HR 19 IH
ments on access for individuals who are eli-
1
gible for benefits under a State plan or 
2
waiver under this title to medically nec-
3
essary covered outpatient drugs and re-
4
lated treatments; 
5
‘‘(ii) an analysis of the impact of such 
6
agreements on overall State and Federal 
7
spending under this title; 
8
‘‘(iii) an assessment of the impact of 
9
such agreements on drug prices, including 
10
launch price and price increases; and 
11
‘‘(iv) such recommendations to Con-
12
gress as the Secretary deems appropriate. 
13
‘‘(8) GUIDANCE AND REGULATIONS.— 
14
‘‘(A) IN GENERAL.—Not later than Janu-
15
ary 1, 2022, the Secretary shall issue guidance 
16
to States seeking to enter into risk-sharing 
17
value-based payment agreements under this 
18
subsection that includes a model template for 
19
such agreements. The Secretary may issue any 
20
additional guidance or promulgate regulations 
21
as necessary to implement and enforce the pro-
22
visions of this subsection. 
23
‘‘(B) MODEL AGREEMENTS.— 
24
00:26 Apr 24, 2021
H19
139 
•HR 19 IH
‘‘(i) IN
GENERAL.—If a State ex-
1
presses an interest in pursuing a risk-shar-
2
ing value-based payment agreement under 
3
this subsection with a manufacturer for 
4
the purchase of a covered outpatient drug, 
5
the Secretary may share with such State 
6
any risk-sharing value-based agreement be-
7
tween a State and the manufacturer for 
8
the purchase of such drug that has been 
9
approved under this subsection. While such 
10
shared agreement may serve as a template 
11
for a State that wishes to propose, the use 
12
of a previously approved agreement shall 
13
not affect the submission and approval 
14
process for approval of a proposed risk- 
15
sharing value-based payment agreement 
16
under this subsection, including the re-
17
quirements under paragraph (2)(A). 
18
‘‘(ii) CONFIDENTIALITY.—In the case 
19
of a risk-sharing value-based payment 
20
agreement that is disclosed to a State by 
21
the Secretary under this subparagraph and 
22
that is only in effect with respect to a sin-
23
gle State, the confidentiality of information 
24
00:26 Apr 24, 2021
H19
140 
•HR 19 IH
provisions 
described 
in 
subsection 
1
(b)(3)(D) shall apply to such information. 
2
‘‘(C) OIG CONSULTATION.— 
3
‘‘(i) IN
GENERAL.—The Secretary 
4
shall consult with the Office of the Inspec-
5
tor General of the Department of Health 
6
and Human Services to determine whether 
7
there are potential program integrity con-
8
cerns with agreement approvals or tem-
9
plates and address accordingly. 
10
‘‘(ii) OIG POLICY UPDATES AS NEC-
11
ESSARY.—The Inspector General of the 
12
Department of Health and Human Serv-
13
ices shall review and update, as necessary, 
14
any policies or guidelines of the Office of 
15
the Inspector General of the Department 
16
of Human Services (including policies re-
17
lated to the enforcement of section 1128B) 
18
to accommodate the use of risk-sharing 
19
value-based payment agreements in accord-
20
ance with this section. 
21
‘‘(9) RULES OF CONSTRUCTION.— 
22
‘‘(A) MODIFICATIONS.—Nothing in this 
23
subsection or any regulations promulgated 
24
under this subsection shall prohibit a State 
25
00:26 Apr 24, 2021
H19
141 
•HR 19 IH
from requesting a modification from the Sec-
1
retary to the terms of a risk-sharing value- 
2
based payment agreement. A modification that 
3
is expected to result in any increase to pro-
4
jected net State or Federal spending under the 
5
agreement shall be subject to recertification by 
6
the Chief Actuary as described in paragraph 
7
(2)(A)(ii) before the modification may be ap-
8
proved. 
9
‘‘(B) REBATE AGREEMENTS.—Nothing in 
10
this subsection shall be construed as requiring 
11
a State to enter into a risk-sharing value-based 
12
payment agreement or as limiting or super-
13
seding the ability of a State to enter into a sup-
14
plemental rebate agreement for a covered out-
15
patient drug. 
16
‘‘(C) FFP FOR PAYMENTS UNDER RISK- 
17
SHARING
VALUE-BASED
PAYMENT
AGREE-
18
MENTS.—Federal financial participation shall 
19
be available under this title for any payment 
20
made by a State to a manufacturer for a cov-
21
ered outpatient drug under a risk-sharing 
22
value-based payment agreement in accordance 
23
with this subsection, except that no Federal fi-
24
nancial participation shall be available for any 
25
00:26 Apr 24, 2021
H19
142 
•HR 19 IH
payment made by a State to a manufacturer 
1
under such an agreement on and after the ef-
2
fective date of a disapproval of such agreement 
3
by the Secretary. 
4
‘‘(D) CONTINUED APPLICATION OF OTHER 
5
PROVISIONS.—Except as expressly provided in 
6
this subsection, nothing in this subsection or in 
7
any regulations promulgated under this sub-
8
section shall affect the application of any other 
9
provision of this Act. 
10
‘‘(10) APPROPRIATIONS.—For fiscal year 2022 
11
and each fiscal year thereafter, there are appro-
12
priated to the Secretary $5,000,000 for the purpose 
13
of carrying out this subsection. 
14
‘‘(11) DEFINITIONS.—In this subsection: 
15
‘‘(A) CHIEF ACTUARY.—The term ‘Chief 
16
Actuary’ means the Chief Actuary of the Cen-
17
ters for Medicare & Medicaid Services. 
18
‘‘(B) INSTALLMENT YEAR.—The term ‘in-
19
stallment year’ means, with respect to a risk- 
20
sharing value-based payment agreement, a 12- 
21
month period during which a covered outpatient 
22
drug is administered under the agreement. 
23
‘‘(C) POTENTIALLY CURATIVE TREATMENT 
24
INTENDED FOR ONE-TIME USE.—The term ‘po-
25
00:26 Apr 24, 2021
H19
143 
•HR 19 IH
tentially curative treatment intended for one- 
1
time use’ means a treatment that consists of 
2
the administration of a covered outpatient drug 
3
that— 
4
‘‘(i) is a form of gene therapy for a 
5
rare disease, as defined by the Commis-
6
sioner of Food and Drugs, designated 
7
under section 526 of the Federal Food, 
8
Drug, and Cosmetics Act, and approved 
9
under section 505 of such Act or licensed 
10
under subsection (a) or (k) of section 351 
11
of the Public Health Service Act to treat 
12
a serious or life-threatening disease or con-
13
dition; 
14
‘‘(ii) if administered in accordance 
15
with the labeling of such drug, is expected 
16
to result in either— 
17
‘‘(I) the cure of such disease or 
18
condition; or 
19
‘‘(II) a reduction in the symp-
20
toms of such disease or condition to 
21
the extent that such disease or condi-
22
tion is not expected to lead to early 
23
mortality; and 
24
00:26 Apr 24, 2021
H19
144 
•HR 19 IH
‘‘(iii) is expected to achieve a result 
1
described in clause (ii), which may be 
2
achieved over an extended period of time, 
3
after not more than 3 administrations. 
4
‘‘(D) RELEVANT CLINICAL PARAMETER.— 
5
The term ‘relevant clinical parameter’ means, 
6
with respect to a covered outpatient drug that 
7
is the subject of a risk-sharing value-based pay-
8
ment agreement— 
9
‘‘(i) a clinical endpoint specified in the 
10
drug’s labeling or supported by one or 
11
more of the compendia described in section 
12
1861(t)(2)(B)(ii)(I) that— 
13
‘‘(I) is able to be measured or 
14
evaluated on an annual basis for each 
15
year of the agreement on an inde-
16
pendent basis by a provider or other 
17
entity; and 
18
‘‘(II) is required to be achieved 
19
(based on observed metrics in patient 
20
populations) under the terms of the 
21
agreement; or 
22
‘‘(ii) a surrogate endpoint (as defined 
23
in section 507(e)(9) of the Federal Food, 
24
Drug, and Cosmetic Act), including those 
25
00:26 Apr 24, 2021
H19
145 
•HR 19 IH
developed by patient-focused drug develop-
1
ment tools, that— 
2
‘‘(I) is able to be measured or 
3
evaluated on an annual basis for each 
4
year of the agreement on an inde-
5
pendent basis by a provider or other 
6
entity; and 
7
‘‘(II) has been qualified by the 
8
Food and Drug Administration. 
9
‘‘(E) RISK-SHARING
VALUE-BASED
PAY-
10
MENT
AGREEMENT.—The term ‘risk-sharing 
11
value-based payment agreement’ means an 
12
agreement between a State plan and a manu-
13
facturer— 
14
‘‘(i) for the purchase of a covered out-
15
patient drug of the manufacturer that is a 
16
potentially curative treatment intended for 
17
one-time use; 
18
‘‘(ii) under which payment for such 
19
drug shall be made pursuant to an install-
20
ment-based payment structure that meets 
21
the requirements of paragraph (3); 
22
‘‘(iii) which conditions payment on the 
23
achievement of at least 2 relevant clinical 
24
00:26 Apr 24, 2021
H19
146 
•HR 19 IH
parameters (as defined in subparagraph 
1
(C)); 
2
‘‘(iv) which provides that— 
3
‘‘(I) the State plan will directly 
4
reimburse the manufacturer for the 
5
drug; or 
6
‘‘(II) a third party will reimburse 
7
the manufacture in a manner ap-
8
proved by the Secretary; and 
9
‘‘(v) is approved by the Secretary in 
10
accordance with paragraph (2). 
11
‘‘(F) 
TOTAL
INSTALLMENT
YEAR 
12
AMOUNT.—The term ‘total installment year 
13
amount’ means, with respect to a risk-sharing 
14
value-based payment agreement for the pur-
15
chase of a covered outpatient drug and an in-
16
stallment year, an amount equal to the product 
17
of— 
18
‘‘(i) the unit price of the drug charged 
19
under the agreement; and 
20
‘‘(ii) the number of units of such drug 
21
administered under the agreement during 
22
such installment year.’’. 
23
(b) CONFORMING AMENDMENTS.— 
24
00:26 Apr 24, 2021
H19
147 
•HR 19 IH
(1) Section 1903(i)(10)(A) of the Social Secu-
1
rity Act (42 U.S.C. 1396b(i)(10)(A)) is amended by 
2
striking ‘‘or unless section 1927(a)(3) applies’’ and 
3
inserting ‘‘, section 1927(a)(3) applies with respect 
4
to such drugs, or such drugs are the subject of a 
5
risk-sharing value-based payment agreement under 
6
section 1927(l)’’. 
7
(2) Section 1927(b) of the Social Security Act 
8
(42 U.S.C. 1396r–8(b)) is amended— 
9
(A) in paragraph (1)(A), by inserting ‘‘(ex-
10
cept for drugs for which payment is made by a 
11
State under a risk-sharing value-based payment 
12
agreement under subsection (l))’’ after ‘‘under 
13
the State plan for such period’’; and 
14
(B) in paragraph (3)— 
15
(i) in subparagraph (C)(i), by insert-
16
ing ‘‘or subsection (l)(2)(A)’’ after ‘‘sub-
17
paragraph (A)’’; and 
18
(ii) in subparagraph (D), in the mat-
19
ter preceding clause (i), by inserting ‘‘, 
20
under subsection (l)(2)(A),’’ after ‘‘under 
21
this paragraph’’. 
22
00:26 Apr 24, 2021
H19
148 
•HR 19 IH
SEC. 207. APPLYING MEDICAID DRUG REBATE REQUIRE-
1
MENT TO DRUGS PROVIDED AS PART OF OUT-
2
PATIENT HOSPITAL SERVICES. 
3
(a) IN GENERAL.—Section 1927(k)(3) of the Social 
4
Security Act (42 U.S.C. 1396r–8(k)(3)) is amended to 
5
read as follows: 
6
‘‘(3) LIMITING DEFINITION.— 
7
‘‘(A) IN
GENERAL.—The term ‘covered 
8
outpatient drug’ does not include any drug, bio-
9
logical product, or insulin provided as part of, 
10
or as incident to and in the same setting as, 
11
any of the following (and for which payment 
12
may be made under this title as part of pay-
13
ment for the following and not as direct reim-
14
bursement for the drug): 
15
‘‘(i) Inpatient hospital services. 
16
‘‘(ii) Hospice services. 
17
‘‘(iii) Dental services, except that 
18
drugs for which the State plan authorizes 
19
direct reimbursement to the dispensing 
20
dentist are covered outpatient drugs. 
21
‘‘(iv) Physicians’ services. 
22
‘‘(v) Outpatient hospital services. 
23
‘‘(vi) Nursing facility services and 
24
services provided by an intermediate care 
25
facility for the mentally retarded. 
26
00:26 Apr 24, 2021
H19
149 
•HR 19 IH
‘‘(vii) Other laboratory and x-ray serv-
1
ices. 
2
‘‘(viii) Renal dialysis. 
3
‘‘(B) OTHER
EXCLUSIONS.—Such term 
4
also does not include any such drug or product 
5
for which a National Drug Code number is not 
6
required by the Food and Drug Administration 
7
or a drug or biological used for a medical indi-
8
cation which is not a medically accepted indica-
9
tion. 
10
‘‘(C) STATE OPTION.—At the option of a 
11
State, such term may include any drug, biologi-
12
cal product, or insulin for which the State is 
13
the primary payer under this title or a dem-
14
onstration project concerning this title, and that 
15
is provided on an outpatient basis as part of, or 
16
as incident to and in the same setting as, de-
17
scribed in clause (iv) or (v) of subparagraph (A) 
18
and for which payment is made as part of pay-
19
ment for such services. 
20
‘‘(D) NO EFFECT ON BEST PRICE.—Any 
21
drug, biological product, or insulin excluded 
22
from the definition of such term as a result of 
23
this paragraph shall be treated as a covered 
24
outpatient drug for purposes of determining the 
25
00:26 Apr 24, 2021
H19
150 
•HR 19 IH
best price (as defined in subsection (c)(1)(C)) 
1
for such drug, biological product, or insulin.’’. 
2
(b) EFFECTIVE
DATE; IMPLEMENTATION
GUID-
3
ANCE.— 
4
(1) IN
GENERAL.—The amendment made by 
5
subsection (a) shall take effect on the date that is 
6
1 year after the date of enactment of this Act. 
7
(2) IMPLEMENTATION
AND
GUIDANCE.—Not 
8
later than 1 year after the date of enactment of this 
9
Act, the Secretary of Health and Human Services 
10
shall issue guidance and relevant informational bul-
11
letins for States, manufacturers (as defined in sec-
12
tion 1927(k)(5) of the Social Security Act (42 
13
U.S.C. 1396r–8(k)(5))), and other relevant stake-
14
holders, including health care providers, regarding 
15
implementation of the amendment made by sub-
16
section (a). 
17
TITLE III—FOOD AND DRUG 
18
ADMINISTRATION 
19
Subtitle A—Pay-for-Delay 
20
SEC. 301. UNLAWFUL AGREEMENTS. 
21
(a) AGREEMENTS PROHIBITED.—Subject to sub-
22
sections (b) and (c), it shall be unlawful for an NDA or 
23
BLA holder and a subsequent filer (or for two subsequent 
24
filers) to enter into, or carry out, an agreement resolving 
25
00:26 Apr 24, 2021
H19
151 
•HR 19 IH
or settling a covered patent infringement claim on a final 
1
or interim basis if under such agreement— 
2
(1) a subsequent filer directly or indirectly re-
3
ceives from such holder (or in the case of such an 
4
agreement between two subsequent filers, the other 
5
subsequent filer) anything of value, including a li-
6
cense; and 
7
(2) the subsequent filer agrees to limit or fore-
8
go research on, or development, manufacturing, 
9
marketing, or sales, for any period of time, of the 
10
covered product that is the subject of the application 
11
described in subparagraph (A) or (B) of subsection 
12
(g)(8). 
13
(b) EXCLUSION.—It shall not be unlawful under sub-
14
section (a) if a party to an agreement described in such 
15
subsection demonstrates by clear and convincing evidence 
16
that the value described in subsection (a)(1) is compensa-
17
tion solely for other goods or services that the subsequent 
18
filer has promised to provide. 
19
(c) LIMITATION.—Nothing in this section shall pro-
20
hibit an agreement resolving or settling a covered patent 
21
infringement claim in which the consideration granted by 
22
the NDA or BLA holder to the subsequent filer (or from 
23
one subsequent filer to another) as part of the resolution 
24
or settlement includes only one or more of the following: 
25
00:26 Apr 24, 2021
H19
152 
•HR 19 IH
(1) The right to market the covered product 
1
that is the subject of the application described in 
2
subparagraph (A) or (B) of subsection (g)(8) in the 
3
United States before the expiration of— 
4
(A) any patent that is the basis of the cov-
5
ered patent infringement claim; or 
6
(B) any patent right or other statutory ex-
7
clusivity that would prevent the marketing of 
8
such covered product. 
9
(2) A payment for reasonable litigation ex-
10
penses not to exceed $7,500,000 in the aggregate. 
11
(3) A covenant not to sue on any claim that 
12
such covered product infringes a patent. 
13
(d) ENFORCEMENT BY FEDERAL TRADE COMMIS-
14
SION.— 
15
(1) GENERAL APPLICATION.—The requirements 
16
of this section apply, according to their terms, to an 
17
NDA or BLA holder or subsequent filer that is— 
18
(A) a person, partnership, or corporation 
19
over which the Commission has authority pur-
20
suant to section 5(a)(2) of the Federal Trade 
21
Commission Act (15 U.S.C. 45(a)(2)); or 
22
(B) a person, partnership, or corporation 
23
over which the Commission would have author-
24
ity pursuant to such section but for the fact 
25
00:26 Apr 24, 2021
H19
153 
•HR 19 IH
that such person, partnership, or corporation is 
1
not organized to carry on business for its own 
2
profit or that of its members. 
3
(2) UNFAIR OR DECEPTIVE ACTS OR PRACTICES 
4
ENFORCEMENT AUTHORITY.— 
5
(A) IN GENERAL.—A violation of this sec-
6
tion shall be treated as an unfair or deceptive 
7
act or practice in violation of section 5(a)(1) of 
8
the Federal Trade Commission Act (15 U.S.C. 
9
45(a)(1)). 
10
(B) POWERS OF COMMISSION.—Except as 
11
provided in subparagraph (C) and paragraphs 
12
(1)(B) and (3)— 
13
(i) the Commission shall enforce this 
14
section in the same manner, by the same 
15
means, and with the same jurisdiction, 
16
powers, and duties as though all applicable 
17
terms and provisions of the Federal Trade 
18
Commission Act (15 U.S.C. 41 et seq.) 
19
were incorporated into and made a part of 
20
this section; and 
21
(ii) any NDA or BLA holder or subse-
22
quent filer that violates this section shall 
23
be subject to the penalties and entitled to 
24
00:26 Apr 24, 2021
H19
154 
•HR 19 IH
the privileges and immunities provided in 
1
the Federal Trade Commission Act. 
2
(C) JUDICIAL REVIEW.—In the case of a 
3
cease and desist order issued by the Commis-
4
sion under section 5 of the Federal Trade Com-
5
mission Act (15 U.S.C. 45) for violation of this 
6
section, a party to such order may obtain judi-
7
cial review of such order as provided in such 
8
section 5, except that— 
9
(i) such review may only be obtained 
10
in— 
11
(I) the United States Court of 
12
Appeals for the District of Columbia 
13
Circuit; 
14
(II) the United States Court of 
15
Appeals for the circuit in which the 
16
ultimate parent entity, as defined in 
17
section 801.1(a)(3) of title 16, Code 
18
of Federal Regulations, or any suc-
19
cessor thereto, of the NDA or BLA 
20
holder (if any such holder is a party 
21
to such order) is incorporated as of 
22
the date that the application described 
23
in subparagraph (A) or (B) of sub-
24
section (g)(8) or an approved applica-
25
00:26 Apr 24, 2021
H19
155 
•HR 19 IH
tion that is deemed to be a license for 
1
a biological product under section 
2
351(k) of the Public Health Service 
3
Act (42 U.S.C. 262(k)) pursuant to 
4
section 7002(e)(4) of the Biologics 
5
Price Competition and Innovation Act 
6
of 2009 (Public Law 111–148; 124 
7
Stat. 817) is submitted to the Com-
8
missioner of Food and Drugs; or 
9
(III) the United States Court of 
10
Appeals for the circuit in which the 
11
ultimate parent entity, as so defined, 
12
of any subsequent filer that is a party 
13
to such order is incorporated as of the 
14
date that the application described in 
15
subparagraph (A) or (B) of subsection 
16
(g)(8) is submitted to the Commis-
17
sioner of Food and Drugs; and 
18
(ii) the petition for review shall be 
19
filed in the court not later than 30 days 
20
after such order is served on the party 
21
seeking review. 
22
(3) ADDITIONAL ENFORCEMENT AUTHORITY.— 
23
(A) CIVIL
PENALTY.—The Commission 
24
may commence a civil action to recover a civil 
25
00:26 Apr 24, 2021
H19
156 
•HR 19 IH
penalty in a district court of the United States 
1
against any NDA or BLA holder or subsequent 
2
filer that violates this section. 
3
(B) SPECIAL
RULE
FOR
RECOVERY
OF 
4
PENALTY
IF
CEASE
AND
DESIST
ORDER 
5
ISSUED.— 
6
(i) IN GENERAL.—If the Commission 
7
has issued a cease and desist order in a 
8
proceeding under section 5 of the Federal 
9
Trade Commission Act (15 U.S.C. 45) for 
10
violation of this section— 
11
(I) the Commission may com-
12
mence a civil action under subpara-
13
graph (A) to recover a civil penalty 
14
against any party to such order at 
15
any time before the expiration of the 
16
1-year period beginning on the date 
17
on which such order becomes final 
18
under section 5(g) of such Act (15 
19
U.S.C. 45(g)); and 
20
(II) in such civil action, the find-
21
ings of the Commission as to the ma-
22
terial facts in such proceeding shall be 
23
conclusive, unless— 
24
00:26 Apr 24, 2021
H19
157 
•HR 19 IH
(aa) the terms of such order 
1
expressly provide that the Com-
2
mission’s findings shall not be 
3
conclusive; or 
4
(bb) such order became final 
5
by reason of section 5(g)(1) of 
6
such Act (15 U.S.C. 45(g)(1)), in 
7
which case such findings shall be 
8
conclusive if supported by evi-
9
dence. 
10
(ii) RELATIONSHIP TO PENALTY FOR 
11
VIOLATION
OF
AN
ORDER.—The penalty 
12
provided in clause (i) for violation of this 
13
section is separate from and in addition to 
14
any penalty that may be incurred for viola-
15
tion of an order of the Commission under 
16
section 5(l) of the Federal Trade Commis-
17
sion Act (15 U.S.C. 45(l)). 
18
(C) AMOUNT OF PENALTY.— 
19
(i) IN GENERAL.—The amount of a 
20
civil penalty imposed in a civil action under 
21
subparagraph (A) on a party to an agree-
22
ment described in subsection (a) shall be 
23
sufficient to deter violations of this section, 
24
but in no event greater than— 
25
00:26 Apr 24, 2021
H19
158 
•HR 19 IH
(I) if such party is the NDA or 
1
BLA holder (or, in the case of an 
2
agreement between two subsequent fil-
3
ers, the subsequent filer who gave the 
4
value described in subsection (a)(1)), 
5
the greater of— 
6
(aa) 3 times the value re-
7
ceived by such NDA or BLA 
8
holder (or by such subsequent 
9
filer) that is reasonably attrib-
10
utable to the violation of this sec-
11
tion; or 
12
(bb) 3 times the value given 
13
to the subsequent filer (or to the 
14
other subsequent filer) reason-
15
ably attributable to the violation 
16
of this section; and 
17
(II) if such party is the subse-
18
quent filer (or, in the case of an 
19
agreement between two subsequent fil-
20
ers, the subsequent filer who received 
21
the value described in subsection 
22
(a)(1)), 3 times the value received by 
23
such subsequent filer that is reason-
24
00:26 Apr 24, 2021
H19
159 
•HR 19 IH
ably attributable to the violation of 
1
this section. 
2
(ii) FACTORS FOR CONSIDERATION.— 
3
In determining such amount, the court 
4
shall take into account— 
5
(I) the nature, circumstances, ex-
6
tent, and gravity of the violation; 
7
(II) with respect to the violator, 
8
the degree of culpability, any history 
9
of violations, the ability to pay, any 
10
effect on the ability to continue doing 
11
business, profits earned by the NDA 
12
or BLA holder (or, in the case of an 
13
agreement between two subsequent fil-
14
ers, the subsequent filer who gave the 
15
value described in subsection (a)(1)), 
16
compensation received by the subse-
17
quent filer (or, in the case of an 
18
agreement between two subsequent fil-
19
ers, the subsequent filer who received 
20
the value described in subsection 
21
(a)(1)), and the amount of commerce 
22
affected; and 
23
(III) other matters that justice 
24
requires. 
25
00:26 Apr 24, 2021
H19
160 
•HR 19 IH
(D) INJUNCTIONS AND OTHER EQUITABLE 
1
RELIEF.—In a civil action under subparagraph 
2
(A), the United States district courts are em-
3
powered to grant mandatory injunctions and 
4
such other and further equitable relief as they 
5
deem appropriate. 
6
(4) REMEDIES
IN
ADDITION.—Remedies pro-
7
vided in this subsection are in addition to, and not 
8
in lieu of, any other remedy provided by Federal 
9
law. 
10
(5) PRESERVATION OF AUTHORITY OF COMMIS-
11
SION.—Nothing in this section shall be construed to 
12
affect any authority of the Commission under any 
13
other provision of law. 
14
(e) FEDERAL TRADE COMMISSION RULEMAKING.— 
15
The Commission may, in its discretion, by rule promul-
16
gated under section 553 of title 5, United States Code, 
17
exempt from this section certain agreements described in 
18
subsection (a) if the Commission finds such agreements 
19
to be in furtherance of market competition and for the 
20
benefit of consumers. 
21
(f) ANTITRUST LAWS.—Nothing in this section shall 
22
modify, impair, limit, or supersede the applicability of the 
23
antitrust laws as defined in subsection (a) of the first sec-
24
tion of the Clayton Act (15 U.S.C. 12(a)), and of section 
25
00:26 Apr 24, 2021
H19
161 
•HR 19 IH
5 of the Federal Trade Commission Act (15 U.S.C. 45) 
1
to the extent that such section 5 applies to unfair methods 
2
of competition. Nothing in this section shall modify, im-
3
pair, limit, or supersede the right of a subsequent filer 
4
to assert claims or counterclaims against any person, 
5
under the antitrust laws or other laws relating to unfair 
6
competition. 
7
(g) DEFINITIONS.—In this section: 
8
(1) AGREEMENT
RESOLVING
OR
SETTLING
A 
9
COVERED
PATENT
INFRINGEMENT
CLAIM.—The 
10
term ‘‘agreement resolving or settling a covered pat-
11
ent infringement claim’’ means any agreement 
12
that— 
13
(A) resolves or settles a covered patent in-
14
fringement claim; or 
15
(B) is contingent upon, provides for a con-
16
tingent condition for, or is otherwise related to 
17
the resolution or settlement of a covered patent 
18
infringement claim. 
19
(2) COMMISSION.—The term ‘‘Commission’’ 
20
means the Federal Trade Commission. 
21
(3) COVERED PATENT INFRINGEMENT CLAIM.— 
22
The term ‘‘covered patent infringement claim’’ 
23
means an allegation made by the NDA or BLA hold-
24
er to a subsequent filer (or, in the case of an agree-
25
00:26 Apr 24, 2021
H19
162 
•HR 19 IH
ment between two subsequent filers, by one subse-
1
quent filer to another), whether or not included in 
2
a complaint filed with a court of law, that— 
3
(A) the submission of the application de-
4
scribed in subparagraph (A) or (B) of para-
5
graph (9), or the manufacture, use, offering for 
6
sale, sale, or importation into the United States 
7
of a covered product that is the subject of such 
8
an application— 
9
(i) in the case of an agreement be-
10
tween an NDA or BLA holder and a sub-
11
sequent filer, infringes any patent owned 
12
by, or exclusively licensed to, the NDA or 
13
BLA holder of the covered product; or 
14
(ii) in the case of an agreement be-
15
tween two subsequent filers, infringes any 
16
patent owned by the subsequent filer; or 
17
(B) in the case of an agreement between 
18
an NDA or BLA holder and a subsequent filer, 
19
the covered product to be manufactured under 
20
such application uses a covered product as 
21
claimed in a published patent application. 
22
(4) COVERED
PRODUCT.—The term ‘‘covered 
23
product’’ means a drug (as defined in section 201(g) 
24
of the Federal Food, Drug, and Cosmetic Act (21 
25
00:26 Apr 24, 2021
H19
163 
•HR 19 IH
U.S.C. 321(g))), including a biological product (as 
1
defined in section 351(i) of the Public Health Serv-
2
ice Act (42 U.S.C. 262(i))). 
3
(5) NDA OR BLA HOLDER.—The term ‘‘NDA 
4
or BLA holder’’ means— 
5
(A) the holder of— 
6
(i) an approved new drug application 
7
filed under section 505(b)(1) of the Fed-
8
eral Food, Drug, and Cosmetic Act (21 
9
U.S.C. 355(b)(1)) for a covered product; 
10
or 
11
(ii) a biologics license application filed 
12
under section 351(a) of the Public Health 
13
Service Act (42 U.S.C. 262(a)) with re-
14
spect to a biological product; 
15
(B) a person owning or controlling enforce-
16
ment of the patent on— 
17
(i) the list published under section 
18
505(j)(7) of the Federal Food, Drug, and 
19
Cosmetic Act (21 U.S.C. 355(j)(7)) in con-
20
nection with the application described in 
21
subparagraph (A)(i); or 
22
(ii) any list published under section 
23
351 of the Public Health Service Act (42 
24
U.S.C. 262) comprised of patents associ-
25
00:26 Apr 24, 2021
H19
164 
•HR 19 IH
ated with biologics license applications filed 
1
under section 351(a) of such Act (42 
2
U.S.C. 262(a)); or 
3
(C) the predecessors, subsidiaries, divi-
4
sions, groups, and affiliates controlled by, con-
5
trolling, or under common control with any en-
6
tity described in subparagraph (A) or (B) (such 
7
control to be presumed by direct or indirect 
8
share ownership of 50 percent or greater), as 
9
well as the licensees, licensors, successors, and 
10
assigns of each of the entities. 
11
(6) PATENT.—The term ‘‘patent’’ means a pat-
12
ent issued by the United States Patent and Trade-
13
mark Office. 
14
(7) 
STATUTORY
EXCLUSIVITY.—The 
term 
15
‘‘statutory exclusivity’’ means those prohibitions on 
16
the submission or approval of drug applications 
17
under 
clauses 
(ii) 
through 
(iv) 
of 
section 
18
505(c)(3)(E) (5- and 3-year exclusivity), clauses (ii) 
19
through (iv) of section 505(j)(5)(F) (5-year and 3- 
20
year exclusivity), section 505(j)(5)(B)(iv) (180-day 
21
exclusivity), section 527 (orphan drug exclusivity), 
22
section 505A (pediatric exclusivity), or section 505E 
23
(qualified infectious disease product exclusivity) of 
24
the Federal Food, Drug, and Cosmetic Act (21 
25
00:26 Apr 24, 2021
H19
165 
•HR 19 IH
U.S.C. 355(c)(3)(E), 355(j)(5)(B)(iv), 355(j)(5)(F), 
1
360cc, 355a, 355f), or prohibitions on the submis-
2
sion or licensing of biologics license applications 
3
under section 351(k)(6) (interchangeable biological 
4
product exclusivity) or section 351(k)(7) (biological 
5
product reference product exclusivity) of the Public 
6
Health Service Act (42 U.S.C. 262(k)(6), (7)). 
7
(8) SUBSEQUENT
FILER.—The term ‘‘subse-
8
quent filer’’ means— 
9
(A) in the case of a drug, a party that 
10
owns or controls an abbreviated new drug appli-
11
cation submitted pursuant to section 505(j) of 
12
the Federal Food, Drug, and Cosmetic Act (21 
13
U.S.C. 355(j)) or a new drug application sub-
14
mitted pursuant to section 505(b)(2) of the 
15
Federal Food, Drug, and Cosmetic Act (21 
16
U.S.C. 355(b)(2)) and filed under section 
17
505(b)(1) of such Act (21 U.S.C. 355(b)(1)) or 
18
has the exclusive rights to distribute the cov-
19
ered product that is the subject of such applica-
20
tion; or 
21
(B) in the case of a biological product, a 
22
party that owns or controls an application filed 
23
with the Food and Drug Administration under 
24
section 351(k) of the Public Health Service Act 
25
00:26 Apr 24, 2021
H19
166 
•HR 19 IH
(42 U.S.C. 262(k)) or has the exclusive rights 
1
to distribute the biological product that is the 
2
subject of such application. 
3
(h) EFFECTIVE DATE.—This section applies with re-
4
spect to agreements described in subsection (a) entered 
5
into on or after the date of the enactment of this Act. 
6
SEC. 302. NOTICE AND CERTIFICATION OF AGREEMENTS. 
7
(a) NOTICE OF ALL AGREEMENTS.—Section 1111(7) 
8
of the Medicare Prescription Drug, Improvement, and 
9
Modernization Act of 2003 (21 U.S.C. 355 note) is 
10
amended by inserting ‘‘or the owner of a patent for which 
11
a claim of infringement could reasonably be asserted 
12
against any person for making, using, offering to sell, sell-
13
ing, or importing into the United States a biological prod-
14
uct that is the subject of a biosimilar biological product 
15
application’’ before the period at the end. 
16
(b) CERTIFICATION OF AGREEMENTS.—Section 1112 
17
of such Act (21 U.S.C. 355 note) is amended by adding 
18
at the end the following: 
19
‘‘(d) CERTIFICATION.—The Chief Executive Officer 
20
or the company official responsible for negotiating any 
21
agreement under subsection (a) or (b) that is required to 
22
be filed under subsection (c) shall, within 30 days of such 
23
filing, execute and file with the Assistant Attorney General 
24
and the Commission a certification as follows:‘I declare 
25
00:26 Apr 24, 2021
H19
167 
•HR 19 IH
that the following is true, correct, and complete to the best 
1
of my knowledge: The materials filed with the Federal 
2
Trade Commission and the Department of Justice under 
3
section 1112 of the Medicare Prescription Drug, Improve-
4
ment, and Modernization Act of 2003, with respect to the 
5
agreement referenced in this certification—’ ‘ 
6
‘‘ ‘(1) represent the complete, final, and exclu-
7
sive agreement between the parties; 
8
‘‘ ‘(2) include any ancillary agreements that are 
9
contingent upon, provide a contingent condition for, 
10
were entered into within 30 days of, or are otherwise 
11
related to, the referenced agreement; and 
12
‘‘ ‘(3) include written descriptions of any oral 
13
agreements, representations, commitments, or prom-
14
ises between the parties that are responsive to sub-
15
section (a) or (b) of such section 1112 and have not 
16
been reduced to writing.’ ’’. 
17
SEC. 303. FORFEITURE OF 180-DAY EXCLUSIVITY PERIOD. 
18
Section 505(j)(5)(D)(i)(V) of the Federal Food, 
19
Drug, and Cosmetic Act (21 U.S.C. 355(j)(5)(D)(i)(V)) 
20
is amended by inserting ‘‘section 301 of the Lower Costs, 
21
More Cures Act of 2021 or’’ after ‘‘that the agreement 
22
has violated’’. 
23
00:26 Apr 24, 2021
H19
168 
•HR 19 IH
SEC. 304. COMMISSION LITIGATION AUTHORITY. 
1
Section 16(a)(2) of the Federal Trade Commission 
2
Act (15 U.S.C. 56(a)(2)) is amended— 
3
(1) in subparagraph (D), by striking ‘‘or’’ after 
4
the semicolon; 
5
(2) in subparagraph (E), by moving the margin 
6
2 ems to the left and inserting ‘‘or’’ after the semi-
7
colon; and 
8
(3) by inserting after subparagraph (E) the fol-
9
lowing: 
10
‘‘(F) under section 301(d)(3)(A) of the Lower 
11
Costs, More Cures Act of 2021;’’. 
12
SEC. 305. STATUTE OF LIMITATIONS. 
13
(a) IN GENERAL.—Except as provided in subsection 
14
(b), the Commission shall commence any administrative 
15
proceeding or civil action to enforce section 301 of this 
16
Act not later than 6 years after the date on which the 
17
parties to the agreement file the Notice of Agreement as 
18
provided by section 1112(c)(2) and (d) of the Medicare 
19
Prescription Drug, Improvement, and Modernization Act 
20
of 2003 (21 U.S.C. 355 note). 
21
(b) CIVIL ACTION AFTER ISSUANCE OF CEASE AND 
22
DESIST ORDER.—If the Commission has issued a cease 
23
and desist order under section 5 of the Federal Trade 
24
Commission Act (15 U.S.C. 45) for violation of section 
25
301 of this Act and the proceeding for the issuance of 
26
00:26 Apr 24, 2021
H19
169 
•HR 19 IH
such order was commenced within the period required by 
1
subsection (a) of this section, such subsection does not 
2
prohibit the commencement, after such period, of a civil 
3
action under section 301(d)(3)(A) against a party to such 
4
order or a civil action under subsection (l) of such section 
5
5 for violation of such order. 
6
Subtitle B—Advancing Education 
7
on Biosimilars 
8
SEC. 321. EDUCATION ON BIOLOGICAL PRODUCTS. 
9
(a) WEBSITE; CONTINUING EDUCATION.—Subpart 1 
10
of part F of title III of the Public Health Service Act (42 
11
U.S.C. 262 et seq.) is amended by adding at the end the 
12
following: 
13
‘‘SEC. 352A. EDUCATION ON BIOLOGICAL PRODUCTS. 
14
‘‘(a) INTERNET WEBSITE.— 
15
‘‘(1) IN GENERAL.—The Secretary shall main-
16
tain and operate an internet website to provide edu-
17
cational materials for health care providers, patients, 
18
and caregivers, regarding the meaning of the terms, 
19
and the standards for review and licensing of, bio-
20
logical products, including biosimilar biological prod-
21
ucts and interchangeable biosimilar biological prod-
22
ucts. 
23
‘‘(2) CONTENT.—Educational materials pro-
24
vided under paragraph (1) may include— 
25
00:26 Apr 24, 2021
H19
170 
•HR 19 IH
‘‘(A) explanations of key statutory and 
1
regulatory terms, including ‘biosimilar’ and 
2
‘interchangeable’, and clarification regarding 
3
the use of interchangeable biosimilar biological 
4
products; 
5
‘‘(B) information related to development 
6
programs for biological products, including bio-
7
similar biological products and interchangeable 
8
biosimilar biological products and relevant clin-
9
ical considerations for prescribers, which may 
10
include, as appropriate and applicable, informa-
11
tion related to the comparability of such biologi-
12
cal products; 
13
‘‘(C) an explanation of the process for re-
14
porting adverse events for biological products, 
15
including biosimilar biological products and 
16
interchangeable biosimilar biological products; 
17
and 
18
‘‘(D) an explanation of the relationship be-
19
tween biosimilar biological products and inter-
20
changeable biosimilar biological products li-
21
censed under section 351(k) and reference 
22
products (as defined in section 351(i)), includ-
23
ing the standards for review and licensing of 
24
each such type of biological product. 
25
00:26 Apr 24, 2021
H19
171 
•HR 19 IH
‘‘(3) FORMAT.—The educational materials pro-
1
vided under paragraph (1) may be— 
2
‘‘(A) in formats such as webinars, con-
3
tinuing medical education modules, videos, fact 
4
sheets, infographics, stakeholder toolkits, or 
5
other formats as appropriate and applicable; 
6
and 
7
‘‘(B) tailored for the unique needs of 
8
health care providers, patients, caregivers, and 
9
other audiences, as the Secretary determines 
10
appropriate. 
11
‘‘(4) OTHER INFORMATION.—In addition to the 
12
information described in paragraph (2), the Sec-
13
retary shall continue to publish the following infor-
14
mation: 
15
‘‘(A) The action package of each biological 
16
product licensed under subsection (a) or (k). 
17
‘‘(B) The summary review of each biologi-
18
cal product licensed under subsection (a) or (k). 
19
‘‘(5) CONFIDENTIAL AND TRADE SECRET IN-
20
FORMATION.—This subsection does not authorize 
21
the disclosure of any trade secret, confidential com-
22
mercial or financial information, or other matter de-
23
scribed in section 552(b) of title 5. 
24
00:26 Apr 24, 2021
H19
172 
•HR 19 IH
‘‘(b) CONTINUING EDUCATION.—The Secretary shall 
1
advance education and awareness among health care pro-
2
viders regarding biological products, including biosimilar 
3
biological products and interchangeable biosimilar biologi-
4
cal products, as appropriate, including by developing or 
5
improving continuing education programs that advance 
6
the education of such providers on the prescribing of, and 
7
relevant clinical considerations with respect to, biological 
8
products, including biosimilar biological products and 
9
interchangeable biosimilar biological products.’’. 
10
(b) APPLICATION UNDER THE MEDICARE MERIT- 
11
BASED
INCENTIVE
PAYMENT
SYSTEM.—Section 
12
1848(q)(5)(C) of the Social Security Act (42 U.S.C. 
13
1395w–4(q)(5)(C)) is amended by adding at the end the 
14
following new clause: 
15
‘‘(iv) CLINICAL MEDICAL EDUCATION 
16
PROGRAM
ON
BIOSIMILAR
BIOLOGICAL 
17
PRODUCTS.—Completion of a clinical med-
18
ical education program developed or im-
19
proved under section 352A(b) of the Public 
20
Health Service Act by a MIPS eligible pro-
21
fessional during a performance period shall 
22
earn such eligible professional one-half of 
23
the highest potential score for the perform-
24
ance category described in paragraph 
25
00:26 Apr 24, 2021
H19
173 
•HR 19 IH
(2)(A)(iii) for such performance period. A 
1
MIPS eligible professional may only count 
2
the completion of such a program for pur-
3
poses of such category one time during the 
4
eligible professional’s lifetime.’’. 
5
Subtitle C—Other Provisions 
6
SEC. 331. CLARIFYING THE MEANING OF NEW CHEMICAL 
7
ENTITY. 
8
Chapter V of the Federal Food, Drug, and Cosmetic 
9
Act is amended— 
10
(1) in section 505 (21 U.S.C. 355)— 
11
(A) in subsection (c)(3)(E)— 
12
(i) in clause (ii), by striking ‘‘active 
13
ingredient (including any ester or salt of 
14
the active ingredient)’’ and inserting ‘‘ac-
15
tive moiety (as defined by the Secretary in 
16
section 314.3 of title 21, Code of Federal 
17
Regulations (or any successor regula-
18
tions))’’; and 
19
(ii) in clause (iii), by striking ‘‘active 
20
ingredient (including any ester or salt of 
21
the active ingredient)’’ and inserting ‘‘ac-
22
tive moiety (as defined by the Secretary in 
23
section 314.3 of title 21, Code of Federal 
24
00:26 Apr 24, 2021
H19
174 
•HR 19 IH
Regulations (or any successor regula-
1
tions))’’; 
2
(B) in subsection (j)(5)(F)— 
3
(i) in clause (ii), by striking ‘‘active 
4
ingredient (including any ester or salt of 
5
the active ingredient)’’ and inserting ‘‘ac-
6
tive moiety (as defined by the Secretary in 
7
section 314.3 of title 21, Code of Federal 
8
Regulations (or any successor regula-
9
tions))’’; and 
10
(ii) in clause (iii), by striking ‘‘active 
11
ingredient (including any ester or salt of 
12
the active ingredient)’’ and inserting ‘‘ac-
13
tive moiety (as defined by the Secretary in 
14
section 314.3 of title 21, Code of Federal 
15
Regulations (or any successor regula-
16
tions))’’; 
17
(C) in subsection (l)(2)(A)(i), by striking 
18
‘‘active ingredient (including any ester or salt of 
19
the active ingredient)’’ and inserting ‘‘active 
20
moiety (as defined by the Secretary in section 
21
314.3 of title 21, Code of Federal Regulations 
22
(or any successor regulations))’’; 
23
(D) in subsection (s), in the matter pre-
24
ceding paragraph (1), by striking ‘‘active ingre-
25
00:26 Apr 24, 2021
H19
175 
•HR 19 IH
dient (including any ester or salt of the active 
1
ingredient)’’ and inserting ‘‘active moiety (as 
2
defined by the Secretary in section 314.3 of 
3
title 21, Code of Federal Regulations (or any 
4
successor regulations))’’; and 
5
(E) in subsection (u)(1), in the matter pre-
6
ceding subparagraph (A)— 
7
(i) by striking ‘‘active ingredient (in-
8
cluding any ester or salt of the active in-
9
gredient)’’ and inserting ‘‘active moiety (as 
10
defined by the Secretary in section 314.3 
11
of title 21, Code of Federal Regulations (or 
12
any successor regulations))’’; and 
13
(ii) by striking ‘‘same active ingre-
14
dient’’ and inserting ‘‘same active moiety’’; 
15
(2) 
in 
section 
512(c)(2)(F) 
(21 
U.S.C. 
16
360b(c)(2)(F))— 
17
(A) in clause (i), by striking ‘‘active ingre-
18
dient (including any ester or salt of the active 
19
ingredient)’’ and inserting ‘‘active moiety (as 
20
defined by the Secretary in section 314.3 of 
21
title 21, Code of Federal Regulations (or any 
22
successor regulations))’’; 
23
(B) in clause (ii), by striking ‘‘active ingre-
24
dient (including any ester or salt of the active 
25
00:26 Apr 24, 2021
H19
176 
•HR 19 IH
ingredient)’’ and inserting ‘‘active moiety (as 
1
defined by the Secretary in section 314.3 of 
2
title 21, Code of Federal Regulations (or any 
3
successor regulations))’’; and 
4
(C) in clause (v), by striking ‘‘active ingre-
5
dient (including any ester or salt of the active 
6
ingredient)’’ and inserting ‘‘active moiety (as 
7
defined by the Secretary in section 314.3 of 
8
title 21, Code of Federal Regulations (or any 
9
successor regulations))’’; 
10
(3) 
in 
section 
524(a)(4)(C) 
(21 
U.S.C. 
11
360n(a)(4)(C)), by striking ‘‘active ingredient (in-
12
cluding any ester or salt of the active ingredient)’’ 
13
and inserting ‘‘active moiety (as defined by the Sec-
14
retary in section 314.3 of title 21, Code of Federal 
15
Regulations (or any successor regulations))’’; 
16
(4) in section 529(a)(4)(A)(ii) (21 U.S.C. 
17
360ff(a)(4)(A)(ii)), by striking ‘‘active ingredient 
18
(including any ester or salt of the active ingredient)’’ 
19
and inserting ‘‘active moiety (as defined by the Sec-
20
retary in section 314.3 of title 21, Code of Federal 
21
Regulations (or any successor regulations))’’; and 
22
(5) in section 565A(a)(4)(D) (21 U.S.C. 
23
360bbb–4a(a)(4)(D)), by striking ‘‘active ingredient 
24
(including any ester or salt of the active ingredient)’’ 
25
00:26 Apr 24, 2021
H19
177 
•HR 19 IH
and inserting ‘‘active moiety (as defined by the Sec-
1
retary in section 314.3 of title 21, Code of Federal 
2
Regulations (or any successor regulations))’’. 
3
TITLE IV—REVENUE PROVISION 
4
SEC. 401. SAFE HARBOR FOR HIGH DEDUCTIBLE HEALTH 
5
PLANS WITHOUT DEDUCTIBLE FOR INSULIN. 
6
(a) IN GENERAL.—Section 223(c)(2)(C) of the Inter-
7
nal Revenue Code of 1986 is amended by inserting ‘‘or 
8
for insulin or any device for the delivery of insulin’’ before 
9
the period at the end. 
10
(b) EFFECTIVE DATE.—The amendment made by 
11
this section shall apply to months beginning after the date 
12
of the enactment of this Act. 
13
TITLE V—MISCELLANEOUS 
14
SEC. 501. PAYMENT FOR BIOSIMILAR BIOLOGICAL PROD-
15
UCTS DURING INITIAL PERIOD. 
16
Section 1847A(c)(4) of the Social Security Act (42 
17
U.S.C. 1395w–3a(c)(4)) is amended— 
18
(1) in each of subparagraphs (A) and (B), by 
19
redesignating clauses (i) and (ii) as subclauses (I) 
20
and (II), respectively, and moving such subclauses 2 
21
ems to the right; 
22
(2) by redesignating subparagraphs (A) and 
23
(B) as clauses (i) and (ii) and moving such clauses 
24
2 ems to the right; 
25
00:26 Apr 24, 2021
H19
178 
•HR 19 IH
(3) by striking ‘‘UNAVAILABLE.—In the case’’ 
1
and inserting ‘‘UNAVAILABLE.— 
2
‘‘(A) IN
GENERAL.—Subject to subpara-
3
graph (B), in the case’’; and 
4
(4) by adding at the end the following new sub-
5
paragraph: 
6
‘‘(B) LIMITATION
ON
PAYMENT
AMOUNT 
7
FOR BIOSIMILAR BIOLOGICAL PRODUCTS DUR-
8
ING
INITIAL
PERIOD.—In the case of a bio-
9
similar biological product furnished on or after 
10
July 1, 2023, in lieu of applying subparagraph 
11
(A) during the initial period described in such 
12
subparagraph with respect to the biosimilar bio-
13
logical product, the amount payable under this 
14
section for the biosimilar biological product is 
15
the lesser of the following: 
16
‘‘(i) The amount determined under 
17
clause (ii) of such subparagraph for the 
18
biosimilar biological product. 
19
‘‘(ii) The amount determined under 
20
subsection (b)(1)(B) for the reference bio-
21
logical product.’’. 
22
SEC. 502. GAO STUDY AND REPORT ON AVERAGE SALES 
23
PRICE. 
24
(a) STUDY.— 
25
00:26 Apr 24, 2021
H19
179 
•HR 19 IH
(1) IN GENERAL.—The Comptroller General of 
1
the United States (in this section referred to as the 
2
‘‘Comptroller General’’) shall conduct a study on 
3
spending for applicable drugs under part B of title 
4
XVIII of the Social Security Act. 
5
(2) APPLICABLE DRUGS DEFINED.—In this sec-
6
tion, the term ‘‘applicable drugs’’ means drugs and 
7
biologicals— 
8
(A) for which reimbursement under such 
9
part B is based on the average sales price of 
10
the drug or biological; and 
11
(B) that account for the largest percentage 
12
of total spending on drugs and biologicals under 
13
such part B (as determined by the Comptroller 
14
General, but in no case less than 25 drugs or 
15
biologicals). 
16
(3) REQUIREMENTS.—The study under para-
17
graph (1) shall include an analysis of the following: 
18
(A) The extent to which each applicable 
19
drug is paid for— 
20
(i) under such part B for Medicare 
21
beneficiaries; or 
22
(ii) by private payers in the commer-
23
cial market. 
24
00:26 Apr 24, 2021
H19
180 
•HR 19 IH
(B) Any change in Medicare spending or 
1
Medicare beneficiary cost-sharing that would 
2
occur if the average sales price of an applicable 
3
drug was based solely on payments by private 
4
payers in the commercial market. 
5
(C) The extent to which drug manufactur-
6
ers provide rebates, discounts, or other price 
7
concessions to private payers in the commercial 
8
market for applicable drugs, which the manu-
9
facturer includes in its average sales price cal-
10
culation, for— 
11
(i) formulary placement; 
12
(ii) utilization management consider-
13
ations; or 
14
(iii) other purposes. 
15
(D) Barriers to drug manufacturers pro-
16
viding such price concessions for applicable 
17
drugs. 
18
(E) Other areas determined appropriate by 
19
the Comptroller General. 
20
(b) REPORT.—Not later than 2 years after the date 
21
of the enactment of this Act, the Comptroller General shall 
22
submit to Congress a report on the study conducted under 
23
subsection (a), together with recommendations for such 
24
00:26 Apr 24, 2021
H19
181 
•HR 19 IH
legislation and administrative action as the Secretary de-
1
termines appropriate. 
2
SEC. 503. REQUIRING PRESCRIPTION DRUG PLANS AND 
3
MA–PD 
PLANS 
TO 
REPORT 
4
FRAUD, WASTE, AND ABUSE TO THE SEC-
5
RETARY OF HHS. 
6
Section 1860D–4 of the Social Security Act (42 
7
U.S.C. 1395w–104) is amended by adding at the end the 
8
following new subsection: 
9
‘‘(p) REPORTING POTENTIAL FRAUD, WASTE, AND 
10
ABUSE.—Beginning January 1, 2022, the PDP sponsor 
11
of a prescription drug plan shall report to the Secretary, 
12
as specified by the Secretary— 
13
‘‘(1) any substantiated or suspicious activities 
14
(as defined by the Secretary) with respect to the 
15
program under this part as it relates to fraud, 
16
waste, and abuse; and 
17
‘‘(2) any steps made by the PDP sponsor after 
18
identifying such activities to take corrective ac-
19
tions.’’. 
20
SEC. 504. ESTABLISHMENT OF PHARMACY QUALITY MEAS-
21
URES UNDER MEDICARE PART D. 
22
Section 1860D–4(c) of the Social Security Act (42 
23
U.S.C. 1395w–104(c)) is amended by adding at the end 
24
the following new paragraph: 
25
00:26 Apr 24, 2021
H19
182 
•HR 19 IH
‘‘(8) APPLICATION
OF
PHARMACY
QUALITY 
1
MEASURES.— 
2
‘‘(A) IN GENERAL.—A PDP sponsor that 
3
implements incentive payments to a pharmacy 
4
or price concessions paid by a pharmacy based 
5
on quality measures shall use measures estab-
6
lished or approved by the Secretary under sub-
7
paragraph (B) with respect to payment for cov-
8
ered part D drugs dispensed by such pharmacy. 
9
‘‘(B) 
STANDARD
PHARMACY
QUALITY 
10
MEASURES.—The Secretary shall establish or 
11
approve standard quality measures from a con-
12
sensus and evidence-based organization for pay-
13
ments described in subparagraph (A). Such 
14
measures shall focus on patient health outcomes 
15
and be based on proven criteria measuring 
16
pharmacy performance. 
17
‘‘(C) EFFECTIVE DATE.—The requirement 
18
under subparagraph (A) shall take effect for 
19
plan years beginning on or after January 1, 
20
2023, or such earlier date specified by the Sec-
21
retary if the Secretary determines there are suf-
22
ficient measures established or approved under 
23
subparagraph (B) to meet the requirement 
24
under subparagraph (A).’’. 
25
00:26 Apr 24, 2021
H19
183 
•HR 19 IH
SEC. 505. IMPROVING COORDINATION BETWEEN THE FOOD 
1
AND DRUG ADMINISTRATION AND THE CEN-
2
TERS FOR MEDICARE & MEDICAID SERVICES. 
3
(a) IN GENERAL.— 
4
(1) PUBLIC MEETING.— 
5
(A) IN
GENERAL.—Not later than 12 
6
months after the date of the enactment of this 
7
Act, the Secretary of Health and Human Serv-
8
ices (referred to in this section as the ‘‘Sec-
9
retary’’) shall convene a public meeting for the 
10
purposes of discussing and providing input on 
11
improvements to coordination between the Food 
12
and Drug Administration and the Centers for 
13
Medicare & Medicaid Services in preparing for 
14
the availability of novel medical products de-
15
scribed in subsection (c) on the market in the 
16
United States. 
17
(B) ATTENDEES.—The public meeting 
18
shall include— 
19
(i) representatives of relevant Federal 
20
agencies, including representatives from 
21
each of the medical product centers within 
22
the Food and Drug Administration and 
23
representatives from the coding, coverage, 
24
and payment offices within the Centers for 
25
Medicare & Medicaid Services; 
26
00:26 Apr 24, 2021
H19
184 
•HR 19 IH
(ii) stakeholders with expertise in the 
1
research and development of novel medical 
2
products, including manufacturers of such 
3
products; 
4
(iii) representatives of commercial 
5
health insurance payers; 
6
(iv) stakeholders with expertise in the 
7
administration and use of novel medical 
8
products, including physicians; and 
9
(v) stakeholders representing patients 
10
and with expertise in the utilization of pa-
11
tient experience data in medical product 
12
development. 
13
(C) TOPICS.—The public meeting shall in-
14
clude a discussion of— 
15
(i) the status of the drug and medical 
16
device development pipeline related to the 
17
availability of novel medical products; 
18
(ii) the anticipated expertise necessary 
19
to review the safety and effectiveness of 
20
such products at the Food and Drug Ad-
21
ministration and current gaps in such ex-
22
pertise, if any; 
23
(iii) the expertise necessary to make 
24
coding, coverage, and payment decisions 
25
00:26 Apr 24, 2021
H19
185 
•HR 19 IH
with respect to such products within the 
1
Centers for Medicare & Medicaid Services, 
2
and current gaps in such expertise, if any; 
3
(iv) trends in the differences in the 
4
data necessary to determine the safety and 
5
effectiveness of a novel medical product 
6
and the data necessary to determine 
7
whether a novel medical product meets the 
8
reasonable and necessary requirements for 
9
coverage and payment under title XVIII of 
10
the Social Security Act pursuant to section 
11
1862(a)(1)(A) of such Act (42 U.S.C. 
12
1395y(a)(1)(A)); 
13
(v) the availability of information for 
14
sponsors of such novel medical products to 
15
meet each of those requirements; and 
16
(vi) the coordination of information 
17
related to significant clinical improvement 
18
over existing therapies for patients between 
19
the Food and Drug Administration and the 
20
Centers for Medicare & Medicaid Services 
21
with respect to novel medical products. 
22
(D) TRADE SECRETS AND CONFIDENTIAL 
23
INFORMATION.—No information discussed as a 
24
part of the public meeting under this paragraph 
25
00:26 Apr 24, 2021
H19
186 
•HR 19 IH
shall be construed as authorizing the Secretary 
1
to disclose any information that is a trade se-
2
cret or confidential information subject to sec-
3
tion 552(b)(4) of title 5, United States Code. 
4
(2) IMPROVING
TRANSPARENCY
OF
CRITERIA 
5
FOR MEDICARE COVERAGE.— 
6
(A) DRAFT GUIDANCE.—Not later than 18 
7
months after the public meeting under para-
8
graph (1), the Secretary shall update the final 
9
guidance titled ‘‘National Coverage Determina-
10
tions with Data Collection as a Condition of 
11
Coverage: Coverage with Evidence Develop-
12
ment’’ to address any opportunities to improve 
13
the availability and coordination of information 
14
as described in clauses (iv) through (vi) of para-
15
graph (1)(C). 
16
(B) FINAL GUIDANCE.—Not later than 12 
17
months after issuing draft guidance under sub-
18
paragraph (A), the Secretary shall finalize the 
19
updated guidance to address any such opportu-
20
nities. 
21
(b) REPORT ON CODING, COVERAGE, AND PAYMENT 
22
PROCESSES UNDER MEDICARE
FOR NOVEL MEDICAL 
23
PRODUCTS.—Not later than 12 months after the date of 
24
the enactment of this Act, the Secretary shall publish a 
25
00:26 Apr 24, 2021
H19
187 
•HR 19 IH
report on the internet website of the Department of 
1
Health and Human Services regarding processes under 
2
the Medicare program under title XVIII of the Social Se-
3
curity Act (42 U.S.C. 1395 et seq.) with respect to the 
4
coding, coverage, and payment of novel medical products 
5
described in subsection (c). Such report shall include the 
6
following: 
7
(1) A description of challenges in the coding, 
8
coverage, and payment processes under the Medicare 
9
program for novel medical products. 
10
(2) Recommendations to— 
11
(A) incorporate patient experience data 
12
(such as the impact of a disease or condition on 
13
the lives of patients and patient treatment pref-
14
erences) into the coverage and payment proc-
15
esses within the Centers for Medicare & Med-
16
icaid Services; 
17
(B) decrease the length of time to make 
18
national and local coverage determinations 
19
under the Medicare program (as those terms 
20
are defined in subparagraph (A) and (B), re-
21
spectively, of section 1862(l)(6) of the Social 
22
Security Act (42 U.S.C. 1395y(l)(6))); 
23
(C) streamline the coverage process under 
24
the Medicare program and incorporate input 
25
00:26 Apr 24, 2021
H19
188 
•HR 19 IH
from relevant stakeholders into such coverage 
1
determinations; and 
2
(D) identify potential mechanisms to incor-
3
porate novel payment designs similar to those 
4
in development in commercial insurance plans 
5
and State plans under title XIX of such Act 
6
(42 U.S.C. 1396 et seq.) into the Medicare pro-
7
gram. 
8
(c) NOVEL MEDICAL PRODUCTS DESCRIBED.—For 
9
purposes of this section, a novel medical product described 
10
in this subsection is a medical product, including a drug, 
11
biological (including gene and cell therapy), or medical de-
12
vice, that has been designated as a breakthrough therapy 
13
under section 506(a) of the Federal Food, Drug, and Cos-
14
metic Act (21 U.S.C. 356(a)), a breakthrough device 
15
under section 515B of such Act (21 U.S.C. 360e–3), or 
16
a regenerative advanced therapy under section 506(g) of 
17
such Act (21 U.S.C. 356(g)). 
18
SEC. 506. PATIENT CONSULTATION IN MEDICARE NA-
19
TIONAL AND LOCAL COVERAGE DETERMINA-
20
TIONS IN ORDER TO MITIGATE BARRIERS TO 
21
INCLUSION OF SUCH PERSPECTIVES. 
22
Section 1862(l) of the Social Security Act (42 U.S.C. 
23
1395y(l)) is amended by adding at the end the following 
24
new paragraph: 
25
00:26 Apr 24, 2021
H19
189 
•HR 19 IH
‘‘(7) PATIENT
CONSULTATION
IN
NATIONAL 
1
AND LOCAL COVERAGE DETERMINATIONS.—The Sec-
2
retary may consult with patients and organizations 
3
representing patients in making national and local 
4
coverage determinations.’’. 
5
SEC. 507. MEDPAC REPORT ON SHIFTING COVERAGE OF 
6
CERTAIN MEDICARE PART B DRUGS TO MEDI-
7
CARE PART D. 
8
(a) STUDY.—The Medicare Payment Advisory Com-
9
mission (in this section referred to as the ‘‘Commission’’) 
10
shall conduct a study on shifting coverage of certain drugs 
11
and biologicals for which payment is currently made under 
12
part B of title XVIII of the Social Security Act (42 U.S.C. 
13
1395j et seq.) to part D of such title (42 U.S.C. 1395w– 
14
21 et seq.). Such study shall include an analysis of— 
15
(1) differences in program structures and pay-
16
ment methods for drugs and biologicals covered 
17
under such parts B and D, including effects of such 
18
a shift on program spending, beneficiary cost-shar-
19
ing liability, and utilization management techniques 
20
for such drugs and biologicals; and 
21
(2) the feasibility and policy implications of 
22
shifting coverage of drugs and biologicals for which 
23
payment is currently made under such part B to 
24
such part D. 
25
00:26 Apr 24, 2021
H19
190 
•HR 19 IH
(b) REPORT.— 
1
(1) IN
GENERAL.—Not later than June 30, 
2
2023, the Commission shall submit to Congress a re-
3
port containing the results of the study conducted 
4
under subsection (a). 
5
(2) CONTENTS.—The report under paragraph 
6
(1) shall include information, and recommendations 
7
as the Commission deems appropriate, regarding— 
8
(A) formulary design under such part D; 
9
(B) the ability of the benefit structure 
10
under such part D to control total spending on 
11
drugs and biologicals for which payment is cur-
12
rently made under such part B; 
13
(C) changes to the bid process under such 
14
part D, if any, that may be necessary to inte-
15
grate coverage of such drugs and biologicals 
16
into such part D; 
17
(D) any other changes to the program that 
18
Congress should consider in determining wheth-
19
er to shift coverage of such drugs and 
20
biologicals from such part B to such part D; 
21
and 
22
(E) the feasibility and policy implications 
23
of creating a methodology to preserve the 
24
00:26 Apr 24, 2021
H19
191 
•HR 19 IH
healthcare provider’s ability to take title of the 
1
drug, including a methodology under which— 
2
(i) prescription drug plans negotiate 
3
reimbursement rates and other arrange-
4
ments with drug manufacturers on behalf 
5
of a wholesaler; 
6
(ii) wholesalers purchase the drugs 
7
from the manufacturers at the negotiated 
8
rate and ship them through distributors to 
9
physicians to administer to patients; 
10
(iii) physicians and hospitals purchase 
11
the drug from the wholesaler via the dis-
12
tributor; 
13
(iv) after administering the drug, the 
14
physician submits a claim to the MAC for 
15
their drug administration fee; 
16
(v) to be reimbursed for the purchase 
17
of the drug from the distributor, the physi-
18
cian furnishes the claim for the drug itself 
19
to the wholesaler and the wholesaler would 
20
refund the cost of the drug to the physi-
21
cian; and 
22
(vi) the wholesaler passes this claim to 
23
the PDP to receive reimbursement. 
24
00:26 Apr 24, 2021
H19
192 
•HR 19 IH
SEC. 508. REQUIREMENT THAT DIRECT-TO-CONSUMER AD-
1
VERTISEMENTS FOR PRESCRIPTION DRUGS 
2
AND 
BIOLOGICAL 
PRODUCTS 
INCLUDE 
3
TRUTHFUL AND NON-MISLEADING PRICING 
4
INFORMATION. 
5
Part A of title XI of the Social Security Act is 
6
amended by adding at the end the following new section: 
7
‘‘SEC. 1150C. REQUIREMENT THAT DIRECT-TO-CONSUMER 
8
ADVERTISEMENTS 
FOR 
PRESCRIPTION 
9
DRUGS 
AND 
BIOLOGICAL 
PRODUCTS 
IN-
10
CLUDE 
TRUTHFUL 
AND 
NON-MISLEADING 
11
PRICING INFORMATION. 
12
‘‘(a) IN GENERAL.—The Secretary shall require that 
13
each direct-to-consumer advertisement for a prescription 
14
drug or biological product for which payment is available 
15
under title XVIII or XIX includes an appropriate disclo-
16
sure of truthful and non-misleading pricing information 
17
with respect to the drug or product. 
18
‘‘(b) DETERMINATION BY CMS.—The Secretary, act-
19
ing through the Administrator of the Centers for Medicare 
20
& Medicaid Services, shall determine the components of 
21
the requirement under subsection (a), such as the forms 
22
of advertising, the manner of disclosure, the price point 
23
listing, and the price information for disclosure.’’. 
24
00:26 Apr 24, 2021
H19
193 
•HR 19 IH
SEC. 509. CHIEF PHARMACEUTICAL NEGOTIATOR AT THE 
1
OFFICE OF THE UNITED STATES TRADE REP-
2
RESENTATIVE. 
3
(a) IN GENERAL.—Section 141 of the Trade Act of 
4
1974 (19 U.S.C. 2171) is amended— 
5
(1) in subsection (b)(2)— 
6
(A) by striking ‘‘and one Chief Innovation 
7
and Intellectual Property Negotiator’’ and in-
8
serting ‘‘one Chief Innovation and Intellectual 
9
Property Negotiator, and one Chief Pharma-
10
ceutical Negotiator’’; 
11
(B) by striking ‘‘or the Chief Innovation 
12
and Intellectual Property Negotiator’’ and in-
13
serting ‘‘the Chief Innovation and Intellectual 
14
Property Negotiator, or the Chief Pharma-
15
ceutical Negotiator’’; and 
16
(C) by striking ‘‘and the Chief Innovation 
17
and Intellectual Property Negotiator’’ and in-
18
serting ‘‘the Chief Innovation and Intellectual 
19
Property Negotiator, and the Chief Pharma-
20
ceutical Negotiator’’; and 
21
(2) in subsection (c), by adding at the end the 
22
following new paragraph: 
23
‘‘(7) The principal function of the Chief Phar-
24
maceutical Negotiator shall be to conduct trade ne-
25
gotiations and to enforce trade agreements relating 
26
00:26 Apr 24, 2021
H19
194 
•HR 19 IH
to United States pharmaceutical products and serv-
1
ices. The Chief Pharmaceutical Negotiator shall be 
2
a vigorous advocate on behalf of United States phar-
3
maceutical interests. The Chief Pharmaceutical Ne-
4
gotiator shall perform such other functions as the 
5
United States Trade Representative may direct.’’. 
6
(b) COMPENSATION.—Section 5314 of title 5, United 
7
States Code, is amended by striking ‘‘Chief Innovation 
8
and Intellectual Property Negotiator, Office of the United 
9
States Trade Representative.’’ and inserting the following: 
10
‘‘Chief Innovation and Intellectual Property Ne-
11
gotiator, Office of the United States Trade Rep-
12
resentative. 
13
‘‘Chief Pharmaceutical Negotiator, Office of the 
14
United States Trade Representative.’’. 
15
(c) REPORT REQUIRED.—Not later than the date 
16
that is one year after the appointment of the first Chief 
17
Pharmaceutical Negotiator pursuant to paragraph (2) of 
18
section 141(b) of the Trade Act of 1974, as amended by 
19
subsection (a), and annually thereafter, the United States 
20
Trade Representative shall submit to the Committee on 
21
Finance of the Senate and the Committee on Ways and 
22
Means of the House of Representatives a report describing 
23
in detail— 
24
00:26 Apr 24, 2021
H19
195 
•HR 19 IH
(1) enforcement actions taken by the United 
1
States Trade Representative during the one-year pe-
2
riod preceding the submission of the report to en-
3
sure the protection of United States pharmaceutical 
4
products and services; and 
5
(2) other actions taken by the United States 
6
Trade Representative to advance United States 
7
pharmaceutical products and services. 
8
Æ 
00:26 Apr 24, 2021
H19
